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Abstract
The analysis of structure-activity relationships (SARs) of small bioactive com-
pounds is a central task in medicinal chemistry and pharmaceutical research.
The study of SARs is in principle not limited to computational methods, how-
ever, as data sets rapidly grow in size, advanced computational approaches
become indispensable for SAR analysis. Activity landscapes are one of the
preferred and widely used computational models to study large-scale SARs.
Activity cliffs are cardinal features of activity landscape representations and
are thought to contain high SAR information content.
This work addresses major challenges in systematic SAR exploration and
specifically focuses on the design of novel activity landscape models and com-
prehensive activity cliff analysis. In the first part of the thesis, two conceptu-
ally different activity landscape representations are introduced for compounds
active against multiple targets. These models are designed to provide an in-
tuitive graphical access to compounds forming single and multi-target activity
cliffs and displaying multi-target SAR characteristics. Further, a systematic
analysis of the frequency and distribution of activity cliffs is carried out. In
addition, a large-scale data mining effort is designed to quantify and analyze
fingerprint-dependent changes in SAR information. The second part of this
work is dedicated to the concept of activity cliffs and their utility in the prac-
tice of medicinal chemistry. Therefore, a computational approach is introduced
to search for detectable SAR advantages associated with activity cliffs. In addi-
tion, the question is investigated to what extent activity cliffs might be utilized
as starting points in practical compound optimization efforts. Finally, all ac-
tivity cliff configurations formed by currently available bioactive compounds
are thoroughly examined. These configurations are further classified and their
frequency of occurrence and target distribution are determined. Furthermore,
the activity cliff concept is extended to explore the relation between chemical
structures and compound promiscuity. The notion of promiscuity cliffs is in-
troduced to deduce structural modifications that might induce large-magnitude
promiscuity effects.
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Chapter 1
Introduction
Over the past decades, the study of small bioactive molecules and their interac-
tions with biological targets has played, and continues to play, a central role in
elucidating biological processes and understanding protein functions. To these
ends, understanding the relation between the chemical structures and the bio-
logical activity of active compounds, commonly referred to as structure-activity
relationships (SARs), is a primary task in medicinal chemistry and pharma-
ceutical research.1 The fundamental goal of SAR analysis is to demonstrate
how structural changes might affect the biological activity of compounds, and
further identify structural modifications which translate into compound po-
tency improvement. Supported by a wealth of observations, the SARs are often
in accord with the similarity-property principle (SPP)2 - a central paradigm
in medicinal chemistry, stating that similar molecules should exhibit similar
biological functions. However, it is also well-appreciated that exceptions do
exist, and that structurally analogous compounds may display different SAR
characteristics. For example, small structural modifications can dramatically
change the biological activity, thereby significantly increasing or decreasing the
compound activity.3 These considerations have demonstrated that SARs are
multi-faceted in nature, an observation that still greatly challenges the SAR
exploration and makes it a highly sophisticated task.
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Molecular Similarity
To assess the relationship between structural modifications and biological activ-
ity, molecules must be represented in a consistent and well-defined manner. In
addition, to compare changes in biological responses, potency annotations for
the underlying compounds must be provided. Furthermore, mostly, but not ex-
clusively, the SAR analysis of compound data sets frequently relies on pairwise
structural comparisons of small molecules. To these ends, the application of
similarity measures that quantify the degree of structural relatedness between
compounds becomes indispensable for the SAR analysis.
The assessment of structural similarity of compounds can be regarded as a
two-step procedure. First, a molecular representation is chosen that encodes
relevant molecular and/or chemical features. A similarity metric, often termed
a similarity coefficient, is then used to quantitatively evaluate the molecular
similarity on the basis of the chosen molecular representation. Hence, the out-
come of similarity evaluation might substantially be influenced by the chosen
molecular representation and similarity metric.4,5
Molecular Representations
A variety of molecular representations have been introduced thus far.6,7 In gen-
eral, representations can be subdivided into three different categories: one-,
two-, and three-dimensional (1D, 2D, and 3D, respectively). Examples for 1D-
representations include simple chemical composition formula and more complex
notations, such as the SMILES8 language that serves as a universal chemical
nomenclature to represent chemical structure information.
One of the best known and most widely used representations of small molecules
is the molecular graph (Figure 1.1). These 2D graphs can be considered as the
“natural language of medicinal chemists” and serve as simplified and intuitive
models of molecular structures. In these graphs, nodes denote atoms using
atomic symbols and edges encode bonding information. Therefore, 2D molec-
ular graphs represent the connectivity between atoms and the topology of the
molecules.
2
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To account for conformational information, 3D representations based on
the spacial arrangements of the atoms have been introduced. Notable examples
include molecular surfaces and pharmacophore models. A pharmacophore is
defined as the 3D arrangement of atoms, groups, or functions that is essential
for a molecule to specifically interact with a biological target.
On the basis of different molecular representations, mathematical models
have been introduced to capture a variety of chemical properties and are com-
monly termed molecular descriptors. Examples of simple descriptors include
molecular weight, number of heavy atoms and number of aromatic rings. Simi-
lar to the molecular representations, descriptors are classified as 1D, 2D, or 3D,
depending on the dimensionality of the utilized representation.
Molecular fingerprints are a special kind of descriptors that are used to
characterize chemical structure and/or molecular properties of a molecule. In
chemoinformatics and pharmaceutical research, fingerprints are generally de-
fined as bit string representations. Over the past years, a variety of fingerprints
have been introduced that considerably differ in their design, composition, and
complexity.9 Although fingerprints are string representations, and hence one-
dimensional, they are typically classified as 2D (i.e., based on molecular graphs)
and 3D (i.e., based on molecular conformations) fingerprints.
Usually, but not exclusively, fingerprints are in a binary format, i.e., each bit
position accounts for the presence or absence of a given feature. If the feature
is present, the corresponding bit is set to 1, otherwise it is set to 0. In addition,
fingerprints are mostly of a fixed length.
Substructure fingerprints are one of the major prototypes of 2D fingerprints
and can be considered as dictionaries of predefined substructures. Classical
examples for substructure fingerprints (also termed keyed fingerprints) include
the Molecular ACCess System (MACCS)10 structural keys consisting of 166
structural features each corresponding to a specific bit position. An example
of a keyed fingerprint is shown in Figure 1.1a in which features present in the
molecule are colored in gray. The corresponding bits are set to 1 (gray shades)
in the representation. Non-binary versions of fingerprints, also termed count
fingerprints, have also been developed. Here, each position numerically accounts
for the frequency of occurrence of the underlying feature.11,12
3
CHAPTER 1. INTRODUCTION
Layer Atom 
0 C 
1 C C C 
2 N O N N N 
b) Topological FP 
c) Pharmacophore FP 
6.76 Ǻ 
H 
H 11 
A 
8 
5 Ar 
H 
D 
13 
5 
7 
a) Keyed FP 
Molecular graph 
Figure 1.1: Molecular fingerprints. Three different types of molecular fingerprints are
shown. Specific molecular structure information used to derive the corresponding fingerprint
representation is highlighted. Adapted from [13].
On the basis of molecular topologies, topological fingerprints have been in-
troduced and account for connectivity pathways between atoms in a molecule.
Representative examples include the Daylight fingerprint often consisting of
2048 bits and the MOLPRINT 2D14,15 fingerprint that has a variable length.
In Daylight fingerprint, paths through the molecule are calculated until a pre-
defined length is reached (bond distance). By applying a hashing function,
these paths are subsequently mapped onto a string of a fixed length. In con-
trast to keyed fingerprints, individual bit positions in hashed fingerprints do not
correspond to individual structural features and hence, cannot be chemically
interpreted. Different from the Daylight fingerprint, the ECFP4 fingerprint16
is designed to capture connectivity information in layered atom environments
with a maximum diameter of four bonds around each atom. These calculations
are molecule-specific resulting in a fingerprint of variable length. The atom
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environment perception of a topological fingerprint of bond diameter four is
schematically illustrated on Figure 1.1b.
Pharmacophore fingerprints capture pharmacophore patterns. Examples in-
clude the Typed Graph Triangle (TGT)17 and Typed Graph Distance (TGD)17
fingerprints consisting of 1704 and 420 bit positions, respectively, which are
Molecular Operating Environment (MOE)17 internal developments. In the
TGD fingerprint, shortest distances (in terms of number of bonds) in the molec-
ular graph between two atoms (represented as seven pharmacophore features)
are calculated and assigned to 15 distance ranges to monitor distances between
feature pairs. In contrast, the TGT fingerprint is designed to capture three-
point pharmacophore patterns in molecular graphs. Atoms are assigned to one
of four different atom types (hydrogen-bond donor, hydrogen-bond acceptor,
donor/acceptor, or hydrophobic). Applied are graph (bond) distances subdi-
vided into six distance ranges. Exemplary 2D pharmacophore pattern infor-
mation encoded in a pharmacophore-based fingerprint is highlighted in Figure
1.1c.
Similarity Coefficients
As stated above, similarity coefficients are applied to account for the degree
of similarity between compounds. Although a wide-range of coefficients and
distance functions have been introduced, the most widely used is the Jaccard
or Tanimoto coefficient (Tc).6,18 For two fingerprints A and B, the Tanimoto
coefficient calculates the ratio of the number of bits set on in both fingerprints
over the number of bits set on in either fingerprint. Formally, the Tc is defined
as follows:
Tc(A,B) =
c
a + b− c
where a and b denote the number of bits set on in fingerprint A and B, respec-
tively, whereas c denotes the number of bits set on in both fingerprints. The Tc
ranges between 0 and 1, with 0 corresponding to no fingerprint overlap and 1 to
identical fingerprints. It should be noted that, identical fingerprints do not nec-
5
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essarily correspond to identical molecules (as fingerprints are only abstractions
of molecular structures). Furthermore, as defined by the above formula, the
Tc only takes into account bits set to 1 (i.e., features present in the molecule).
Hence, the magnitude of the Tc value will be greatly influenced by the bit
density in the underlying fingerprint, which on the other hand, increases with
molecular size and complexity.19
The calculation of Tc translates structural similarity into numerical values
and can be interpreted as the “percentage of structural features shared between
two compounds”, yet it is debatable which Tc value corresponds to “significant
similarity”. There is no generally applicable Tc threshold for the indication of
structural similarity, which is dependent on the molecular fingerprint applied.20
However, for SAR applications, a threshold value of 55% and 85% are typically
used in combination with ECFP4 and MACCS fingerprints, respectively.21
Matched Molecular Pairs
A variety of molecular representations and similarity coefficients have been uti-
lized to assess compound similarity in the SAR analysis. However, for medici-
nal chemistry applications, the outcome of such whole-molecule similarity cal-
culations is often difficult to chemically reconcile. In general, when different
fingerprints are utilized, different similarity values will be obtained.1,2 Hence,
compounds that are considered similar on the basis of one fingerprint repre-
sentation might not be classified as similar when other fingerprints are used.
Furthermore, as pointed above, no generally applicable similarity thresholds
exist.20
To depart from the whole-molecule and global similarity techniques, the
concept of matched molecular pairs (MMPs)22 has been introduced that is in-
dependent of subjectively determined similarity thresholds and conveys a local
molecular similarity perspective. This framework provides a consistent and gen-
erally applicable basis to establish structural relationships between compounds,
and relate chemical modifications to changes in biological activity. In recent
years, this formalism has become increasingly popular and has a significant im-
6
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pact on a number medicinal chemistry applications, especially on the large-scale
SAR exploration.
In general terms, an MMP is defined as a pair of compounds that can be
interconverted into one another by a well-defined chemical transformation, i.e.,
the exchange of a substructure. Consequently, molecules forming MMPs are
structurally related, yet the structural relationship is not a priori defined. More
precisely, the term MMP refers to two compounds that are only distinguished by
a small structural modification at a single site, also termed single point MMP.
An example of an MMP is depicted in Figure 1.2. Exchanged substructures
defining the chemical transformation are highlighted in blue.
MMP 
Figure 1.2: Matched molecular pair. Shown are two compounds forming a matched
molecular pair (MMP). Exchanged substructures are highlighted.
A large spectrum of algorithms have been developed to systematically gener-
ate MMPs. Regardless of methodological details and varying applications, these
methods can be categorized into two major classes, i.e., maximum common
substructure- (MCS-) based and fragmentation-based methodologies. MCS-
based approaches23,24 translate the task of finding small structural modifica-
tions between a pair of compounds to finding the largest shared substructure
between these molecules. It can be accomplished by performing a MCS search
(MCSS). Despite many successful applications on large data sets,23 the MCSS
represents a special case of subgraph isomorphism problem that is known to
be NP-complete. Furthermore, pairwise compound comparisons are required,
which further increases the computational complexity.
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Alternatively, fragmentation-based approaches have been introduced to iden-
tify shared substructures between a pair of compounds. In general, these ap-
proaches can be viewed as a two-step procedure. First, all compounds are
subjected to a fragmentation process. Second, by subsequent indexing of the
detected substructures, compounds are identified that share a common sub-
structure. Fragmentation-based algorithms are computationally more efficient
than MCS-based approaches as each molecule is processed only once.
One of the most widely used fragmentation-based approaches has been in-
troduced by Hussain and Rea.25 Here, molecules are fragmented by systemati-
cally deleting all single non-ring bonds (single cuts) between two non-hydrogen
atoms, as well as two- and three-bond (double and triple cuts) combinations,
resulting in different numbers of fragments. An index table is created to store
fragments for each molecule, in which the larger substructure are deposited as
keys and the remaining smaller substructures as values. In this way, MMPs
can be effectively identified by searching the table for keys with more than one
value. To confine the MMPs to only structurally analogous compounds that are
only distinguished by a functional group or a single ring system, transformation
size-restricted MMPs have been introduced.26
The most prominent feature of the MMP formalism is that it provides a
basis for a descriptor-independent, metric-free, and chemically intuitive way to
assess structural similarity of bioactive compounds. Hence, it circumvents, at
least to some extent, the subjective nature of similarity calculations based on
molecular fingerprints.
The exploration of SARs contained in sets of bioactive compounds is a hot
spot topic in medicinal chemistry. Yet, the question of what represents impor-
tant SAR information and how to best extract and evaluate it is challenging,
for several reasons. Molecular representations and structural similarity assess-
ments provide the fundamental basis for SAR analysis. However, depending on
the chosen molecular representation and similarity metrics, the outcome of the
SAR study may substantially vary. In addition, depending on the size (large
sets vs sets of limited size), composition (homogeneous vs. structurally diverse)
and origin (HTS vs. compound optimization data) of the data set under inves-
tigation, the SAR analysis can, and essentially must, be approached in different
8
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ways. In many instances the outcome of the investigation of SARs is driven by
the scientist’s intuition, experience and field of expertise.27–30 In the following
section, conventional and currently available approaches to explore and exploit
SARs contained in data sets will be introduced and discussed.
SAR Exploration
Traditionally, the SAR analysis has been mostly focused on individual com-
pound series, i.e., on structurally homogeneous compounds active against a
given target. At late stages of compound design, optimization efforts typically
focus only on analogs of a single chemotype. When only a limited number of
structurally analogous compounds are available, SARs can be effectively ex-
plored on a case-by-case basis. To these ends, R-group tables are utilized that
represent the conventional and still most widely used data structure to study the
effect of small structural modifications on compound potency (or other prop-
erties). On the basis of molecular graphs of the underlying analogs, R-group
tables are generated that display the substituents of individual compounds and
the corresponding compound activity.
Despite their simplicity, R-group tables become infeasible for structurally
heterogeneous compounds or data sets of large size.27 Such tools cannot provide
a comprehensive readout of the underlying SARs, and more advanced compu-
tational approaches become indispensable for SAR analysis.
Large-Scale SAR Analysis
Since the 1960s, numerous computational methods have been developed to as-
sist in the systematic exploration of SARs contained in a data set. These
methods can be roughly classified as predictive, i.e., attempting to ultimately
predict biological activity, and descriptive, i.e., methods that primarily aim to
deconvolute and/or visualize SAR information and further identify SAR deter-
minants.
Currently available approaches mostly, but not exclusively, rely on the
quantitative SAR paradigm, and hence, are predictive in nature. Powerful
9
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and widely used computational approaches include classical quantitative SAR
(QSAR) models.31 The ultimate goal of QSAR approaches is the prediction of
biological activity for novel, as of yet untested compounds. Using statistical
approaches, QSAR methods attempt to establish a (linear) correlation between
the biological activity of compounds and their structural or chemical proper-
ties. The underlying hypothesis is that if a linear relationship can be derived
for a set of known active compounds, then this model can be applied to pre-
dict, in quantitative terms, the potency of newly designed analogs. Common
to all QSAR methods is that they conceptually rely on one of the fundamental
principles in chemoinformatics and medicinal chemistry, the so-called similarity
property principle2 (vide supra).
As a computational technique, QSAR analysis is in principle applicable to
(very) large compound data sets. However, this approach is intrinsically limited
to structurally homogeneous data sets for which linear relationships can be
more reliably derived than for data sets containing more structurally diverse
compounds. Hence, test compounds of a different chemotype than the reference
molecules fall outside of the applicability domain of most QSAR models, and
their activity cannot be reliably predicted.32 Furthermore, it cannot be assumed
that SARs are in general linear in nature.
Activity Landscapes
Going beyond QSAR-based predictive methodologies, activity landscape mod-
els have been developed that systematically combine structural and activity
information. These powerful computational models are descriptive in nature
and can be used to conceptualize SAR characteristics.
In general terms, activity landscapes can be regarded as any graphical rep-
resentation that integrates structural and potency similarity relationships be-
tween compounds sharing the same biological activity.27 Typically, chemical
reference spaces generated from numerical descriptors of molecular structures
and other molecular properties serve as a basis for activity landscape mod-
els. Each descriptor corresponds to one dimension in the chemical reference
10
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space. Therefore, a set of N descriptors comprises a chemical space of N
dimensions. Such high-dimensional space can be further transformed into a
human-accessible two-dimensional one with the aid of dimension reduction tech-
niques.33,34 Subsequently, bioactive compounds are projected onto the x/y-plane
to study the relationship between their molecular properties. The distances be-
tween compounds principally relate to the structural similarity of compounds.
Hence, structurally similar compounds have shorter distances between them in
the space.
In medicinal chemistry and chemoinformatics, activity landscapes are one of
the preferred and widely used models to study large-scale SARs. As graphical
representations they provide an intuitive access to global and/or local SAR
information contained in compound data sets under investigation, and hence
facilitate compound selection for further chemical exploration and compound
design.
3D Activity Landscapes
Maggiora and colleagues35 envisioned activity landscapes as topological maps
that are reminiscent of actual geographical landscapes. These maps represent
one of the most prominent types of landscape models, i.e., the hypothetical 3D
activity landscapes. Essentially, 3D activity landscapes are generated by adding
an activity hypersurface to a set of compounds projected on a 2D chemical
reference space. Activity hypersurface provides information about compound
potency distribution and compounds with comparable or significantly different
potency values can be clearly observed in 3D activity landscapes. Recently, such
3D models have been generated for actual compound sets and their topology
has been extensively studied.36
The Nature of SARs
The major goal of SAR exploration is to elucidate how biological activity re-
sponds to structural changes. Importantly, different SAR phenotypes can be
conceptualized with the aid of idealized 3D activity landscapes and visualized.
11
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Depending on the underlying SAR characteristics of the data set compounds,
activity landscapes can be either smooth and easily traversed or may have
rugged surfaces.
In general, there are three major SAR categories: continuous, discontinu-
ous, and heterogeneous SARs.1 Presence of continuous SARs is indicated by
gradual changes in compound structures leading to moderate changes in their
potency.27 Furthermore, continuous SARs correspond to smooth regions or gen-
tly rolling hills in activity landscapes as shown in Figure 1.3a. This type of
SARs is consistent with the SPP (vide supra). Therefore, continuous SARs
provide the conceptual basis for similarity searching and ligand-based virtual
screening.37 From a medicinal chemists’ point of view, SARs with predictable
potency progression are of high interest in compound design.27 In such cases,
SAR continuity is an essential consideration.
In contrast, small structural changes resulting in large differences in po-
tency account for discontinuous SARs. The discontinuous character of a set
of compounds is represented by rough regions in activity landscape models as
illustrated in Figure 1.3b. In hit-to-lead optimization campaigns, SAR discon-
tinuity plays a crucial role, and compounds falling into highly discontinuous
regions represent focal points for further chemical exploration.
It is frequently observed that continuous and discontinuous SARs coexist
in compound sets sharing the same biological activity.38 Accordingly, the com-
bination of continuity and discontinuity in a single data set is considered to
represent heterogeneous SARs. Activity landscapes characterized by heteroge-
neous SARs are also termed variable activity landscapes (Figure 1.3c).1 Hence,
SAR characteristics of bioactive compounds are essentially continuous, discon-
tinuous, or heterogeneous in nature.27,39
Numerical SAR Analysis
The systematic SAR analysis can also be addressed by introducing numerical
functions to quantify the SAR information contained in sets of bioactive com-
pounds. In general terms, the SAR functions are based on pairwise calculations
12
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Figure 1.3: SAR phenotypes. Hypothetical 3D activity landscapes of different SAR phe-
notypes (a, continuous; b, discontinuous; c, heterogeneous) are shown. In these landscapes,
compound potency is added as a third coordinate to the 2D projection of the original (high-
dimensional) chemical space. Potency distributions are hypothetical. Distances in the 2D
projection reflect structural dissimilarity. Adapted from [27].
of structural and activity similarity for data set compounds. Prominent exam-
ples include the SAR Index (SARI)40 and the Structure-Activity Landscape
Index (SALI).41
The SARI score is calculated for a set of compounds and is a composite of in-
dividual SAR continuity and SAR discontinuity scores. A three-step procedure
is applied to obtain the final data set score. First, raw scores are calculated, as
introduced below. These scores are subsequently transformed into Z-scores on
the basis of a panel of reference activity classes. Finally, cumulative probabili-
ties are calculated to map Z-scores onto the value range [0, 1].
For a given data set A, the raw (non-normalized) continuity (contraw(A))
and discontinuity (discraw(A)) scores are defined as follows:
13
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contraw(A) =
∑
{i,j|i>j}
wij
1
1+sim(i,j)∑
{i,j|i>j}
wij
, wij =
Pi · Pj
1 + |Pi − Pj|
and
discraw(A) =
∑
{i,j|sim(i,j)>T,|Pi−Pj |>1,i>j}
|Pi − Pj| · sim(i, j)
|{i, j|sim(i, j) > T, |Pi − Pj| > 1, i > j}|
where P denotes potency, T a similarity threshold value, and sim(i, j) the
calculated fingerprint similarity for two data set compounds i and j.
The raw continuity score is calculated as the mean of potency weighted
pairwise compound dissimilarity and accounts for the presence of structurally
dissimilar compounds having high potency, yet small potency differences. On
the other hand, the raw discontinuity score is defined as the average of the pro-
duct of the pairwise potency difference between compounds and their structural
similarity. Accordingly, it emphasizes structurally similar compounds having
significantly different potency. For discontinuity score calculations, a similar-
ity threshold is selected to limit the calculation to only structurally similar
compound pairs. As indicated above, no generally applicable threshold values
exist. However, for SAR analysis, a MACCS Tc threshold of 0.85 is typically
used to indicate structural similarity.5 Furthermore, a potency difference cut off
of one is applied to focus on compounds with more than one order of magnitude
difference.
The final SARI score is then calculated on the basis of normalized scores
and defined as
SARI(A) =
1
2
(contnorm(A) + (1− discnorm(A)))
thereby balancing the relative contributions of individual scores. The SARI
score ranges between 0 and 1 where high values correspond to predominantly
continuous SAR and low values to mainly discontinuous SAR.
14
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Furthermore, the global discontinuous score has been modified to obtain a
local, per-compound score. For example, for a given data set compound i, its
raw discontinuity score is defined as
discraw(i) =
∑
{j|i 6=j,sim(i,j)>T}
|Pi − Pj| · sim(i, j)
|{j|sim(i, j) > T, i 6= j}|
where P denotes potency, T a similarity threshold, and sim(i, j) the cal-
culated fingerprint similarity between i and its structural neighbors. Similar
to its global counterpart, the raw scores are converted into Z-scores by using
the intra-set score distribution and then normalized by calculating the cumu-
lative probability on a normal distribution, ultimately mapping the score onto
the range [0, 1]. Accordingly, it quantifies the contribution of individual com-
pounds to the global data set discontinuity. The score is derived from the
average pairwise potency differences of compounds multiplied by their struc-
tural similarity. Local structural neighborhoods are typically calculated on the
basis of fingerprints. In contrast to the global discontinuity score, all structural
neighbors (with respect to a given fingerprint and a similarity threshold value)
of a given compound are included in the calculation of its local discontinuity
score. Accordingly, a compound obtains a high local discontinuity score if its
structural neighbors have significantly different potency values.
Numerical functions provide a quantitative measure of the SAR information
content present in sets of bioactive compounds. Raw scores, as introduced
above, are normalized with respect to the score distribution in the activity class
under investigation. Hence, care must be taken to select a suitable molecular
representation as it will inevitably affect, in a characteristic manner, the final
data set score.
Therefore, the SARI score can be used as a diagnostic of different SAR phe-
notypes for activity classes. These functions often complement the landscape-
based SAR analysis. Over the past years, activity landscapes have become
increasingly attractive tools to assess SAR information contained in compound
data sets and gained a lot of interest in the medicinal chemistry and phar-
maceutical research. As graphical representations, these models help to view
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different SAR information in context and provide intuitive and direct access to
SAR characteristics of compound data sets.
Classical Activity Landscape Views
One of the earliest and simplest, and still widely utilized 2D activity landscape
representations is the Structure-Activity Similarity (SAS) map.42 A prototyp-
ical SAS Map is shown in Figure 1.4. In a SAS map, structural similarity
of data set compounds is plotted against their activity similarity. Typically,
fingerprints are used as molecular representations and the popular Tc6 as the
similarity metric. A unit data point in the map represents a pair of compounds
for which structural and activity similarity relationships are systematically de-
termined. In the schematic representation in Figure 1.4 structural similarity is
shown on the x-axis and Tc values vary between 0 (indicating low similarity)
and 1 (indicating high similarity). Activity similarity can be represented in
different ways, for example, as logarithmic potency difference (e.g., ∆pIC50 or
∆pKi) or normalized potency difference ranging between 0 (identical compound
activities) and 1 (maximal potency difference).
A key feature of SAS maps is that it provides the basis for the classifica-
tion of compounds with different activity landscape features. Selected activity
and structural similarity thresholds subdivide the map into four different re-
gions corresponding to four activity landscape features associated with different
degrees of SAR information content:
1. Compound pairs at the upper-left region, commonly termed featureless
pairs, are characterized by low structural and activity similarity. They
are not SAR informative and, therefore, of least importance to the SAR
analysis.
2. The lower-left region is populated by structurally diverse compound pairs
with similar activity. This section corresponds to similarity cliffs. From
an information-theoretic point of view this is the most prevalent and hence
the least informative activity landscape feature. Yet, similarity cliffs can
16
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Figure 1.4: Structure-Activity Similarity maps. Shown is a schematic illustration
of a Structure-Activity Similarity (SAS) map. On the basis of SAS maps four different
activity landscape feature regions are identified. For each compound pair, structural and
activity similarity is calculated, thereby uniquely mapping the pair to one of the four regions.
Adapted from [43].
aid in the identification of new class of active compounds with similar
activity, and are therefore considered SAR informative.
3. The lower-right section consists of structurally related compounds with
similar activity. Importantly, these pairs characterize the presence of
SAR continuity (small structural modifications lead to moderate changes
in activity) and are commonly referred to as smooth pairs.
4. Activity cliffs21,44–46 are generally defined as structurally similar com-
pounds having significant potency difference and populate the upper-right
region in the SAS map. As such, they represent an extreme form of SAR
discontinuity42 and are the most prominent activity landscape feature.
Activity cliffs are often rarely present in compound data sets, yet they
are focal points of SAR analysis as they directly link structural modifica-
tion to compound potency improvement.
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Hence, activity landscape features are represented by pairs of compounds
having varying well-defined structural and activity relationship, typically on the
basis of selected structural and activity similarity thresholds. Although they
are probably best distinguished on the basis of SAS maps, they are integral
part of any activity landscape representation and can also be explored using
other models.
SAR Network Modeling
In addition to the simple SAS maps, molecular network representations have
been developed to organize and display structural and activity relationships
among sets of bioactive compounds, including the Network-like Similarity Graphs
(NSGs).47 In these graphs, all data set compounds are represented as nodes.
To account for structural similarity relationships, edges are drawn between two
nodes if the structural similarity between the corresponding compounds exceeds
a predefined threshold. In addition, nodes are color-coded according to the com-
pound activity. A continuous color spectrum is applied ranging from green (low
activity) over yellow (moderate activity) to red (high activity). Furthermore,
nodes are scaled in size with respect to the local per-compound discontinuity
score (vide supra). Hence, large nodes correspond to compounds with high
discontinuity scores that are predominantly involved in activity cliff formation,
and thereby having significant contributions to the global discontinuity of the
underlying data set. An exemplary NSG illustrating different information lay-
ers is shown in Figure 1.5. It should be noted, that the topological arrangement
of individual compounds and clusters of compounds has no chemical meaning.
The node positions and the edge lengths are determined by a 2D force-directed
graph layout algorithm.48
NSGs are landscapes of conceptually different design compared to SAS
maps. Here, the focus is on elucidating how local SAR features relate to the
global SAR character of the data set. In NSGs, compound subsets (clusters)
having different local SAR phenotypes can be easily identified.47 For example,
clusters of similarly colored and sized nodes highlight regions that are continu-
ous in nature. On the contrary, groups of densely connected compounds that
18
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Figure 1.5: Network-like Similarity Graphs. A schematic illustration of a Network-
like Similarity Graph (NSG) and its major information layers are shown. Nodes represent
compounds and edges reflect structural similarity. In addition, compounds are color-coded
according to compound potency (red, high activity; yellow, moderate activity; green, low
activity). Furthermore, nodes are scaled to account for local discontinuity scores.
have different colors indicate the presence of local SAR discontinuity. Further-
more, centers of SAR discontinuity can be graphically assessed by selecting
large nodes (high local discontinuity score) having many structural neighbors
of varying color.
The landscape view provided by NSGs is rich in information layers account-
ing for different aspects related to global and local SAR characteristics. NSGs
are easy to comprehend and navigate, and present one of the most preferred
activity landscapes to rationalize SARs in data sets of various size and composi-
tion. NSGs have been mostly, but not exclusively, applied to explore compound
optimization data. However, the concept has also been successfully applied to
high-throughput screens (HTS) typically comprising very large sets of mainly
weakly potent compounds.49
Approaches to systematic SAR analysis often focus on target-specific com-
pound potency. In lead optimization campaigns, however, potency is only one
of several important factors to be considered. A promising drug candidate must
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show a desired selectivity profile against a number of targets. An increasing
amount of evidence suggests that selective drugs are more the exception rather
than the rule and that drugs tend to simultaneously interact with multiple bi-
ological targets.50 In this respect, selectivity is, in many instances, likely to
result from differences in compound potency against multiple targets, rather
than from exclusive binding to a single target. For compounds active against
multiple targets, the resulting multi-target SARs can be complex and difficult to
rationalize. However, they can ultimately reveal a different degree of compound
selectivity and hence visualization tools to support a systematic multi-target
SAR exploration and exploitation are of high interest. Selectivity NSGs51 pro-
vide a first step towards modification and adaptation of graphical representa-
tions to capture structure-selectivity relationships between compounds active
against two targets.
Activity Cliffs
Activity landscapes are designed to highlight SAR features and provide graph-
ical access to key compounds for further chemical exploration. Therefore,
the study of landscape models and their most prominent feature, the activ-
ity cliffs, are central themes in SAR analysis and medicinal chemistry. Activity
cliffs,21,44–46 as introduced above, are formed by two structurally similar com-
pounds having a large difference in potency. They represent the extreme form
of SAR discontinuity and are thought to be rich in SAR information.42 Accord-
ingly, their exploration is of prime interest in compound optimization efforts.
In the context of SAR analysis, graphical representations are powerful and
indispensable tools, and activity cliffs have mostly been studied using differ-
ent activity landscape models. The use of activity landscapes greatly benefits
from their simplicity, intuitiveness, and the ability to visually prioritize key
compounds that predominantly form cliffs.
To gauge the importance and relevance of cliffs in medicinal chemistry, activ-
ity cliffs and their distributions have been extensively studied through mining
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large databases such as ChEMBL52 and Binding DB,53 which represent two
major compound data sources for systematic large-scale SAR analysis.
Despite the increasing interest in activity cliff exploration, the definition of
activity cliffs is still a matter of debate, for understandable reasons. The two
major critical aspects of this formalism are the way the structural similarity is
assessed and the notion of “significant difference in potency”. Hence, prior to
the systematic assessment of cliffs, structural similarity and activity difference
criteria must be specified.
Undoubtedly, the most essential task is the assessment of chemical simi-
larity. Tanimoto similarity on the basis of different fingerprint representations
has been predominantly used. However, Tanimoto similarity is greatly influ-
enced by the molecular representations used. Hence, different distributions
could be obtained when different fingerprints are used as representations.46 To
circumvent these limitations, attempts have been made to replace the sub-
jective whole-molecule similarity evaluation by more structurally conservative
and, from a medicinal chemistry perspective, more chemically intuitive meth-
ods. Exemplary substructure-based representations include MMPs (vide supra)
and molecular scaffolds.
In addition, data variability also plays an important role in the identifica-
tion of activity cliffs. Care should be taken to restrict the analysis to only
high-confidence data. To these ends, different potency measurements such as
equilibrium constants Ki (i.e., theoretically assay-independent) and half maxi-
mal inhibitory concentration (IC50; assay-dependent) should be considered sep-
arately. Also, care should be taken when multiple potency measurements are
provided for a given compound and a target. In such cases, computing the
average, minimum or maximum can be considered as the final potency value
for the given compound. However, the choice of final annotation notably affects
activity cliff distributions, as it has been previously demonstrated.54
Activity Cliff Extensions
The concept of activity cliffs has become increasingly popular in medicinal
chemistry. The formalism has been extended in various ways to explore SAR
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determinants from different perspectives. Notable extensions are based on dif-
ferent molecular representations that enable assessing the cliff formation at
different structural levels. For example, based on the MMP formalism, the
notion of MMP-cliffs26 was introduced to limit the cliff analysis to only chem-
ically intuitive and accessible modifications. An MMP-cliff is defined by two
compounds that form a transformation size-restricted MMP26 and, in addition,
have significantly different potency. Typically 100-fold potency difference (cor-
responding to 2 orders of magnitude on a logarithmic scale) was considered as a
criterion for cliff formation. Transformation-size restricted MMPs ensure that
chemical modification distinguishing activity cliff compounds are small.26 An
exemplary MMP-cliff is shown on Figure 1.6b.
Recently, activity cliffs have also been defined using molecular scaffolds55
(obtained from compounds by removal of R-groups).56 On the basis of this
categorization, cliffs can be identified having different scaffold/R-group rela-
tionships. An R-group based cliff induced by different R-group replacements at
the same scaffold is shown in Figure 1.6c.
In general, activity cliffs are explored on a per-target basis. However, it has
been frequently observed that many bioactive compounds are active against two
or three targets. To these ends, selectivity cliffs51 were introduced to rationalize
dual-target activity (i.e., selectivity) relationships. Precisely, a selectivity cliff is
formed by two structurally similar compounds having significantly different ac-
tivity against their targets. Importantly, this concept represents a first attempt
towards multi-target activity cliff exploration. A representative selectivity cliff
is shown in Figure 1.6d.
The activity cliff concept has been extended in many different ways.26,51,56–58
On the basis of statistical analysis a generally preferred definition has been
proposed.59 Accordingly, cliff analysis should be confined to only size-restricted
MMP-cliffs with potency difference of at least two orders of magnitude. In ad-
dition, if available, only equilibrium constants should be considered as potency
measurements.
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Figure 1.6: Activity cliffs and activity cliff extensions. Shown is an exemplary ac-
tivity cliff (a) and three representative cliff extensions (b-d). In addition, structural changes
between cliff-forming compounds are color-coded and potency values are reported. In (d),
compound activity for two targets (cathepsin L and B) are provided. Selectivity scores (L/B)
are calculated as the potency difference against the target pair.
Thesis Outline
This work addresses major challenges in systematic SAR exploration in medic-
inal chemistry and pharmaceutical research. The main focal points have been
the design of novel activity landscape models and comprehensive activity cliff
analysis.
In this dissertation, eight representative studies are introduced and orga-
nized in individual chapters:
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• For compounds active against multiple targets, the resulting multi-target
SARs are complex and difficult to rationalize. To these ends, a first multi-
target activity landscape has been designed to capture multi-target SARs
and provide an intuitive graphical access to interesting compounds. The
methodology is reported in Chapter 2.
• Activity landscapes introduced in the previous chapter can be meaning-
fully applied to compounds active against limited number of target (3−5)
and are not suitable for compounds with activities against many targets
(50− 100). Chapter 3 introduces the ligand-target differentiation (LTD)
map – a first high-dimensional activity landscape model to navigate high-
dimensional activity spaces.
• Activity cliffs have been extensively studied, however, it has been un-
known how cliffs are distributed in publicly available compounds databases.
Chapter 4 investigates the distribution, directionality, and the statistical
significance of single- and multi-target activity cliffs formed by currently
available bioactive compounds.
• It is well-appreciated that different molecular representations (e.g., molec-
ular fingerprints) inevitably change the numerical assessment of structural
similarity, and therefore also the SARs contained in compound data sets.
Chapter 5 addresses the influence of representative fingerprints on the
SAR information content associated with individual compounds
• Activity cliffs have been studied from many different perspectives. Never-
theless, thus far their utility to aid in the compound optimization efforts
has not been systematically analyzed. Chapter 6 introduces the concept
of compound pathway models to evaluate the SAR information gain pro-
vided by activity cliffs.
• Activity cliffs are thought to contain high SAR information content, thereby
providing starting points for further chemical exploration. Chapter 7 ad-
dresses, from a chemoinformatics perspective, the relevance and utiliza-
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tion of the activity cliff concept in medicinal chemistry, and its ability to
support medicinal chemistry optimization campaigns.
• Recent statistical studies46,60 report that the majority of activity cliffs are
formed in a coordinated manner and involve multiple active compounds
and cliffs. Chapter 8 describes the topology, composition and frequency
of occurrence of coordinated cliffs formed by currently available bioactive
compounds. Moreover, recurrent topologies are identified and analyzed.
• Chapter 9 reports an extension of the activity cliff concept to capture
structure-promiscuity relationships. Furthermore, chemical changes were
identified that led to large-magnitude promiscuity effects.
Finally, major findings and key observations of the work presented in this dis-
sertation are summarized and discussed in Chapter 10.
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Chapter 2
Design of Multi-Target Activity
Landscapes That Capture
Hierarchical Activity Cliff
Distributions
Introduction
Understanding SAR characteristics of bioactive compounds is a central task in
medicinal chemistry and pharmaceutical research. To facilitate SAR analysis,
different activity landscape models have been developed. Regardless of their
methodological differences, these methods focus only on a single or at most
two targets, in the latter case giving rise to selectivity landscapes. The design
of landscape representations for compounds active against multiple targets is
a challenging and, as of yet, unsolved task. In this work, a first multi-target
activity landscape approach is introduced that is based on a numerical encoding
scheme of activity profiles. The model facilitates the identification and selection
of compounds, or groups of compounds, involved in multi-target activity cliffs.
Furthermore, the contribution of individual compounds to global multi-target
SARs can be monitored.
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ABSTRACT: An activity landscape model of a compound data set can be rationalized
as a graphical representation that integrates molecular similarity and potency relation-
ships. Activity landscape representations of different design are utilized to aid in the
analysis of structure-activity relationships and the selection of informative compounds.
Activity landscapemodels reported thus far focus on a single target (i.e., a single biological
activity) or at most two targets, giving rise to selectivity landscapes. For compounds
active against more than two targets, landscapes representing multitarget activities are
difficult to conceptualize and have not yet been reported. Herein, we present a first
activity landscape design that integrates compound potency relationships across multiple
targets in a formally consistent manner. These multitarget activity landscapes are based
on a general activity cliff classification scheme and are visualized in graph representations,
where activity cliffs are represented as edges. Furthermore, the contributions of individual
compounds to structure-activity relationship discontinuity across multiple targets are
monitored. The methodology has been applied to derive multitarget activity landscapes for compound data sets active against
different target families. The resulting landscapes identify single-, dual-, and triple-target activity cliffs and reveal the presence of
hierarchical cliff distributions. From these multitarget activity landscapes, compounds forming complex activity cliffs can be readily
selected.
’ INTRODUCTION
The concept of activity landscapes provides the basis for a
comprehensive analysis of structure-activity relationships con-
tained in large compound sets.1 For example, activity landscape
models aid in the rationalization of global and local SAR features
and the selection of compounds for chemical exploration.1 Acti-
vity landscapes are generally defined as representations that
integrate structure and potency relationships between com-
pounds having the same biological activity.2 As such, activity
landscapes can be represented in rather different ways, ranging
from simple 2-D plots that compare the structural and activity
similarity between data set compounds in a pairwise manner3 and
potency-annotated molecular network representations4,5 to de-
tailed 3-D landscape views.6 In such 3-D activity landscape
models, an interpolated potency surface is added to a 2-D
projection of chemical reference space as the third dimension,6
giving rise to landscapes that are reminiscent of topographical
maps.2,7
Regardless of the specifics of different activity landscape
representations, the assessment of pairwise molecular similarity
relationships is a key element of landscape design. It has been
shown that chosen molecular representations for similarity
evaluation very often influence the topology of landscape
models.6,8 The most prominent features of activity landscapes,
however they might be represented, are activity cliffs that are
formed by pairs or groups of structurally similar compounds, for
example, analog series, with large differences in potency.2,9
Regions spanning multiple activity cliffs are rich in SAR informa-
tion content and represent primary focal points of landscape
analysis.
Although a common feature of most activity landscape
representations reported thus far is that they focus on activity
against a single target, there are no principal reasons to limit
activity landscape modeling to individual targets. However, only
very few studies have considered two biological activities of
compounds for the generation of activity landscapes. Recently,
an extension of the activity landscape concept has been intro-
duced, where potency ratios for compounds active against two
targets have been utilized instead of single-target compound
potency values.10 The use of potency ratios (or logarithmic
potency differences) to annotate similarity-based compound
networks is straightforward, giving rise to selectivity landscapes
and the notion of selectivity cliffs that are formed by similar
compounds having significantly different potency against the two
targets.10 Comparisons of dual-target activity landscapes have
also been carried out in a pairwise manner for analog series with
activity annotations against three targets (i.e., yielding three
pairwise landscape representations).11 In this case, insights into
complex SARs of compound series could be obtained by
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comparing corresponding regions in target-pair landscape
models.11
Going beyond target-pair landscapes and selectivity cliffs, a
currently unsolved problem is the generation of an activity
landscape framework for multiple targets. Generating multitarget
activity landscapes would be relevant, for example, for the study
of ligands active against different members of protein families or
polypharmacological targets. However, activity landscape repre-
sentations for compounds active against three or more targets
cannot be obtained on the basis of currently available models,
and new design concepts are required. Herein, we report a
methodology to derive and visualize multitarget activity land-
scapes and analyze activity cliff distributions. As an exemplary
application, the approach is utilized to characterize compound
data sets active against members of different target families.
’MATERIALS AND METHODS
Potency Binning and Encoding. A three-level scheme is
applied for encoding compound activity profiles.
(1) Potency values are assigned to three different ranges
(bins) in order to classify compounds as weakly potent
(pKi e 5), moderately potent (pKi > 5 and pKi e 7), or
highly potent (pKi > 7). Hence, a compound is considered
weakly potent against a given target if its potency is less
than or equal to 10 μM,moderately potent if its potency is
greater than 10 μM but lower than or equal to 100 nM,
and highly potent if its potency is higher than 100 nM
(these potency intervals can be adjusted for different
applications).
(2) Weakly potent compounds are assigned the ternary digit
“0”, moderately potent the digit “1”, and highly potent the
digit “2”. These potency bin values define a ternary
numeral system. A ternary numeral system represents
numeric values using only the digits 0, 1, and 2. To
simplify the notation, we denote a ternary number v of a
length n by a sequence of ternary digits of length n, i.e.,v =
v1...vn with vi ∈ {0,1,2} for all 1 e i e n.
(3) The activity profile of a compound active against n targets
is uniquely mapped to a ternary number of length n. For a
given ternary number v and number of targets n, we
denote by [v]i the ternary digit at position i in v. This
ternary number can also be converted into a decimal code
that serves as a compound label defining its multitarget
activity profile.
Figure 1 illustrates our three-level potency classification and
encoding scheme.
Multitarget Graphs. For graphical representations of multi-
target activity landscapes, we have modified and further extended
the network-like similarity graph (NSG) data structure,5 a JAVA
implementation that is publicly available as part of the SARANEA
program suite.12 For multitarget landscape displays, this similarity-
based compound network was annotated with compound activ-
ity profiles. For visualization, a layout algorithm13 is applied that
places groups of densely connected vertices in close vicinity,
while separating weakly connected regions of the graph from
Figure 1. Generation and encoding of compound activity profiles. The
schematic illustration summarizes the steps involved in converting
compound potencies against multiple targets into activity profiles and
representing these activity profiles as ternary numbers (or correspond-
ing optional decimal codes). Ternary (or decimal) codes are used as
node labels in the multitarget activity landscape representations.
Figure 2. Activity landscape representation. The design of multitarget
activity landscapes and the components and information layers of these
network-like graphs are schematically illustrated.
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each other. Multitarget graphs are interactively navigated. They
can be zoomed and edited, and nodes are graphically associated
with compound structures (a structure is displayed when the
cursor is placed on a node). The data structure can also be
systematically searched for structural relationships or activity
cliffs.
Figure 2 summarizes the design elements of these multitarget
graphs. Compounds are represented as nodes that are connected
by type-1 edges if their pairwise structural similarity, calculated as
Tanimoto similarity for ECFP4 fingerprints,14 exceeds a thresh-
old of 0.4. Nodes are labeled with ternary (or decimal) codes that
represent their activity profiles and are color-coded to highlight
selected profiles: compounds highly potent against only one,
two, three, or four targets are colored green, blue, red, and purple,
respectively, and compounds with intermediate potency against
all targets are colored light gray. All compounds with potency
profiles different from these four categories (i.e., different com-
binations of moderate and/or low potencies) are colored yellow.
Nodes are scaled in size according to a multitarget discontinuity
score (as described below) such that large nodes represent high
discontinuity score values. Single-target and multitarget activity
cliffs formed by pairs of compounds are identified by type-2
edges, i.e., an edge is drawn between two compounds if they form
an activity cliff. Single-target and multiple target activity cliffs are
selectively displayed.
Multitarget Discontinuity Score. A multitarget discontinu-
ity score (mtDiscScore) is defined to quantitatively account for
the degree of multitarget SAR discontinuity that an individual
compound introduces in the activity landscape. This score is a
variant of the SAR Index per-compound discontinuity score we
previously introduced.5 For conventional single-target activity
landscapes, the per-compound discontinuity scores identifies
compounds that have large potency deviations from their
immediate structural neighbors. Here, the mtDiscScore is de-
fined in analogy to the per-compound discontinuity score. Thus,
the mtDiscScore quantitatively compares potency differences
across multiple targets for each data set compound with its
structural neighbors in a pairwise manner. Formally, let n be the
number of targets. Two compounds are considered similar if
their ECFP4 value is greater than 0.4. For every compound c we
define the set N(c) as the set of all structural neighbors.
Furthermore, let |N(c)| = m. For a ligand c, we define [c]i as
the potency value of c against target i. Then the mtDiscScore is
defined as
mtDiscScorerawðcÞ ¼ 1n 3m
X
c0∈NðcÞsimðc, c0Þ>0:4
Xn
i¼1
j½ci
-½c0ij 3 simðc, c0Þ
The raw scores are standardized on the basis of Z-score
calculations including all compounds in a data set and normalized
by calculating the cumulative probability for a normal distribu-
tion, yielding final scores falling into the range [0,1].
Given this formalism, a compound makes large contributions
to multitarget SAR discontinuity (and achieves a high score) if it
has many structural neighbors with different potency profiles.
Data Sets. For the introduction of multitarget activity land-
scapes, we selected four compound data sets from ChEMBL15
with (antagonistic or inhibitory) activity against three or four
targets belonging to four different families, i.e., adenosine
receptors (AR), monoamine transporters (MT), opioid recep-
tors (OR), and carbonic anhydrases (CA). The composition of
these compound sets is summarized in Table 1. Only potency
measurements were selected with the highest target confidence
level (i.e., target confidence score 9) for direct interactions (i.e.,
target relationship type “D”). Potency measurements containing
threshold values (i.e., reported as > or <) were not considered.
For compounds with multiple potency values reported against
the same target, the arithmetic mean was calculated to yield the
final potency.
’RESULTS AND DISCUSSION
Activity Landscape Design Principles and Applications.
The generation of activity landscape models generally requires
the integration of compound similarity and potency relation-
ships. Assessing similarity relationships is independent of the
number of targets and a constant for different landscape models
representing the same data set. Conventional single-target activ-
ity landscapes are utilized to extract SAR information from
compound data sets and identify prominent activity cliffs, i.e.,
structurally similar compounds having large potency differences.
The major challenge of multitarget activity landscape design is
how to combine compound potency relationships for several
targets and best represent activity profiles. For two targets, this
can be accomplished by assigning potency ratios to compounds
instead of individual potency values. However, for more than two
targets, this simple approach is no longer feasible and different
data structures are required. For this purpose, we introduce
herein a multitarget potency encoding scheme that is based on a
ternary numeral system.
The representation of multitarget activity landscapes does not
only provide a methodological challenge, but is also of practical
relevance for pharmaceutical research. For example, in order to
selectively optimize compounds against an individual target
compared to closely related ones, multitarget landscapes provide
an access to multitarget activity cliffs, their most prominent
features. A multitarget activity cliff is formed by compounds
with differential potency against two or more targets. Com-
pounds forming such cliffs are most likely to provide information
about structural modifications that change compound potency
against two or more targets in either the same or opposite
directions. This information would be valuable to guide selective
Table 1. Compound Data Setsa
set activity no. of compounds no. of targets targets
AR adenosine receptor antagonists 342 3 adenosine receptors A1, A2a, A3
MT monoamine transporter inhibitors 299 3 dopamine (DA), norepinephrine (NE), serotonin (5HT) transporters
OR opioid receptor antagonists 98 4 δ-, κ-, μ-opioid receptor, nociceptin (O) receptor
CA carbonic anhydrase (CA) inhibitors 96 4 carbonic anhydrases 1, 2, 9, 12
a Four compound data sets were collected from ChEMBL. For each set, the specific activity (activity), number of antagonists or inhibitors (no. of
compounds), number of targets (no. of targets), and target names (targets) are reported.
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optimization efforts. In multitarget landscapes, as introduced
herein, compounds forming such cliffs are readily identified, and
their potency profiles can then be directly compared.
Activity Profile Encoding. By classifying compounds as
weakly (“0”), moderately (“1”), or highly potent (“2”), we
encode multitarget activity profiles as ternary numbers, e.g.,
“121” for three or “0112” for four targets. Applying this simple
formalism, each possible compound activity profile is uniquely
encoded. The activity profiles can be systematically organized in
different ways. For example, in Figure 3, activity profiles are
arranged on the basis of high compound potency against one to
three (Figure 3a) or one to four (Figure 3b) targets, which is a
prerequisite for the systematic organization of all theoretically
possible activity cliffs, as discussed in the following section. The
top level in these graphs represents activity profiles of compounds
that do not have high potency against any target, the second level
compounds with high potency against only one target, the third
level compounds with high potency against two targets, and so on.
Activity Cliff Organization. On the basis of our encoding
scheme, we define that an activity cliff is formed by any pair of
compounds representing a “2-0” potency combination against
any target, i.e., a cliff is formed by one compound with high and
one with low potency. Hence, for compounds with activity
against three targets, we can formally distinguish between
single-, dual-, and triple-target activity cliffs, and for compounds
active against four targets, quadruple-target activity cliffs can in
principle also be formed. In Figure 3a, all possible activity profiles
for highly potent compounds and three or four targets are
reported that can participate in the formation of activity cliffs.
For three and four targets, there are a total of 7 and 15 high-
potency profile categories, respectively, that can form activity
cliffs. In Figure 3a, the ternary codes of activity profiles repre-
senting each type are also provided. These activity profiles can be
systematically paired with “0”-containing profiles to yield the
theoretically possible numbers of single- and multiple-target
activity cliffs. It should be noted that compounds with moderate
potency against all targets cannot participate in the formation of
activity cliffs. The corresponding activity profiles for three and
four targets are “111” and “1111”, respectively.
We have calculated the numbers of all principally possible
single- and multiple-target activity cliffs that result from unique
profile combinations. For three targets, there are 147, 42, and 4
different types of single-, dual-, and triple-target activity cliffs
possible, respectively. For four targets, the corresponding numbers
are 1372 single-, 588 dual-, and 112 triple-target cliffs. In addition, in
this case, 16 types of quadruple-target cliffs could be formed. Each of
these potential activity cliffs is identified by a unique code combina-
tion. For example, activity profile “222” (representing compounds
with high potency against three targets) forms a single-target activity
cliff with profile “201”.
For three or four targets, ternary numbers might be directly
used as node labels. If more target annotations would be
available, ternary codes might become too large, and hence, they
could be transformed into shorter decimal codes for visualization
(as illustrated in Figure 1), for example, using “16” instead of
“121” or “14” for “0112”. Decimal codes are less intuitive than
ternary numbers, but can be interpreted, for example, with the
help of a conversion table.
Multitarget Activity Landscapes. In Figure 4, the multi-
target graph for theMT compound set is shown. For the descrip-
tion and interpretation of our multitarget activity landscape
design, we focus on the MT compound set in the text and pro-
vide corresponding representations for the three other data sets
in the Supporting Information. Figure S1 of the Supporting
Information shows the multitarget graphs for the AR, OR, and
CA sets. In addition, for the four-target CA set, a graph with
decimal node labels is also shown for comparison to illustrate the
decimal coding scheme. Detailed descriptions of the graphs of
these three data sets are provided in the Results section of the
Supporting Information. In all graph representations, type-1
edges indicating pairwise compound similarity relationships are
not displayed for clarity.
The MT inhibitor landscape displays extensive clustering of
compound subsets, revealing regions with densely packed nodes
that are separated from other clusters. In many cases, compounds
in individual clusters have similar activity profiles, i.e., they have
the same node color and the same or similar codes. The presence
of similar activity profiles would be expected for compounds that
are active against closely related targets. Several clusters of
structurally similar compounds are observed that include pre-
dominantly highly potent (red; code 222) or weakly potent
(yellow; code 000) compounds. Furthermore, the graph contains
Figure 3. Activity profiles. Shown is the formal organization of activity
profiles containing highly potent compounds for (a) three and (b) four
targets. Asterisks indicate ternary digits of either 0 or 1. In (a), sets of all
ternary numbers covered by the generic profiles are shown as gray tags.
The colors correspond to the node coloring scheme introduced for
multitarget activity landscapes. This organization scheme provides a
basis for the systematic enumeration of all principally possible single-
target and multitarget activity cliffs and specification of different activity
cliff types using decimal code combinations.
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numerous gray nodes (code 111), representing compounds of
consistently moderate potency against multiple targets that
cannot form activity cliffs according to our classification scheme.
However, the MT activity landscape also reveals clusters that
are rich in differently colored nodes representing compounds
with different activity profiles. Selected clusters characterized by
the presence of rather different activity profiles are encircled in
Figure 4. Such regions of heterogeneous node composition are
prime candidates for activity cliff formation. Furthermore, the
graph contains many differently sized nodes that indicate differ-
ent compound contributions tomultitarget SAR discontinuity, as
discussed below.
Activity Cliff Distribution. We next identified activity cliffs
contained in all four data sets. The activity cliff distributions are
reported in Table 2. In the AR, MT, and OR sets, single- and
dual-target cliffs were detected, and in the CA set, single-, dual-,
and triple-target cliffs were identified. The activity cliffs were
unevenly distributed. For each data set, they involved different
target combinations, and not all targets were involved in the
formation of cliffs. For AR, MT, OR, and CA, 121, 32, 54, and 49
single-target cliffs were found and 9, 5, 4, and 16 dual-target cliffs,
respectively. In addition, for CA, 15 triple-target cliffs were
identified. Thus, multitarget activity cliffs were more sparsely
distributed than single-target cliffs in these compounds sets
directed at closely related members of different protein families.
We also found that certain activity profiles were more frequently
involved in activity cliff formation than others, and consequently,
some activity cliff types were preferentially formed. Table 2
reports the three most frequently occurring activity cliff types for
Figure 4. Multitarget graph. Shown is the multitarget activity landscape representation for the MT compound data set. Selected clusters are encircled
and shown in detail in Figure 5.
Table 2. Activity Cliff Statisticsa
activity cliff distribution
set stc dtc ttc type count degree
AR 121 9 0 212-002 84 single
222- 102 15 single
222-002 9 dual
MT 32 5 0 112-000 9 single
122-120 7 single
122-020 7 single
OR 54 4 0 2112-0001 26 single
2112-0011 19 single
2122-0001 4 dual
CA 49 16 15 2222-1012 14 single
2222-0002 11 triple
2122-0002 8 dual
a Four each compound data set, the number of single- (stc), dual- (dtc),
and triple-target activity cliffs (ttc) is reported. In addition, “activity cliff
distribution” reports the three most frequently occurring activity cliff
types for each data set, and “degree” identifies single-, dual-, or triple-
target cliffs.
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each data set. Certain activity cliff types occurred with higher
frequency than others, and frequent activity cliffs varied in a data
set-specific manner.
Activity Cliff Patterns. We then identified compound clus-
ters in the different data sets where activity cliffs mostly occurred.
Figure 5 shows enlarged clusters from the multitarget graph of the
MTdata set (encircled in Figure 4) that contain single- (Figure 5a)
and dual-target cliffs (Figure 5b). In addition, Figure S2 of the
Supporting Information shows activity cliff-containing clusters for
the other compound sets. In these representations, type-2 edges
are displayed, each of which marks an activity cliff. For each data
set, single-target activity cliffs involving an exemplary target are
shown, and activity cliff views involving the remaining targets are
provided in Figure S3 of the Supporting Information. For the AR,
OR, and CA sets, detailed descriptions are given in the Results
section of the Supporting Information. We generally observe that
compounds have very different node sizes according tomultitarget
discontinuity scoring. In conventional single-target landscapes,
compounds with large nodes typically have a potency that
significantly differs from their structural neighbors, introduce local
SAR discontinuity, and are most frequently involved in the
formation of activity cliffs.5 However, in multitarget landscapes,
SAR discontinuity is a much more complex phenomenon because
of the many different potency relationships that can result from
comparisons ofmultitarget activity profiles. A characteristic feature
of the activity cliff distributions in Figure 5 and Figure S2 of the
Supporting Information is that compounds with large nodes (i.e.,
compounds that introduce notable multitarget SAR discontinuity)
are often not involved in the formation of well-defined activity
cliffs, but that cliffs are also formed by compounds having rather
different node sizes. Thus, in multitarget activity landscapes, the
introduction of SAR discontinuity and the formation of large-
magnitude activity cliffs do not necessarily correlate because of the
complexity of potency relationships between compounds active
against multiple targets. However, similar to single-target land-
scapes, key compounds also emerge that make large contributions
to multitarget SAR discontinuity and form multiple activity cliffs.
For example, in the most densely connected region of the CA data
set, the only compound set where triple-target cliffs were detected,
overlapping yet distinct subsets of nodes form dual- (Figure S2f of
the Supporting Information) and triple-target activity cliffs (Figure
S2g of the Supporting Information). Most triple-target cliffs are
formed by three large purple nodes and one large red node (code
2221) that also participate in the formation of dual-target cliffs.
These compounds form prominent activity cliffs and, together
with surrounding green nodes (code 0002 and 1002), make large
contributions to SAR discontinuity. Furthermore, in the MT data
set, a cluster is identified (cluster 3 in Figure 5b) where all
compounds make large contributions to SAR discontinuity. Here,
a compound represented by a blue node (code 221) forms three
dual-target cliffs with different weakly potent compounds (code
000).
Such compounds that make large contributions to multitarget
SAR discontinuity and also form prominent activity cliffs are a
key component of multitarget activity landscapes and prime
candidates for the exploration of multitarget SAR determinants.
The analysis of structural features that distinguish these activity
cliff markers and their activity profiles from each other, as
discussed below, is of high relevance for practical applications.
Interpretation of Exemplary Activity Cliffs. Compounds
forming exemplary single- and dual-target activity cliffs in theMT
data set are shown in Figure 6, and compounds forming prom-
inent activity cliffs in the other compound sets are reported in
Figure S4 of the Supporting Information. In Figure 6a, exemplary
MT single- and dual-target activity cliffs are displayed. The
compound pair on the left forms a single-target cliff. Comparing
the structures, it is evident that the removal of a carboxyl group
renders a compound highly potent against all three transporters
and hence nonselective. By contrast, the analogue containing the
carboxyl group is selective for 5HT over DA and, to a lesser
extent, NE. The compound pair on the right forms a dual-target
cliff. Here, the replacement of an N-substituted piperidine ring
with a chemically more complex seven-membered heteroalipha-
tic ring system leads to a significant change in the activity profile
Figure 5. Compound clusters forming activity cliffs. For the MT data
set, compound clusters are displayed where prominent single- or dual-
target cliffs are formed. In (a), single-target cliffs are reported for the
dopamine transporter, and in (b), dual-target cliffs are reported for the
norepinephrine and serotonin transporter. Selected activity cliffs are
highlighted, and the structures of the corresponding compounds and
further details are shown in Figure 6.
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and is responsible for high potency against all three transporters.
In Figure 6b, the key compound from cluster 4 in Figure 5b is
shown (blue node, code 221) that is involved in the formation of
three dual-target activity cliffs together with its cliff partners. Also
shown are the four remaining compounds from this cluster that
are moderately potent against NE and 5HT or only 5HT and not
involved in the formation of activity cliffs. This compound series
contains a conserved thiophene ring and a differently substituted
naphthalene moiety. Comparing the structures of analogs in-
volved in the formation of dual-target cliffs, it is evident that the
weakly potent compounds differ from the highly potent one by
two features, including single or dual hydroxyl (or hydroxyl and
ether) substituents at the naphthalene ring and, in addition,
different chirality of a carbon atom of the “ether bridge” connect-
ing the naphthalene and thiophene moieties. Thus, by only
comparing these four analogs, it cannot be concluded with
certainty which structural changes might be responsible for the
dramatic reduction in potency against all three transporters,
leading to the formation of dual-target cliffs. However, by
inspecting the structures of compounds in the vicinity of these
activity cliffs it becomes clear that the chiral center plays a major
role. All consistently weakly, or weakly and moderately, potent
compounds from this cluster display the same chirality, and one
of these compounds is the exact enantiomer of the potent key
Figure 6. Exemplary activity cliffs. (a) Structures, node combinations, and activity profiles are shown for compounds forming representative single- and
dual-target activity cliffs in theMT compound set. Target and activity cliff degree abbreviations are according to Table 1 and Table 2, respectively. (b) A
compound involved in the formation of three dual target activity cliffs and its partner compounds are shown (see cluster 4 in Figures 4 and 5b). In
addition, structures of compounds in the vicinity of these cliffs are also shown. The stereocenters of the two enantiomers with codes “221” and “110” are
highlighted.
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compound represented by the blue node. Comparing the activity
profiles of these enantiomers and other compounds in the
cluster, further conclusions can be drawn. The code of the highly
potent enantiomer is “221”, and the code of the weakly potent
one is “110”. Thus, it appears that the stereochemical switch leads
to a general reduction in potency against all three transporters,
whereas hydrophilic substitutions at the naphthalene ring further
reduce potency in a transporter-selective manner. Thus, the
analysis of this activity cliff region alone in the MT data set
provides helpful information about the multitarget structure-
activity relationships of these compounds. We would conclude
that hydrophilic substitutions of the high-potency “221” enan-
tiomer might be a promising route to generate analogs with
differentiated MT activity profiles. The identification of key
compounds that provide interpretable structure-activity profile
relationship information represents a prime application for
multitarget activity landscape models, as introduced herein.
Concluding Remarks. Activity landscape models of com-
pound data sets are obtained on the basis of systematic compar-
isons of structural and potency relationships. Landscape models
are useful computational tools for the study of SAR features
contained in compound sets and the identification of key
compounds that determine local or global SAR characteristics.1,2
For compounds active against an individual target, the generation
and analysis of activity landscapes is straightforward, and differ-
ent types of 2-D and 3-D representations of varying complexity
have been introduced.2 For compounds active against two
targets, selectivity landscapes have also been generated. How-
ever, the design of multitarget activity landscapes is difficult to
conceptualize and has remained an unsolved problem as of yet.
Herein, we have introduced a first approach to construct multi-
target activity landscapes that is based on a numerical encoding
scheme of compound activity profiles derived from potency
values against multiple targets. On the basis of systematic activity
profile comparisons, we have derived a generally applicable
formal organization of single-target and multitarget activity cliffs.
The multitarget landscapes are displayed using a modified and
extended version of network-like similarity graphs. In these
representations, single-target and multitarget activity cliffs are
easily identified. They are also formally defined by ternary code
signatures that can be utilized for systematic mining of the data
structure. Our multitarget activity landscape approach has been
applied to characterize four compound data sets directed against
three or four members of different target families. Compounds
with confirmed activity annotations against more than four
targets were difficult to find in public domain sources. As one
might expect, compounds active against closely related protein
family members often had similar activity profiles, and conse-
quently, multitarget activity cliffs were generally more sparsely
distributed than single-target cliffs. However, dual- or triple-
target activity cliffs were readily identified in the activity land-
scapes of different data sets. In a number of instances, multitarget
activity cliffs were centered on small sets of compounds that
formed complex cliff patterns in multitarget graphs. The multi-
target activity landscape approach and activity cliff hierarchy
introduced herein is thought to provide a basis for the analysis of
complex activity landscapes.
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CHAPTER 2: SUMMARY
Summary
A first multi-target activity landscape was developed by modifying and fur-
ther extending the NSG data structure to capture compounds active against
multiple targets. Based on a numerical encoding scheme and systematic ac-
tivity profile comparisons, a hierarchical organization of multi-target activity
cliffs was derived. The approach was applied to characterize compounds ac-
tive against three or four closely related targets belonging to the same target
family. Accordingly, the majority of the activity cliffs were single-target cliffs.
However, dual- and triple-target cliffs were also detected. My contribution to
this work has been the design and analysis of the activity landscape model.
The landscape model introduced herein is in principle not limited in the
number of targets. However, high-dimensional activity spaces (e.g., defined by
compound activity annotations against more than 50 targets) can be difficult to
navigate and comprehend using network representations. In the next study, we
have introduced a first high-dimensional activity landscape that greatly reduces
the complexity of bioactivity spaces and accounts for complex ligand-target
relationships.
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Chapter 3
Navigating High-Dimensional
Activity Landscapes: Design and
Application of the Ligand-Target
Differentiation Map
Introduction
A major limitation for the design and development of activity landscapes for
high-dimensional activity spaces has been the lack of publicly available profiling
data. Such bioactivity spaces represent indispensable sources of activity data for
pharmaceutical research, however, they are difficult to navigate and rationalize.
In the following study, a first high-dimensional activity landscape, the ligand-
target differentiation (LTD) map, will be introduced. Using a publicly available
subset of 1496 kinase inhibitors with activity data for 172 kinases1 the utility
of the LTD mapto capture complex ligand-target relationships and deconvolute
compound activity patterns will be demonstrated.
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ABSTRACT: The transformation of high-dimensional bioactivity spaces into activity landscape
representations is as of yet an unsolved problem in computational medicinal chemistry. High-
dimensional activity spaces result from the experimental evaluation of compound sets on large
numbers of targets. We introduce a first concept to represent and navigate high-dimensional activity
landscapes that is based on a data structure termed ligand-target differentiation (LTD) map. This
approach is designed to reduce the complexity of high-dimensional bioactivity spaces and enable the
identification and further analysis of compound subsets with interesting activity and structural
relationships. Its utility has been demonstrated using a set of more than 1400 inhibitors with exact
activity measurements for varying numbers of 172 kinases.
1. INTRODUCTION
The experimental evaluation of compounds on arrays of
biological targets, often referred to as compound profiling, has
become an important source of activity data for pharmaceutical
research and chemical biology.1 Compound profiling is often
carried out for major therapeutic target families such as G
protein coupled receptors2 or protein kinases.3 In profiling
campaigns, structurally diverse or, alternatively, focused
compound collections are screened against varying numbers
of targets. This is often (but not always) done for targets
providing a representative subset of a given family. The
resulting profiling data constitute high-dimensional bioactivity
spaces, which are generally difficult to represent and navigate.4
However, in such activity spaces, ligand-binding profiles of
targets, compound activity patterns, and ligand-target relation-
ships can be explored. Furthermore, it might be attempted to
identify chemical probes that differentiate between related
targets4 or prioritize compounds for further chemical
exploration and discovery efforts.3
On the basis of the activity landscape concept,5,6
representations of activity spaces are often generated by
integrating structure and activity relationships between sets of
compounds.6 Activity landscapes provide an intuitive access to
structure−activity relationship (SAR) information but are
usually focused on a specific biological activity, i.e., a single
target. However, the activity landscape concept has also been
extended to pairs of targets7 or more than two targets8 in order
to explore the target selectivity of active compounds or the
formation of multi-target activity cliffs.9 Only recently, multi-
target activity landscape representations have been introduced,
including annotated molecular networks, the original multi-
target landscape design,8 structural similarity and activity
similarity difference maps that utilize plots of compound
activity versus structural similarity,10 and a landscape layout
based on self-organizing maps to group structurally similar
compounds together and encode their activity relationships.11
However, in these representations, activities against only a few
targets (e.g., three or four) can be captured in a meaningful and
interpretable way. The representation of high-dimensional
activity spaces (e.g., involving 50, 100, or more targets) in an
activity landscape format has thus far not been reported.
The design of high-dimensional activity landscapes has been
hampered by the limited availability of compound profiling data
in the public domain. Although a number of pharmaceutical
companies have already generated large bodies of profiling data
for popular therapeutic targets, most of this data is kept
proprietary, for understandable reasons. A notable exception
has been a recent study by a group from Abbott Laboratories.12
For the generation of kinase interaction networks and the
exploration of polypharmacology patterns, a total of 3858
compounds were tested against varying numbers of 172 kinases
representing a diverse sample of the kinome.12 As a part of this
investigation, structures and activity data for a subset of 1496 of
these compounds were made publicly available, hence
providing a significant source of profiling data for further
studies. Using this data set, we have developed and applied a
first concept for the design and analysis of high-dimensional
activity landscapes that is reported herein.
2. ACTIVITY DATA
From the publicly released Abbott data set, all compounds with
unique 2D molecular representations13 were extracted for
which a Ki value for at least one kinase was available, leading to
the selection of 1473 compounds. These compounds were
annotated with pKi values for one to 122 kinases. The activity
annotations included all 172 kinases investigated in the Abbott
study. A maximum of 101 kinases were shared between
individual compounds. In our analysis, only absolute equili-
brium constants were considered as activity measurements and
threshold measurements were ignored. For activity landscape
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design, this data set presented a challenging test case because
the underlying profiling matrix was high-dimensional yet
incomplete, i.e., compounds were assayed against varying
numbers of targets and activity profiles only partly overlapped
in many instances. The activity profile of a compound consists
of all of its target annotations.
3. LIGAND-TARGET DIFFERENTIATION MAP
On the basis of our evaluation, annotated molecular network
representations, which were previously utilized for the
generation of single- and multi-target activity landscapes, were
not suitable for capturing and representing high-dimensional
activity spaces. The design of high-dimensional activity
landscapes presents challenges that go beyond the analysis of
single-target SARs6 or multi-target SAR discontinuity pat-
terns.6,8 In particular, ligand-target relationships need to be
systematically explored and compared in light of structural
features of active compounds. Therefore, it was required to
investigate new representation concepts. In the following, the
basic design principles of the Ligand-Target Differentiation
(LTD) map, our central data structure for high-dimensional
activity landscape analysis, and its elements are discussed. In
addition, the extraction of compound and activity information
from the map is illustrated.
3.1. Design Concept. As an activity landscape representa-
tion, the LTD map must systematically account for compound
potency and similarity relationships in high-dimensional data
sets. A major goal of such representations is to provide
complete coverage of experimental data. For the analysis of
compound profiling data, it must be considered that high-
dimensional matrices are often incomplete. Hence, the
graphical data structure must be flexible and capable of
capturing profiling matrices of different composition.
Figure 1 shows a schematic representation of an LTD map to
illustrate its design principles. The LTD map is based on four
general principles:
(1) The basic unit of the data structure is a compound pair.
(2) Compounds are differentiated according to the number
of targets they share.
(3) Compounds are further differentiated according to their
activity differences against these targets.
(4) Structural relationships between all molecules are
monitored.
Accordingly, all pairwise target, activity profile, and structural
relationships between active compounds are initially deter-
mined. The LTD map then relates the number of targets shared
by any pair of compounds to the number of targets against
which these two compounds display significant differences in
potency using a “unit cell” as its basic data element. In our
analysis, the threshold for the potency difference between
compounds in a pair against a common target is set to 1 order
of magnitude (a flexible criterion, depending on data set
characteristics). The relative frequencies of detected target and
structural relationships are then captured through color coding
and map annotation. Figure 1 summarizes the basic elements of
the LTD map, and Figure 2 shows the LTD map representation
of the entire kinase inhibitor data set, as further discussed in the
following.
3.2. Elements of Graphical Representation. In the map,
a unit cell is represented as a square. The constant dimensions
of a unit cell in Figure 2 are five by five. The numbers of shared
targets and shared targets with more than an order of
magnitude potency difference are reported along the x-axis
and the y-axis, respectively. The LTD map thus consists of an
array of squares that account for all pairwise target and potency
difference relationships in a data set and span the entire ranges.
The number of compound pairs falling into each cell is
Figure 1. Design principles of the ligand-target differentiation map. The schematic illustration summarizes the basic design elements of the ligand-
target differentiation map. Unit cells have constant dimensions and delineate a well-defined range of shared targets (x-axis) and of shared targets with
qualifying potency differences (y-axis). Compound pairs are assigned to a unit cell if the underlying target relationship defined by the cell is met.
Color coding accounts for the number of qualifying compound pairs from light pink (many pairs) over magenta to black (a single pair). Inlay squares
indicate structural relationships and are “inversely” color-coded according to the frequency of structurally related pairs in a unit cell from black (many
pairs) over dark blue to light blue (a single pair).
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determined, and a continuous color code (from black over
magenta to light pink) is used to monitor the frequency of
relationships within the cells (i.e., a cell colored in black
contains a single pair, and a cell in light(est) pink contains the
maximally observed number of pairs). An “empty” cell within
the map indicates that no compound pairs are falling into the
respective data intervals.
Structural relationship information is also incorporated into
the LTD map. For our analysis, compound similarity was
assessed in two complementary ways. Pairwise whole molecule
Tanimoto similarity14 was calculated using MACCS structural
keys.15 As a similarity threshold for selected compound
relationships, a Tanimoto coefficient of 0.8 was applied.
Furthermore, matched molecular pair (MMP) analysis16,17
was carried out to identify substructure relationships between
compounds. For this purpose, all compound pairs were
identified that formed an MMP, i.e., that shared a given key
fragment (core structure), as described previously.17 It should
be noted that increasing the potency and similarity thresholds
decreases the number of qualifying compound pairs and hence
the information content of the analysis. Data noise and
information content must be balanced.
All unit cells that contain compound pairs with structural
relationships are then marked through the addition of “square
inlays”, as schematically illustrated in Figure 1. Furthermore,
Figure 2a captures structural relationships between the kinase
inhibitors on the basis of pairwise Tanimoto similarity
calculations and Figure 2b on the basis of common (MMP-
based) core structures. An inversely shaded color code (from
light blue over dark blue to black) is applied to the inlays in
order to account for the frequency of pairwise structural
relationships per cell (i.e., a cell with a light(est) blue square
inlay contains a single relationship). Hence, annotation of cells
Figure 2. LTD map of kinase inhibitor data. Two versions of the LTD map of the kinase inhibitor data set are shown that only differ in the way
structural relationships between active compounds are determined. In panel (a), MACCS Tanimoto similarity relationships are shown, and in panel
(b) MMP-based substructure equivalences are shown (i.e., cells with inlays contain pairs of compounds with a common core structure).
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monitors the distribution of structural relationships in high-
dimensional activity space.
A consistent numbering scheme is applied to cells in LTD
maps, adhering to “top down” (vertical) followed by “from left
to right” (horizontal) reading directions. Thus, if multiple cells
have the same number of targets with significant potency
differences, they are numbered in the order of increasing
numbers of shared targets. LTD maps were drawn using
routines implemented in the R environment.18
3.3. Interpretation. The LTD map provides an immediate
view of the data distribution in high-dimensional activity space,
as illustrated in Figures 1 and 2. For the kinase inhibitor data
set containing activities against a total of 172 different kinases,
individual compound pairs share up to 101 kinases and up to 69
kinases with potency differences of more than 1 order of
magnitude. As clearly delineated by the cell color code, the bulk
of the activity data falls into the map section spanned by zero to
∼20 shared targets and zero to ∼10 targets with significant
potency differences. In addition, the section of highly populated
cells extends to ∼60 shared targets and ∼30 targets with
potency differences. For further increasing numbers of shared
targets and targets with qualifying potency differences, the
number of compound pairs rapidly declines. The inlay view of
structural relationships between compound pairs adds further
Figure 3. Data set and map modifications. In panel (a), the LTD map of the kinase inhibitor data set was calculated after addition of a hypothetical
compound with 1 mM potency against all 172 kinases. In panel (b), an alternative version of the LTD map is shown for the original data set where
potency deviations from mean compound potency were used instead of absolute potency differences, as rationalized in the text.
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Figure 4. continued
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information to the map. Cells are highlighted that contain
compound pairs with structural relationships. In Figure 2a and
b, Tanimoto similarity relationships and (MMP-based)
substructure equivalences are displayed, respectively. These
figures show how structural similarity relationships are
distributed in high-dimensional activity space. In the kinase
inhibitor data set, the distributions of Tanimoto similarity and
substructure relationships are similar, as revealed in Figure 2.
Most similarity relationships are detected between compounds
that share only a few targets. Frequent similarity relationships
still occur between compounds sharing up to ∼50 targets and
∼10 targets with significant potency differences (dark to
medium blue inlay area in Figure 2). For increasing numbers of
shared targets and targets with potency differences, only few
structural relationships between inhibitors are detected. The
bottom row of cells in the map contains compound pairs that
have similar activity against all kinases against which they have
been tested. This region contains many structurally similar
compounds (as one might expect). By contrast, compound
pairs forming the leftmost (pseudo-diagonal) cell layer display
potency differences against all, or nearly all, of their shared
targets.
On the basis of the information provided by the LTD map,
activity data can be further analyzed by selecting compounds
from map segments or individual cells of interest. In the
following, representative examples are discussed.
3.4. Modifications of LTD Maps. Compounds forming
pairs on the diagonal of the LTD maps include those that
display differential activity against kinases. In addition, cells on
the diagonal might also include compounds having consistently
higher or lower potency against shared targets. These
compounds are less interesting for further analysis. As an
extreme case, a data set might contain one or more compounds
with artificially high or low potency against many targets, which
would result in the formation of many artificial compound pairs
and complicate the analysis of the LTD map. Such compounds
were not present in the kinase inhibitor set. However, if such
compounds exist in a data set, they will exclusively form cells on
the diagonal, which alters the map appearance in a characteristic
manner. This is demonstrated in Figure 3a that shows the LTD
map of the kinase inhibitor data set recalculated after addition
of a hypothetical compound with 1 mM potency (pKi value of
3) against all 172 kinases. Because such compounds only occur
in cells on the diagonal, they (and the pairs they form) can be
easily identified and removed from further analysis.
However, to principally omit this potential complication, the
LTD map can be modified by considering potency differences
with respect to the average potency of compounds for the set of
shared targets instead of absolute potency differences. Thus, for
each compound in a pair, the average potency for its shared
targets is calculated and subtracted from each individual
potency value, which yields relative potency values. These
values reflect whether a compound shows above or below
average potency values for its shared targets. The differences
between these relative potency values are then used for map
construction. The modified LTD map calculated for the
potency difference threshold of 1 order of magnitude as before
is shown in Figure 3b. The diagonal cells are less densely
populated, which is due to the fact that the median of relative
potency differences is only 0.54 compared to 0.80 for absolute
differences. Compounds with artificially high or low potencies
against many targets no longer form pairs with large relative
potency differences and do not populate diagonal cells in this
map. Only compounds with differentiated potency profiles (i.e.,
compounds with selectivity) can induce signals and form pairs
that populate prominent cells. Accordingly, the modified LTD
map in Figure 3b remained essentially constant when it was
recalculated after addition of the hypothetical compound.
Figure 4. Compound information. The figure illustrates how compound information is extracted from the LTD map. In panel (a), the LTD map in
Figure 1a is displayed in simplified form. Map boundaries referred to in the text and exemplary cells are color-coded while other regions are displayed
in light gray. In addition, selected cells are numbered (following the numbering scheme described in the text). The table insert reports the x-axis and
y-axis range for each labeled cell. In panels (b)−(d), compounds taken from selected cells are shown together with their activity profiles. Cells from
which the compounds originate are specified. For pairwise comparisons, the total number of shared kinases and the subset of kinases with significant
potency differences are reported on a pink and light blue background, respectively. In addition, for compound pairs with MACCS Tanimoto
similarity above the threshold value, the Tanimoto coefficient is given on a gray background. In the activity profiles, pKi values for all shared targets
are reported. Compounds and corresponding profiles are color-coded. Kinase abbreviations are used according to ref 12.
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3.5. Alternative Potency Difference Threshold Values.
It should also be mentioned that potency difference threshold
values can not only be prespecified but can also be determined
in a meaningful manner on the basis of the potency
distributions within a given data set, as demonstrated in the
following for the kinase inhibitor set. In order to evaluate the
significance of potency differences for a target observed for
pairs of compounds, the distribution of potency differences for
all pairs of compounds and all shared targets was analyzed.
Thus, for all 786,776 compounds pairs, the potency differences
for one to 101 targets shared between them were pooled.
Observed potency differences ranged from zero to a maximum
of 7.1. The mean value was 1.0, with a standard deviation of 0.8.
These values reflected the asymmetric nature of the
distribution, with values extending from about one standard
deviation below the average to more than seven standard
deviations above the average. This was also indicated by the
median of 0.8 and the interquartile range with a first quartile of
0.4 and a third quartile of 1.5. On the basis of these values, a
potency difference threshold of 1 order of magnitude applied in
our analysis was a reasonable choice for this data set because it
directed the analysis toward compound pairs with a high
number of above average potency differences.
On the basis of these considerations, a statistical analysis of
the significance of compound pairs with a certain number of
targets with above average potency difference with respect to
the total number of commonly annotated targets might be
performed. For example, by taking the median potency
difference as a threshold value, half the potency differences
between a pair of compounds would be expected to have values
beyond the threshold. This gives rise to a binomial distribution
with p = 0.5. In this case, significance at the 0.01 level would
correspond, for instance, to compound pairs with 15 large
potency differences given a total of 20 shared targets. These
values can guide the analysis of the LTD map in order to
identify interesting compound pairs especially considering the
incompleteness of data set annotations.
4. COMPOUND DATA ANALYSIS
Figure 4a points at regions in the LTD map in Figure 2 that
contain interesting compounds for further exploration. Pairs
can be automatically extracted from cells. The consistent
numbering scheme of cells in LTD maps is also illustrated in
Figure 4a. Cell 1 contains a pair of structurally distinct
inhibitors that share 84 targets and yield significant potency
differences for 69 of them. This represents the largest number
of shared targets with qualifying potency differences detected
within the data set. The structures of these compounds and
their activity profiles are shown in Figure 4b. Compound 1 has
mostly higher potency than compound 2, which explains the
overall large number of potency differences (a situation
observed in a number of instances in this region of the map).
However, both compounds display different activity profiles
and significant differentiation potential against many kinases,
with in part large differences in potency, especially in the case
of compound 1. Furthermore, the adjacent cells 2−4 contain
compound pairs active against ∼60 kinases with significant
potency differences against many of them. Figure 4c shows
three exemplary compounds taken from these cells. Com-
pounds 3 and 4 form a pair and have different potencies against
55 of the 60 targets they share. As an additional example,
compound 5 is included in the comparison. Compound 3 has
overall lower potency than compound 4 but the traces of their
activity profiles show notable similarities. Compound 4 has high
kinase differentiation potential, often with relative differences in
potency between kinases of 3 orders of magnitude or more. By
contrast, compound 5 has mostly intermediate potency and
shows rather limited ability to differentiate between kinases.
Cell 104 in Figure 4a maps to another interesting region in the
LTD map. In this region, compounds have similar activity
against many kinases and yield only a limited number of
significant potency differences. Figure 4d shows a pair of
structurally similar compounds taken from cell 104. Their
activity profiles are overall also similar but reveal a number of
notable potency differences against individual kinases. Thus, the
comparison of compounds with many shared targets that
include only a limited number of targets with significant
potency differences might identify potential selectivity probes.
Taken together, these examples illustrate how compound
information can be extracted from the LTD map and how
compound subsets with desired properties can be selected for
further studies.
5. CONCLUDING REMARKS
We have introduced the ligand-target differentiation map that is
designed to navigate high-dimensional bioactivity spaces taking
structural relationships between active compounds into
account. As such, the LTD map represents a high-dimensional
activity landscape. A hallmark of the activity landscape concept
is the graphical integration of compound structure and activity
relationships. One of the difficulties involved in exploring the
design of high-dimensional landscapes has been the limited
availability of relevant compound profiling data, at least in the
public domain. A notable exception is provided by the publicly
available kinase inhibitor data set from Abbott that contains
activity data for more than 1400 inhibitors and 172 different
kinases and probably represents the largest high-dimensional
compound profiling set currently available in the public
domain. Our exploratory efforts have been much supported
by the availability of this data set, leading to the design of the
LTD map structure. A key feature of the newly introduced
approach is the reduction of the inherent complexity of variable
high-dimensional activity spaces. This is accomplished by
systematically accounting for pairwise differences between
multi-target activity profiles of test compounds. Such differ-
ences are graphically represented by monitoring the number of
common targets with significant potency differences as a
function of the total number of targets that are shared by
compound pairs. This representation greatly simplifies the
navigation of high-dimensional activity spaces and makes it
possible to quickly focus on regions in data sets that are most
interesting for further analysis. Another key feature of the LTD
map is its basic data element, a constantly sized cell that
contains compound pairs with well-defined relationships.
Through color coding and cell annotation, both activity and
structural relationship information is provided. From individual
cells or groups of cells, compound pairs and subsets with well-
defined relationships can be selected, as demonstrated herein.
The generation of the LTD map is straightforward, and the
representation is also applicable to smaller data sets of lower
dimensionality. Thus, LTD maps should be helpful for many
applications in multi-target compound data analysis. In
addition, it is hoped that the approach introduced herein
might also catalyze the development of alternative high-
dimensional activity landscape views.
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CHAPTER 3: SUMMARY
Summary
Herein, the first activity landscape to navigate high-dimensional bioactivity
spaces was introduced. The newly designed LTD map had two key features.
First, it reduced the complexity of high-dimensional activity spaces by account-
ing for pairwise potency differences between compounds. Second, it provided
a compound pair-based analysis, i.e., the unit element of the landscape was
a pair of compounds. Pairwise activity profile comparisons were graphically
represented by monitoring the number of targets with significant potency dif-
ferences as a function of the total number of shared targets between a pair
of compounds. Furthermore, a color code was applied to account for pairwise
structural relationships. Taken together, the LTD map greatly facilitated the
analysis of multi-target compound data and enabled to quickly focus on in-
teresting compound subsets for further exploration. My contributions to this
study have been the design of the activity landscape model and its analysis.
In this and the previous study, the concept of activity landscapes has been
extended to capture complex ligand-target relationships and account for multi-
target SARs. Cardinal features of landscape models are activity cliffs (i.e., pairs
of compounds having a significant potency difference). Thus far, activity cliff
distributions have been studied on a per-target basis, and the global distribution
of activity cliffs has been unknown. In the next study, a systematic survey has
been carried out to analyze the cliff frequency and distribution on a large scale.
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Chapter 4
Comprehensive Analysis of
Single- and Multi-Target
Activity Cliffs Formed by
Currently Available Bioactive
Compounds
Introduction
The systematic exploration of activity cliffs has experienced increasing interest
in practical medicinal chemistry and drug development efforts. Activity cliffs
are thought to contain high SAR information content and are cardinal features
of activity landscape models. On the basis of landscape representations, single-
and multi-target cliffs have been detected in various activity classes. Thus far,
the distribution of activity cliffs across different biological targets has not been
reported. Therefore, we have systematically searched for single- and multi-
target activity cliffs in major public domain repositories to statistically account
for their global distribution.
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Activity cliffs are formed by structurally similar
compounds having large potency differences.
Their study is a focal point of SAR analysis. We
present a first systematic survey of single- and
multitarget activity cliffs contained in currently
available bioactive compounds. Approximately
12% of all active compounds were involved in the
formation of activity cliffs. Perhaps unexpectedly,
activity cliffs were found to be similarly distrib-
uted over different protein target families. More-
over, only approximately 5% of all activity cliffs
were multitarget cliffs. Importantly, we also found
that only very few multitarget cliffs were formed
by compounds having different target selectivity.
In addition, ’polypharmacological cliffs’, i.e., mul-
titarget activity cliffs involving targets from dif-
ferent protein families, were also only rarely
found. Taken together, our findings reveal that
only approximately 2% of all pairs of structurally
similar compounds sharing the same biological
activity form activity cliffs but that, on average,
approximately one of 10 active compounds is
involved in the formation of one or two single-
target cliffs of large magnitude (with at least
100-fold difference in potency). These compounds
provide a rich source of SAR information and can
be identified across many different target families.
Key words: activity cliffs, activity landscapes, compound potency,
data mining, polypharmacology, structure–activity relationships, target
families
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In the context of SAR analysis, the concepts of activity landscapes
(1,2) and activity cliffs (2,3) have experienced increasing interest in
recent years (4). Activity landscapes can be rationalized as graphi-
cal representations that integrate molecular similarity and potency
relationships between active compounds (2), and activity cliffs rep-
resent their most prominent features (2,3). An activity cliff is
formed by structurally similar compounds having large differences
in potency (2,3). Therefore, activity cliffs represent the extreme
form of SAR discontinuity (1,2) and their presence in compound
sets is often responsible for difficulties in deriving QSAR models
for activity prediction (3). Given their 'small structural change –
large potency effect' phenotype, activity cliffs are also regarded as
the most informative feature of landscape models (1–3), both from
a medicinal chemistry (1,2) and from a chemoinformatics (5,6) per-
spective. For chemical optimization efforts, the assessment of activ-
ity cliffs in compound series plays an important role.
Activity cliffs have conventionally been analyzed for compounds
active against individual targets ('single-target cliffs'). However, for
compounds with activity against multiple targets, 'multitarget cliffs'
might also occur (7). Such cliffs result from differential potency of a
compound pair against two or more related targets. These targets
might be closely related, i.e., members of the same protein family,
or unrelated, if the cliff-forming compounds display polypharmaco-
logical behavior (8–10).
Although activity cliffs are intensely studied, it is currently unknown
how they are globally distributed across available bioactive com-
pounds and protein targets. Studies reported thus far have focused
on identifying activity cliffs in individual compound sets, but no sys-
tematic assessment of activity cliff distributions has been carried
out. Furthermore, it is currently unknown how frequently multitarget
activity cliffs might actually occur in bioactive compounds. There-
fore, we have systematically searched for single- and multitarget
activity cliffs in public domain compounds with reported activity
against human target proteins.
Materials and Methods
The three major public domain compound repositories were ana-
lyzed, i.e., PubChem ,a BindingDB (11), and ChEMBL (12). PubChem
bioassays contain high-throughput screening data, whereas Binding-
DB and ChEMBL predominantly contain compounds taken from the
medicinal chemistry literature, mostly originating from chemical
optimization efforts. The latest version of BindingDB has integrated
the ChEMBL compound collection for defined protein targets. Thus,
we have analyzed these compounds together, in addition to Pub-
Chem compounds.
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For our analysis, we extracted small compounds from public domain
repositories that contained at least five heavy atoms and had a
molecular weight of not more than 900 Da. A total of 164 165
unique BindingDB ⁄ ChEMBL compounds were obtained (approxi-
mately 140 000 of which originated from ChEMBL) that were
reported to be active against 1355 non-redundant individual human
targets. These compounds yielded 330 526 defined activity annota-
tions (i.e., many compounds were active against multiple targets).
From PubChem, 187 confirmatory inhibition assays for human tar-
gets were extracted that contained 21 532 active compounds with
30 805 defined annotations against 98 different targets. Only Ki or
IC50 values were considered as activity annotations.
Pairwise compound similarities were calculated using the 'extended
connectivity fingerprint with bond diameter 4' (ECFP4) (13) as imple-
mented in Pipeline Pilot.b As a similarity threshold for activity cliff
formation, an ECFP4 Tanimoto coefficient (Tc) value of 0.55 was
applied. This ECFP4 Tc threshold value identifies compounds with
high structural similarity (14). For comparison, the calculations were
also carried out with another molecular representation, the MACCS
structural key fingerprint.c The same number of pairs of similar
compounds above the ECFP4 Tc threshold value of 0.55 was
obtained for the MACCS Tc calculations when a threshold value of
0.85 was applied.
The targets in our analysis were grouped into target families based
on the family organization of UniProt (15). Targets belonging to the
G-protein-coupled receptor 1 family were divided into smaller
groups following the protein classification hierarchy of ChEMBL.
Our analysis was carried out with in-house generated Perl and Java
programs.
Results and Discussion
We found 164 165 BindingDB ⁄ ChEMBL compounds yielding 330 526
activity annotations against 1355 targets and 21 532 PubChem com-
pounds yielding 30 805 activity annotations against 98 targets that
met our selection criteria.
Activity profiles and cliffs
Following compound selection, we generated activity profiles (7) for
all compounds using a constant representation scheme. An activity
profile of a compound consisted of binned activity measurements
for all annotated targets. Potency values were assigned to three
different ranges, i.e., 'weakly potent' (pKi £ 5; bin label '0'), 'moder-
ately potent' (pKi > 5 and pKi £ 7; bin label '1'), or 'highly potent'
(pKi > 7; bin label '2'). Accordingly, a compound was considered
weakly potent against a given target if its potency was lower than
or equal to 10 lM, moderately potent if the potency was higher
than 10 lM but lower than or equal to 100 nM, and highly potent if
it was higher than 100 nM. If multiple measurements were avail-
able, a compound was only included in the analysis if all values fell
into the same potency bin.
For our analysis, we applied the definition that an activity cliff was
formed by a pair of compounds that exceeded the cliff similarity
threshold and in which one compound was highly potent against a
given target and the other only weakly potent (i.e., representing a
'2' versus '0' potency bin combination against the target).
Compounds active against multiple targets can form single- or
multitarget activity cliffs. The latter are termed dual-, triple-,
quadruple-target cliffs, etc. according to the number of targets for
which cliffs occur. In Figure 1A,B, exemplary compound pairs are
shown with their activity profiles that form a single- and dual-target
cliff, respectively.
Activity cliff distribution
After generating compound activity profiles, we systematically
searched for single- and multitarget activity cliffs. In Table 1, we
report the activity cliff distribution for BindingDB ⁄ ChEMBL com-
pounds when, as an approximation, both Ki and IC50 values were
considered as potency annotations. In this case, we detected a
total of 36 063 single-, 1654 dual-, and 233 triple-target activity
cliffs. The number of multitarget cliffs of higher degrees (target
numbers) rapidly declined, although cliffs involving up to seven tar-
gets were detected. Table 1 also reports the corresponding activity
cliff distribution when only directly comparable Ki values were con-
sidered as measurements. Then, 10 063 single-, 330 dual-, and 61
triple-target activity cliffs were detected (i.e., approximately one-
fourth of the cliffs found when both Ki and IC50 values were consid-
ered). In addition, in this case, 17 cliffs involving four targets and
two cliffs involving five targets were identified. For the Ki ⁄ IC50- and
Ki-based distributions, we found that 20 473 and 6194 of 164 165
and 56 795 compounds, respectively, were involved in the formation
of activity cliffs, i.e., approximately 12.5% and approximately
10.9%.
We also determined the total number of compound pairs that could
potentially form activity cliffs, i.e., pairs that exceeded the activity
cliff similarity threshold. When both Ki and IC50 measurements were
considered, 1 530 493 qualifying compound pairs yielded a total of
38 045 (single- and multitarget) cliffs. Hence, only approximately
2.5% of all qualifying compound pairs formed activity cliffs and,
accordingly, approximately 97.5% did not. Furthermore, only 5.2%
of all cliff-forming compound pairs represented multitarget cliffs.
When only Ki values were considered, 574 851 compound pairs
were found that yielded a total of 10 473 cliffs, i.e., only approxi-
mately 1.8% of these pairs formed activity cliffs and only 3.9% of
these were multitarget cliffs. Thus, activity cliffs were only sparsely
distributed among pairs of structurally similar compounds. Control
calculations using the MACCS fingerprint yielded similar statistics;
for example, for the Ki ⁄ IC50-based analysis, 3.2% of all qualifying
compound pairs were found to form activity cliffs and only 4.3%
of these compound pairs formed multitarget cliffs. For the Ki-based
analysis, the corresponding values were 2.5% and 3.8%, respec-
tively.
In addition, for each cliff compound in a ligand set, all activity cliffs
formed with its ECFP4-derived structural neighbors and the ratio of
cliffs versus the number of neighbors were determined. Based on
these calculations, the frequency of cliff formation in qualifying
pairs of compounds involving a cliff compound was on average
approximately 18% (for both the Ki- and Ki ⁄ IC50-based analyses).
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Our active compound pool extracted from PubChem amounted to
approximately one-seventh of the size of BindingDB, and these
screening hits had overall lower potency than BindingDB ⁄ ChEMBL
compounds, as expected. When Ki and IC50 values were taken into
account, only 13 single-target and no multitarget cliffs were
detected. These 13 activity cliffs involved only five different targets.
Thus, the occurrence of activity cliffs in PubChem compounds was
negligible. Hence, the further analysis of activity cliffs was limited
to the BindingDB ⁄ ChEMBL compound collection.
Target family distribution
We then studied the protein target family distribution of all activity
cliffs. The results for the Ki ⁄ IC50- and Ki-based distributions are
reported in Table 2A and 2B, respectively. For the top 10 families in
Table 2A,B, ranked according to the total number of activity cliffs,
significant differences in cliff numbers were observed. However, on
a relative scale (with respect to the total number of pairs of similar
compounds), activity cliffs were similarly distributed over these
target families. The top 10 families included popular therapeutic
A B
C D
Figure 1: Exemplary single- and multi-target activity cliffs. (A) Shown are two compounds and their activity profiles. One of these com-
pounds is active against all three, and the other against two of the serine proteases factor Xa (fXa), thrombin (Thr), and trypsin (Try). Based
on their activity profiles, these two compounds form a single-target activity cliff (stc) for factor Xa. The cliff is indicated by an arrow. (B)
Shown are two compounds that are active against cathepsins K, L, and S. One compound is highly potent against all three cathepsins,
whereas the other is only highly potent against cathepsin S, but weakly potent against cathepsins K and L. Hence, these compounds form a
dual-target cliff (dtc) for cathepsins K and L, indicated by arrows. (C) A compound pair is shown that forms a triple-target cliff (ttc) for matrix
metalloproteases (MMP) 2, 8, and 13. The potency of one compound is consistently high against all three targets, and the potency of the
other is consistently low, i.e., this cliff is directed. (D) A compound pair is shown that forms a triple-target cliff for Aurora serine ⁄ threonine
kinases A and B and the epidermal growth factor receptor (EGFR) tyrosine kinase. In this case, the compounds show differential target selec-
tivity. One compound is highly potent against Aurora kinases A and B and weakly potent against the EGFR kinase, whereas the other com-
pound displays an inverse activity profile. Accordingly, this triple-target cliff is undirected.
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targets for which many qualifying active compound pairs were
available. Most activity cliffs were found for ligands of the short
peptide receptor and peptidase S1 families. The family rankings dif-
fered for the Ki ⁄ IC50-based and Ki-based cliff distributions, but in
both cases, protease, kinase, nuclear hormone receptor, and G-pro-
tein-coupled receptor families were found among the top 10 fami-
lies. For most highly ranked families, the percentage of multitarget
cliffs among all activity cliffs was small (i.e., 0% to less than 10%),
although there were exceptions; for example, for the AGC Ser ⁄ Thr
kinase and the peptidase M10A (matrix metallo proteases) families,
24.1% and 17.5% of all activity cliffs were multitarget cliffs,
respectively (Table 2A), and for the peptidase C1 family, 13.0%
were multitarget cliffs (Table 2B).
Activity cliff directionality
Next we analyzed the directionality of multitarget activity cliffs. In
a 'directed' multitarget cliff pair, the potency of compound A is
consistently high for all targets and the potency of compound B is
consistently low. By contrast, in an 'undirected' multitarget cliff pair,
Table 1: Activity cliff statistics
Potency annotations
Cliff degree Cliff directionality
Poly-cliffs All cliffs1 2 3 4 5 6 7 dir. undir.
Ki ⁄ IC50 values 36 063 1654 233 43 29 21 2 38 019 26 79 38 045
Ki values 10 063 330 61 17 2 0 0 10 469 4 4 10 473
Activity cliff statistics are reported for the Ki ⁄ IC50- and Ki-based analyses. 'Cliff degree' denotes the number of targets per activity cliff. 'All cliffs' gives the
total number of single- and multitarget cliffs. Under 'Cliff directionality' (see text), the number of directed ('dir.') and undirected ('undir.') multitarget cliffs is
reported. In addition, the number of polypharmacological cliffs ('Poly-cliffs'; see text) is given.
Table 2: Target family distribution of activity cliffs
(A)
Target family
Cliff degree
Multitarget
cliffs (%) All cliffs Cliffs (%) Targets1 2 3 4 5 6 7
Short peptide receptor 6657 161 17 1 0 0 0 2.6 6836 2.6 37
Peptidase S1 4006 68 5 3 1 0 0 1.9 4083 3.4 21
Tyr protein kinase 2656 192 37 0 0 0 0 7.4 3085 2.9 29
Peptidase A1 1610 13 6 0 0 0 0 1.2 1629 2.7 69
Prostaglandin G ⁄ H synthase 1585 39 0 0 0 0 0 2.4 1624 7.6 2
AGC Ser ⁄ Thr protein kinase 927 162 71 18 22 21 0 24.1 1221 4.3 16
Peptidase M10A 984 152 32 19 4 0 2 17.5 1193 2.6 9
CMGC Ser ⁄ Thr protein kinase 1052 75 0 0 1 0 0 6.7 1128 2.5 12
Nuclear hormone receptor 899 113 0 0 0 0 0 11.2 1012 2.2 17
Nucleotide-like receptor 955 26 4 0 0 0 0 3.0 985 1.3 6
(B)
Target family
Cliff degree
Multitarget
cliffs (%) All cliffs Cliffs (%) Targets1 2 3 4 5
Short peptide receptor 3203 75 9 0 0 2.6 3287 2.6 32
Peptidase S1 1732 18 0 3 1 1.3 1754 2.4 18
Monoamine receptor 677 39 20 2 1 8.4 739 0.9 24
Nucleotide-like receptor 630 30 0 0 0 4.5 660 0.6 5
Alpha carbonic anhydrase 533 15 0 0 0 2.7 548 3.6 7
Peptidase C1 457 58 10 0 0 13.0 525 9.1 5
G protein-coupled receptor 2 446 0 0 0 0 0.0 446 3.4 2
Lipid-like ligand receptor 406 5 0 0 0 1.2 411 1.6 12
Nuclear hormone receptor 200 8 0 0 0 3.8 208 1.6 11
TKL Ser ⁄ Thr protein kinase 198 0 0 0 0 0.0 198 28.5 1
In (A) and (B), the target family distribution of activity cliffs is reported for the Ki ⁄ IC50- and Ki-based analyses, respectively. In each case, the top 10 target
families are ranked according to the number of single- and multitarget cliffs they cover. The percentage of multitarget cliffs among all activity cliffs is also
reported. Furthermore, for each family, the number of compound pairs that form activity cliffs divided by the number of qualifying pairs of similar compounds
and the number of targets for which activity cliffs occur are reported in the columns 'Cliffs (%)' and 'Targets', respectively.
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compound A has high potency for at least one target for which
compound B is only weakly potent and vice versa. Differences in
cliff directionality are illustrated in Figure 1C,D where an exemplary
directed and undirected triple-target cliff is shown, respectively.
Importantly, only undirected multitarget activity cliffs contain com-
pounds with different target selectivity, whereas in a directed cliff,
the same compound is highly potent against all targets and thus
always selective. In Table 1, we also report the number of undi-
rected multitarget activity cliffs for both cliff distributions. In the
Ki ⁄ IC50-based distribution, only 26 of 1982 multitarget cliffs (approx-
imately 1.3%) were undirected, and in the Ki-based distribution,
only 4 ⁄ 410 were undirected (approximately 1.0%). Thus, nearly all
multitarget cliffs were directed and activity cliff-forming compounds
with different target selectivity were rare, which we considered a
rather unexpected finding.
Polypharmacological cliffs
In addition, we also searched for what we regard as 'polypharma-
cological cliffs', i.e., multitarget activity cliffs that involved targets
belonging to different protein families. Here, only targets with
unambiguous family assignments (see Materials and Methods) were
considered. For the Ki ⁄ IC50-based distribution, we found 79 poly-
pharmacological cliffs that involved a total of 84 compounds. Sev-
enty-one of these cliffs were dual- and eight triple-target cliffs. For
the Ki-based distribution, we identified only four (dual target) poly-
pharmacological cliffs involving seven compounds. Hence, com-
pounds with activity against different target families displayed only
limited polypharmacological cliff potential.
Conclusions
We have carried out a comprehensive analysis of activity cliffs
formed by currently available bioactive compounds. We have
searched for cliffs of large magnitude that are in general least
affected by measurement inaccuracies and that usually provide
focal points of SAR exploration. Furthermore, in our analysis, we
have differentiated between single- and multitarget activity cliffs,
studied the directionality of multitarget cliffs, and also introduced
polypharmacological cliffs, a special type of multitarget cliff. In gen-
eral, single-target cliffs occurred much more frequently than multi-
target cliffs and were similarly distributed over different target
families. We also found that compounds having different target
selectivity only rarely occurred in multitarget cliffs. Although the
percentage of qualifying compound pairs that formed activity cliffs
was only approximately 2%, on average, more than 10% of com-
pounds active against different target families were involved in the
formation of large-magnitude activity cliffs. Thus, for an active com-
pound of interest, a thorough search of its structural neighborhood
is rather likely to reveal activity cliffs from which SAR determinants
might be deduced.
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CHAPTER 4: SUMMARY
Summary
Herein, the distribution and directionality of activity cliffs and the propensity
of currently available bioactive compounds to form activity cliffs were systemat-
ically determined. Single-target cliffs were most frequently observed accounting
for 94.8% of all cliffs. Surprisingly, these cliffs were evenly distributed over dif-
ferent target families. Furthermore, the majority of the multi-target cliffs were
uni-directional and of low degree (i.e., number of targets involved), yet instances
of multi-target cliffs of up to degree 7 were also detected. Only a limited num-
ber of “polypharmacological” cliffs was identified. In addition, approximately
12% of all bioactive compounds were involved in the formation of at least one
activity cliff. My contribution to the study reported herein has been to aid in
the assessment and large-scale analysis of currently available activity cliffs.
Activity cliffs are considered centers of SAR discontinuity and provide di-
rect access to SAR information. Although it is well-appreciated that different
molecular representations will inevitably affect SAR analysis, it is currently un-
known to what extent the use of alternative representation might change the
nature of SARs. To shed light on this question, we have carried out a large
scale analysis of fingerprint dependent changes in SAR information.
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Chapter 5
Quantifying the Fingerprint
Descriptor Dependence of
Structure-Activity Relationship
Information on a Large Scale
Introduction
It is well-understood that the quantitative assessment of molecular similarity is
highly dependent on the chosen molecular representation. Structural similarity
and potency comparisons between bioactive compounds are integral part of SAR
analysis and hence the outcome of the SAR study will inevitably change when
alternative representations are used. Numerical analysis functions (e.g., SARI,
SALI) have been introduced that can be used as a diagnostic of global and local
SAR characteristics. Herein, we address the question of how to quantitatively
assess the fingerprint dependence of SAR information. By systematically calcu-
lating local per-compound discontinuity scores, changes in the SAR phenotype
for individual compounds can be monitored and fingerprint-dependent changes
identified.
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ABSTRACT: It is well-known that different molecular representations, e.g.,
graphs, numerical descriptors, fingerprints, or 3D models, change the numerical
results of molecular similarity calculations. Because the assessment of structure−
activity relationships (SARs) requires similarity and potency comparisons of
active compounds, this representation dependence inevitably also affects SAR
analysis. But to what extent? How exactly does SAR information change when
alternative fingerprints are used as descriptors? What is the proportion of active
compounds with substantial changes in SAR information induced by different
fingerprints? To provide answers to these questions, we have quantified changes
in SAR information across many different compound classes using six different
fingerprints. SAR profiling was carried out on 128 target-based data sets
comprising more than 60 000 compounds with high-confidence activity
annotations. A numerical measure of SAR discontinuity was applied to assess
SAR information on a per compound basis. For ∼70% of all test compounds, changes in SAR characteristics were detected when
different fingerprints were used as molecular representations. Moreover, the SAR phenotype of ∼30% of the compounds
changed, and distinct fingerprint-dependent local SAR environments were detected. The fingerprints we compared were found to
generate SAR models that were essentially not comparable. Atom environment and pharmacophore fingerprints produced the
largest differences in compound-associated SAR information. Taken together, the results of our systematic analysis reveal larger
fingerprint-dependent changes in compound-associated SAR information than would have been anticipated.
■ INTRODUCTION
The assessment of structure−activity relationship (SAR)
information associated with active compounds is of central
relevance in medicinal chemistry.1 A variety of computational
methods are applied to aid in SAR analysis2 including QSAR
approaches,3 visualization techniques,4 and numerical analysis
functions for SAR profiling.5,6 SAR analysis generally requires
the comparison of structures of active compounds and their
potency values. Structure comparison focuses on the assess-
ment of molecular similarity/dissimilarity, in qualitative and/or
quantitative terms.7,8 Both from a medicinal chemistry1,7 and
computational8,9 perspective, molecular similarity is often
difficult to assess.
A quantitative computational assessment of similarity
requires the choice of a consistently applied molecular
descriptors (representations) and a similarity or distance
metric/measure.10,11 Comparisons are typically carried out in
a pairwise manner, either by quantifying the similarity of given
molecular representations or by calculating the distance in
chemical reference space. The molecular descriptor and, to a
lesser extent, metric dependence of similarity calculations are
well-appreciated caveats of molecular similarity analysis.8−12
Similarity relationships display a tendency to change when
alternative molecular representations are used, which inevitably
affects similarity search calculations12 and quantitative SAR
analysis.14 Although this dependence is widely appreciated, its
potential magnitude remains unclear.
In addition to QSAR approaches focusing on individual
compound series, numerical SAR analysis functions,5,6 such as
the SAR index (SARI),5 are available for quantitative SAR
exploration. SARI integrates similarity and potency compar-
isons of active compounds, thereby producing a numerical
score that quantitatively characterizes SAR features. This
characterization can be carried out both at the level of
complete data sets (i.e., describing global SAR features) or
compound subsets (local SARs). Different SAR feature
categories can be distinguished on the basis of numerical
SAR analysis. For example, SAR continuity refers to the
presence of structurally diverse compounds having comparable
potency. The presence of continuous SARs provides the basis
of scaffold hopping13 in similarity searching and virtual
screening.9−12 By contrast, SAR discontinuity refers to the
presence of structurally similar compounds with a large potency
differences.5,14 The extreme form of SAR discontinuity is
represented by activity cliffs14−17 that are rationalized as pairs of
similar compounds (structural analogs) with large potency
differences. For the analysis of activity cliffs, the definition of
similarity and potency difference threshold values is typically
required.16 For large-scale SAR analysis using numerical
analysis functions, different types of fingerprints,9−12 i.e., bit
representations of molecular structure and properties, are
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generally preferred molecular representations and most widely
used for similarity calculations.5,6,14
It is currently unknown to what extent active compounds
across different targets might change their SAR phenotype, e.g.,
from a continuous to a discontinuous one and vice versa, when
different fingerprints are used as molecular representations.
Obtaining this information would provide a first quantification
of fingerprint-dependent changes in SAR characteristics on a
per compound basis and help to estimate the influence of these
effects on the reliability of computational SAR models.
Therefore, we have systematically analyzed 128 compound
sets with high-confidence activity data using different finger-
prints to quantitatively describe and compare changes in SAR
information at the level of individual compounds.
■ MATERIALS AND METHODS
Compound Data Sets. Data sets were assembled from
ChEMBL (version 15).18 For our analysis, only compounds
with precisely specified equilibrium constants (Ki values) below
1 μM for human targets at the highest confidence level
(confidence score 9) were selected. A compound with multiple
measurements for the same target was only considered if it had
consistent potency measurements (i.e., if all values fell within 1
order of magnitude). In this case, the average potency was
calculated as the final annotation. In addition, each data set was
required to contain at least 100 compounds. On the basis of
these selection criteria, 128 target-based data sets comprising a
total of 60 248 compounds were obtained. The data sets are
made freely available via the downloads section of following:
http://www.lifescienceinformatics.uni-bonn.de.
Fingerprints. Six fingerprints of different design and
complexity were used as molecular representations:
(a) Extended connectivity fingerprint with bond diameter 4
(ECFP4)19 producing ∼4 × 109 theoretically possible
features. ECFP4 is a topological fingerprint that encodes
layered atom environments with a maximum diameter of
four bonds around each atom.
(b) Functional class fingerprint with bond diameter 4
(FCFP4) is a closely related derivative of ECFP4 that
replaces atom types with pharmacophore features (such
as hydrogen-bond donors and acceptors, charged, or
aromatic atoms), which renders atom information less
specific compared to ECFP4 and reduces the size of
feature sets.
(c) Molecular access system (MACCS)20 consists of 166
structural fragments with 1−10 nonhydrogen atoms.
(d) Typed graph distances (TGD)21 is an atom pair-type
fingerprint consisting of 420 bits. Shortest distances in
the molecular graph between two atoms (represented as
seven pharmacophore features) are calculated and
assigned to 15 distance ranges.
(e) Typed graph triangles (TGT)21 contains 1704 bits
positions representing three-point pharmacophore pat-
terns in molecular graphs. Each atom is assigned to one
of four atom types (hydrogen-bond donor and acceptor,
donor/acceptor, or hydrophobic), and six bond distance
ranges are applied.
(f) Donor−acceptor polar-hydrophobe triangle (Gpi-
DAPH3)21 is a molecular graph-based three-point
pharmacophore fingerprint generating 30 240 possible
features. In this case, each atom is assigned to one of
eight atom types derived from three atomic properties (π
system, donor, or acceptor), and eight bond distance
ranges are utilized.
All fingerprint representations were calculated using the
Molecular Operating Environment (MOE).21 The TGD, TGT,
and GpiDAPH3 fingerprints are MOE-internal developments.
SARI Discontinuity Score. SARI is a numerical SAR
analysis function to quantify SAR features of compound data
sets and consists of separate terms accounting for SAR
continuity and discontinuity, respectively.5 We have used the
discontinuity score component as a quantitative measure of per
compound SAR discontinuity. The raw (non-normalized)
discontinuity score is defined as5
=
∑ | − |·
| | > > |
| > > i j i j
i j i j x i j
raw
pot( ) pot( ) sim( , )
{ , sim( , ) , }
i j i j x i j
disc
{ , sim( , ) , }
Here, pot(i) is the potency (pKi) value of compound i and
sim(i,j) the calculated fingerprint similarity for compounds i
and j. The raw discontinuity score is derived from the average
of potency differences between pairs of ligands multiplied by
their similarity. Accordingly, the score emphasizes the presence
of structurally similar compounds with large potency differ-
ences. Therefore, it is advisable to limit discontinuity scoring to
compounds that have at least limited molecular similarity.5
Hence, a similarity threshold value (x) is usually applied, as
further discussed below.
Depending on the normalization procedure, raw disconti-
nuity scores can be converted into scores that either quantify
the degree of SAR discontinuity for a complete data set,
compound subsets, or individual compounds.5,22,23 For our
analysis, we utilized per compound discontinuity scores to
assess local SAR discontinuity. Therefore, for each fingerprint,
raw discontinuity scores were systematically calculated for all
128 classes. The raw scores were then converted into Z-scores
using the sample mean and standard deviation of the score
distribution for each individual data set, i.e., the intraclass score
distribution for each fingerprint. Finally, cumulative proba-
bilities were calculated to map scores onto the value range [0,
1].5 All similar compound pairs were taken into consideration,
regardless of potency differences, to fully account for the
structural neighborhood of each individual compound,22,23 a
prerequisite for assessing local SAR discontinuity. As shown
herein, per compound discontinuity scores provide a mean-
ingful measure of compound-associated SAR information and
make it possible to characterize local SAR environments in
compound data sets in detail.
Similarity Calculation and Threshold Correspond-
ence. Pairwise fingerprint similarity was quantified using the
Tanimoto coefficient (Tc).11 As a reference point for the
discontinuity score similarity threshold, a MACCS Tc of 0.70
was applied, which typically indicates remote similarity.12
Compound pairs yielding further increasing MACCS Tc values
become increasingly similar (as an activity cliff criterion, a
MACCS Tc of 0.85 is often applied).16 Across all 128 data sets,
a MACCS Tc of 0.70 yielded 12% of all possible compound
pairs meeting or exceeding this threshold.
In order to determine corresponding Tc threshold values for
all fingerprints yielding the same number of similar compound
pairs, a three-step procedure was applied: (a) For each of the
128 data sets, the number of compound pairs yielding a
MACCS Tc ≥ 0.70 was determined; (b) for each of the
remaining fingerprints, the Tc threshold was determined that
yielded the same number of compound pairs for each set; and
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(c) for each fingerprint, the median of its 128 individual
threshold values was calculated and used as its global threshold.
On the basis of this analysis, the following corresponding Tc
threshold values were derived: MACCS, 0.70; ECFP4, 0.31;
FCFP4, 0.38; TGD, 0.69; TGT, 0.65; GpiDAPH3, 0.15. These
thresholds were applied for the calculation of per-compound
discontinuity scores.
■ RESULTS AND DISCUSSION
Study Concept and Goals. We have aimed to quantify the
influence of different fingerprint descriptors on compound-
associated SAR information on a large scale across many
different targets. To our knowledge, this is the first study that
systematically and quantitatively assesses fingerprint-dependent
changes in SAR information content at the level of individual
active compounds. To these ends, we have selected more than
60 000 compounds with high-confidence activity annotations
for 128 targets and calculated pairwise similarities using six
fingerprints of different design and complexity. For these
Figure 1. Distribution of pairwise score differences. For each
compound, discontinuity score differences are calculated for all pairs
of fingerprints, yielding a total of 15 score differences for an individual
compound. The histogram reports the distribution of the maximal
score differences for all 60 248 active compounds.
Figure 2. Discontinuity score shifts. Five score ranges ([0, 0.2], (0.2,
0.4], (0.4, 0.6], (0.6, 0.8], (0.8, 1]) are defined. Ranges of low,
medium, and high discontinuity are marked. Arrows represent largest
observed score differences and are labeled with the percentage of
compounds displaying such fingerprint-dependent differences.
Table 1. Distribution of Score Differences for Fingerprint
Combinationsa
fingerprint combination Δscore ≥ 0.2 Δscore ≥ 0.4
ECFP4/FCFP4 12.2 3.8
ECFP4/GpiDAPH3 20.5 6.9
ECFP4/MACCS 20.0 6.9
ECFP4/TGT 28.6 11.2
ECFP4/TGD 31.1 12.7
FCFP4/GpiDAPH3 20.1 7.0
FCFP4/MACCS 20.7 7.4
FCFP4/TGT 24.6 9.7
FCFP4/TGD 26.7 10.9
GpiDAPH3/MACCS 25.6 9.1
GpiDAPH3/TGT 25.8 9.9
GpiDAPH3/TGD 27.0 10.7
MACCS/TGT 28.9 11.7
MACCS/TGD 30.2 12.8
TGT/TGD 18.8 7.9
aFor all possible combinations of fingerprints, the percentage of
compounds with discontinuity score differences (Δscore) of at least
0.2 or 0.4 is reported as an average over all classes.
Table 2. Number of Fingerprint Combinations Producing
Large Score Changesa
Δscore ≥ 0.2 Δscore ≥ 0.4
no. FP
combinations
no.
cpds
%
cpds
avg. no.
neigh
no.
cpds
%
cpds
avg. no.
neigh
0 18 509 30.7 108.2 42 217 70.1 94.1
1 4155 6.9 96.6 3639 6.0 66.5
2 4079 6.8 88.5 3045 5.1 60.9
3 3655 6.1 82.3 2358 3.9 55.1
4 4077 6.8 78.9 2255 3.7 54.0
5 7126 11.8 64.3 2822 4.7 38.4
6 3459 5.7 70.1 1044 1.7 49.1
7 3249 5.4 64.9 795 1.3 41.7
8 4774 7.9 58.2 1445 2.4 30.0
9 3552 5.9 49.7 561 0.9 24.9
10 1671 2.8 48.6 52 0.1 19.4
11 1510 2.5 37.5 15 0.0 21.3
12 360 0.6 32.2 0 0 0
13 71 0.1 23.6 not possible
14 1 0.0 3.2 not possible
15 0 0 0 not possible
aThe number of fingerprint (FP) combinations yielding a score
difference (Δscore) of at least 0.2 and 0.4 is determined for all
compounds. For all combinations, the corresponding number and
percentage of compounds (cpds) are reported. In addition, the average
number of structural neighbors (no. neigh) calculated for all
fingerprints (no. FP = combinations 0) and for only those fingerprints
that participate in pairs with Δscore ≥ 0.2 or Δscore ≥ 0.4 (no. FP
combinations ≥1) are reported. It should be noted that the maximal
number of fingerprint combinations that can yield Δscore ≥ 0.2 and
Δscore ≥ 0.4 is 15 and 12, respectively. Hence, it is not possible that
all numbers of combinations of six fingerprints can meet the Δscore ≥
0.4 condition. The three numbers of combinations for which Δscore ≥
0.4 cannot be obtained (13, 14, and 15) are designated as “not
possible”.
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fingerprints, corresponding Tc threshold values were deter-
mined to ensure that the same proportion of all possible
compound pairs was classified as similar.
SAR discontinuity is an indicator of SAR information
content.14,15 In order to account for SAR discontinuity in a
consistent manner, a SAR discontinuity scoring scheme was
applied that quantifies the discontinuity contributions of
individual compounds.14 The latter criterion is of critical
relevance for our current analysis. What does local SAR
discontinuity mean? Local SAR discontinuity is high if a
compound has a potency value that substantially deviates from
the potency of its structural neighbors.
Through systematic assessment of compound-centric SAR
discontinuity, fingerprint-dependent changes in SAR informa-
tion were quantified for all test compounds and local SAR
environments were analyzed.
Distribution of Discontinuity Score Differences. For
each compound, discontinuity scores using all 6 fingerprints
and score differences for all possible 15 pairwise fingerprint
combinations were calculated. In Figure 1, the distribution of
the maximal score differences per compound is reported. For
∼70% and ∼30% of all compounds, maximal score differences
(Δscore) ≥0.2 and ≥0.4 were detected, respectively.
Discontinuity score differences ≥0.2 are substantial, and score
differences ≥0.4 indicate a major change in SAR information
associated with a given compound. This is the case because a
score change of magnitude 0.4 or larger transforms a
compound with low SAR discontinuity into one with
intermediate or high discontinuity and vice versa, as further
discussed below. Thus, for ∼30% of all active compounds
across the 128 target-based data sets, large-magnitude changes
in SAR information were observed that altered their SAR
phenotype, giving rise to fingerprint-dependent SAR phenotype
switches, which were quantified for the first time. Overall, an
unexpectedly high proportion of compounds active against 128
different targets was found to change their SAR phenotype
when different fingerprints were used. On the basis of
fingerprint similarity value distributions,24 a much smaller
proportion of compounds would have been predicted. This
meant that the structural neighborhood of many compounds
substantially changed when different fingerprints were used,
thereby completely changing many local SAR environments, as
further discussed below. In Figure 2, the range distribution of
score differences is reported. Differences were not confined to
certain score subranges. Rather, shifts of varying magnitudes
across the entire discontinuity score range were observed.
Fingerprint Comparison. In Table 1, the proportion of
compounds with discontinuity score differences ≥0.2 or ≥0.4 is
reported for all 15 pairwise fingerprint combinations, ranging
from12.2−31.1% (score difference ≥0.2) and 3.8−12.8%
(≥0.4). All fingerprint combinations were found to induce
substantial discontinuity score differences including closely
related fingerprints, such as ECFP4/FCFP4, for which 12.2%
and 3.8% of the compounds displayed score differences ≥0.2
and ≥0.4, respectively. The comparison made it possible to
identify combinations of fingerprint types that generated
inconsistent SAR models. A major finding has been that atom
environment fingerprints and 2D pharmacophore fingerprints
produced largely different SAR models. For example, the
ECFP4/TGD combination yielded score differences ≥0.2 and
≥0.4 for 31.1% and 12.7% of active compounds, respectively.
On the basis of the fingerprint pair-based score differences in
Table 1, all 15 fingerprint combinations were considered for
further analysis of discontinuity score distributions.
Score Differences and Fingerprint Combinations.
Table 2 reports the number of fingerprint combinations that
produced large score differences and the corresponding
numbers of compounds. In addition, the average number of
neighbors (meeting or exceeding the fingerprint similarity
thresholds) of these compounds is reported. For 30.7% and
70.1% of all compounds, no fingerprint combination generated
score differences ≥0.2 and ≥0.4, respectively. These data are
consistent with the score difference distribution in Figure 1.
However, 1−11 different fingerprint combinations yielded
score differences ≥0.2 for thousands of compounds each and
1−8 combinations differences ≥0.4 for comparable numbers of
compounds. Thus, multiple fingerprint combinations were
generally responsible for substantial changes in SAR disconti-
nuity, and large proportions of active compounds experienced
large changes in their structural neighborhoods for multiple
fingerprints.
Fingerprint Combinations and Compound Neighbor-
hoods. Table 2 also reveals a steady decrease in the number of
structural neighbors of compounds for which increasing
numbers of fingerprint combinations generated large changes
in SAR discontinuity. For compounds that did not yield score
differences ≥0.2 and ≥0.4, on average more than 100 and 90
structural neighbors were detected, respectively. Thus, these
compounds were very similar to many others. By contrast, for
compounds for which increasing numbers of fingerprint
combinations led to substantial score changes, decreasing
numbers of structural neighbors were detected. For example,
Table 3. Compound Neighborhood Statistics for Different
Fingerprint Combinationsa
Δscore ≥ 0.2 Δscore ≥ 0.4
no. FP combinations category A category B category A category B
0 2.9 97.1 2.3 97.6
1 1.1 98.9 4.4 95.5
2 1.6 98.4 6.1 93.9
3 2.1 97.9 8.2 91.8
4 3 97.0 10.4 89.6
5 9.9 90.2 29 70.9
6 4.2 95.8 15.8 84.2
7 4.6 95.4 23.2 76.8
8 11.5 88.5 39.2 60.7
9 14.3 85.7 46.5 53.4
10 13.5 86.5 62.4 37.7
11 25.3 74.7 69.1 30.9
12 30.7 69.3 0 0
13 42.4 57.6 not possible
14 78.5 21.4 not possible
15 0 0 not possible
aThe number of fingerprint combinations yielding a score difference
(Δscore) of at least 0.2 and 0.4 is reported for all compounds. For
each pair of fingerprints, the fingerprint-dependent compound
neighborhoods are determined and classified as distinct (i.e., two
fingerprints produce different sets of structural neighbors; category A)
or overlapping (i.e., two fingerprints produce a subset of shared
structural neighbors; category B). In addition, the average percentage
of distinct and overlapping neighborhoods calculated for all finger-
prints (no. FP combinations = 0) and for only those fingerprints that
participate in pairs yielding Δscore ≥ 0.2 or Δscore ≥ 0.4 (no. FP
combinations ≥1) are reported. Three numbers of fingerprint
combinations for which Δscore ≥0.4 cannot be obtained (see legend
of Table 2) are designated as “not possible”.
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for compounds whose discontinuity scores were notably
changed by eight different fingerprint combinations, on average
only 58 (Δscore ≥0.2) and 30 (Δscore ≥0.4) neighbors were
identified (Table 2). Thus, compounds whose SAR character-
istics were increasingly fingerprint-dependent formed fewer
similarity relationships than other compounds; another
unexpected finding.
Compound neighborhoods are further analyzed in Table 3.
Most of the compound neighborhoods generated with different
fingerprints were overlapping (Category B). However, for
compounds for which multiple fingerprint combinations
produced substantial score changes, increasing numbers of
distinct neighborhoods (Category A) were observed, i.e.,
neighborhoods that did not share any compounds. For
example, for compounds whose scores were significantly altered
by eight different fingerprint combinations, on average ∼12%
(Δscore ≥0.2) and ∼39% (Δscore ≥0.4) of their neighbor-
hoods generated with these fingerprints were distinct (Table 3).
Thus, different fingerprints often produced nonoverlapping
similarity relationships that led to large changes in local SAR
discontinuity.
Local SAR Environments. In Figure 3, local SAR
environments centered on exemplary compounds are compared
for different fingerprints with the aid of similarity-based
molecular networks,23 which illustrate changes in local SAR
information. In Figure 3A, an active compound is shown for
which two fingerprints (ECFP4, MACCS) did not yield
structural neighbors. Thus, in these cases, the compound was
Figure 3. Local SAR environments. In (A) and (B), the chemical neighborhood of two exemplary compounds in their data sets is shown when
similarity relationships are calculated using the six different fingerprints. Compounds A and B are muscarinic acetylcholine receptor M5 antagonists
(ChEMBL ID 2035). Sections of network-like similarity graphs (NSGs)23 are displayed representing the fingerprint-dependent neighborhoods of
each compound. In NSGs, compounds are represented as nodes and edges similarity relationships. For each fingerprint, the corresponding Tc
similarity threshold values reported in the Materials and Methods section are applied as a similarity (edge) criterion. Nodes are numbered, color-
coded by compound potency using a color spectrum ranging from red (high) over yellow (intermediate) to green (low potency) and scaled in size
by local discontinuity scores. For compounds A and B and each fingerprint, the discontinuity score and the number of structural neighbors (#Neigh)
applying the fingerprint-dependent Tc threshold values are reported.
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a singleton carrying essentially no SAR information. In
addition, two other fingerprints (FCFP4, GpiDAPH3)
identified only a single neighbor. By contrast, TGT and
especially TGD detected multiple neighbors with varying
potency. Thus, in these local environments, the test compound
introduced a high degree of SAR discontinuity. Discontinuity
scores for this compound varied from 0.11 (MACCS) to 0.88
(TGD). In the TGD-dependent neighborhood, the compound
formed multiple activity cliffs (combinations of large red and
green nodes in Figure 3A) and hence obtained a high
discontinuity score. Thus, the SAR character of this compound
and its associated SAR information content completely changed
dependent on the fingerprint that was used.
Furthermore, in Figure 3B, another exemplary compound is
shown for which different fingerprints consistently detected
multiple neighbors. The fingerprint-dependent neighborhoods
were partly overlapping and distinct and resulted in very
different local SAR environments, reflected by either low or
high discontinuity scores ranging from 0.28 (MACCS) to 0.97
(TGT). For MACCS, TGD, and TGT, the test compound
formed increasing numbers of activity cliffs in its neighborhood
and was thus highly discontinuous. Thus, in these cases, this
compound would be assigned a key compound for SAR
analysis. By contrast, in the ECFP4-, FCFP4-, and GpiDAPH3-
dependent environments, most structural neighbors had
potency values very similar to the test compound, which
resulted in low/intermediate discontinuity scores. In these
cases, the compound would not be considered as a focal point
of SAR analysis. Thus, the SAR characteristic of the compound
in Figure 3B also fundamentally changed with different
fingerprint representations.
The exemplary compounds in Figure 3 had score differences
≥0.4 for eight (compound A) and nine (B) different fingerprint
combinations, respectively. Score differences were in seven (A)
and four (B) cases due to the presence of distinct neighbors
and in one (A) and five (B) cases due to partly overlapping
fingerprint-dependent neighborhoods. Thus, the local SAR
environments of these exemplary compounds often fundamen-
tally differed. These findings illustrate that a very different
conclusion concerning local SAR features in compound data
sets might be drawn when alternative fingerprints are used.
■ CONCLUSIONS
Herein we have reported a first quantitative and large-scale
analysis of fingerprint-dependent changes in SAR information
associated with ∼60 000 compounds active against 128
different targets. Different types of 2D fingerprints were
compared including structural fragment, atom environment,
and pharmacophore fingerprints. The analysis was facilitated by
a consistent quantitative assessment of per compound SAR
discontinuity and revealed a number of unexpected findings, as
summarized in the following: For ∼70% of all compounds,
substantial changes in SAR discontinuity were detected, and for
∼30% of all compounds, different numbers of fingerprint
combinations were found to change their SAR phenotype; a
much larger proportion of compounds that would have been
estimated on the basis of similarity score distributions.
Furthermore, we have found that compounds forming below-
average numbers of similarity relationships to others displayed a
particularly strong fingerprint dependence of their local SAR
environments. Moreover, we have determined that in nearly all
of the combinations of fingerprints we analyzed (except the
most closely related ones such as ECFP4 and FCFP4), we led
to large differences in compound-associated SAR information,
more so than we had anticipated. Atom environment and
pharmacophore fingerprints produced largest differences in
SAR information. A major conclusion from our study is that
SAR phenotypes of many compounds change when alternative
fingerprints are used. Thus, ensuing SAR differences are not
gradual but often fundamental. This makes it essentially
impossible to draw general conclusions concerning local
SARs and individual compounds. Key compounds representing
centers of SAR discontinuity in data sets identified with a given
fingerprint might not be detected when other fingerprints are
used. In SAR analysis, awareness should be raised concerning
the unexpectedly large magnitude of these effects and the
resulting inconsistency of many SAR models produced by
widely used fingerprints. In the future, the current analysis
might be further extended to alternative sets of numerical
descriptors, which are typically preferred for QSAR modeling.
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CHAPTER 5: SUMMARY
Summary
A large-scale SAR profiling analysis was carried out on more than 60, 000 com-
pounds that were organized into 128 target-based sets. Local per-compound
discontinuity scores were calculated and changes in the score for nearly 70% of
the compounds observed. Furthermore, for ∼ 30% of all compounds, the use of
alternative fingerprint representations led to a change in the SAR phenotype.
In addition, compounds involved in relatively limited numbers of structural re-
lationships displayed a stronger tendency to change their SAR characteristics
when alternative fingerprints were used. In light of these observations, SAR
characteristics often considerably changed and hence were highly fingerprint-
dependent. My contributions to this work have been the systematic assessment
of local discontinuity scores and data analysis.
In this and the previous study, we have addressed the fingerprint-dependent
changes of SAR characteristics and analyzed the frequency of occurrence of
activity cliffs. Another thus far unexplored question has been whether SAR
information associated with activity cliffs might more frequently result in com-
pound series with steadily increasing potency. Therefore, we have designed a
study to investigate the potential activity cliff advantage for SAR progression.
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Chapter 6
Compound Pathway Model To
Capture SAR Progression:
Comparison of Activity
Cliff-Dependent and
-Independent Pathways
Introduction
The SAR exploration has a major influence on compound optimization and
practical medicinal chemistry. Activity cliffs are focal points of SAR analysis
and have been extensively studied from many different perspectives. However,
it is currently unknown if there is a detectable SAR advantage in optimizing
compounds involved in activity cliffs compared to other compounds available
as starting points for SAR analysis. To investigate this question, we have de-
signed a computational compound pathway model to represent compound series
with steadily increasing potency ultimately leading to highly potent data set
compounds. Three major pathway categories have been introduced and distin-
guished by their origin. Relative pathway frequencies have been determined to
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serve as a diagnostic for SAR information gain associated with different types
of data set compounds.
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ABSTRACT: A compound pathway model is introduced to
monitor SAR progression in compound data sets. Pathways are
formed by sequences of structurally analogous compounds with
stepwise increasing potency that ultimately yield highly potent
compounds. Hence, the model was designed to mimic compound
optimization efforts. Different pathway categories were defined.
Pathways originating from any active compound in a data set were
systematically identified including compounds forming activity
cliffs. The relative frequency of activity cliff-dependent and
-independent pathways was determined and compared. In 23 of
39 different compound data sets that qualified for our analysis, significant differences in the relative frequency of activity cliff-
dependent and -independent pathways were observed. In 17 of these 23 data sets, activity cliff-dependent pathways occurred with
higher relative frequency than cliff-independent pathways. In addition, pathways originating from the majority of activity cliff
compounds displayed desired SAR progression, reflecting SAR information gain associated with activity cliffs.
■ INTRODUCTION
Capturing SAR information in compound data sets of any
source is a prime task in computational medicinal chemistry,1,2
in addition to, for example, QSAR-based compound activity
predictions.3 SAR information can be extracted from
compound activity data through numerical and/or graphical
analysis.1,2 In general terms, SAR information extraction
requires the systematic study of structural and potency
relationships between active compounds and the identification
of series with defined SAR characteristics such as SAR
continuity or discontinuity.2 Numerical and graphical analysis
components are typically combined to model activity landscape
representations of compound data sets that integrate structural
and potency relationships in a systematic manner.2 Cardinal
features of activity landscapes are activity cliffs that are formed
by pairs or groups of compounds with large potency
differences.4−6 The activity cliff concept is popular because
activity cliffs encode small structural changes leading to large
potency alterations, which is generally thought to associate
activity cliff compounds with high SAR information content.4,6
Activity landscapes and activity cliffs have been studied using a
variety of molecular representations and similarity meas-
ures2,6−8 also including structurally conservative approaches
that limit the formation of cliffs to analogous compounds.9
Compared to whole-molecule similarity calculations, the latter
approach further supports the interpretation of activity cliffs
from a chemical perspective, which is important for practical
SAR analysis. Systematic surveys of activity cliffs in public
domain compounds have been carried out to characterize
activity cliff populations10,11 and their potency range distribu-
tions.11 Depending on the chosen molecular representations
and similarity criteria considered, only ∼4−6% of all pairs of
qualifying similar active compounds formed activity cliffs,
confirming that cliffs are a rare activity landscape feature. On
the other hand, ∼20−30% of all compounds with high-
confidence activity annotations across different targets were
found to be involved in the formation of at least one large-
magnitude activity cliff.11 Thus, activity cliffs can be identified
in essentially all compound data sets and provide possible
starting points for SAR exploration.
Although activity cliffs have been studied in different ways,
either from a more computational or chemical perspective, they
have thus far not been evaluated in the context of SAR
progression, which refers to compound series with steadily
increasing potency that ultimately yield highly potent
compounds. Therefore, we put the evaluation of activity cliffs
here into the broader context of compound pathway analysis.
Introducing a pathway model that mimics chemical optimiza-
tion, we systematically monitored SAR progression in a variety
of data sets evolving over time by considering any compound as
a potential starting point including compounds forming activity
cliffs. Overall, activity cliff-dependent pathways leading to
highly potent compounds were observed with higher relative
frequency than pathways originating from other active
compounds. These findings further support the preferential
consideration of activity cliffs for SAR exploration and
compound optimization.
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■ MATERIALS AND METHODS
Transformation Size-Restricted Matched Molecular
Pairs. A matched molecular pair (MMP)12 is formed by two
structurally related compounds that are distinguished at a single
site through the exchange of a substructure, a so-called chemical
transformation.13 Transformation size restrictions have been
introduced to confine MMPs to structurally analogous
compounds distinguished by functional groups or an individual
ring system.9 Such transformation size-restricted MMPs were
calculated using an in-house implementation of the algorithm
by Hussain and Rea.13 If several transformations met the size
limitations for a given compound pair, the smallest trans-
formation was selected.
Activity Cliff Criteria. In our analysis, we followed the
definition of MMP cliffs,9 a structurally conservative approach
that usually limits the formation of cliffs to structural analogs,
which we considered important in the context of compound
pathway analysis. Accordingly, as a similarity criterion, the
formation of a transformation size-restricted MMP was applied,
and as a potency difference criterion, a difference in equilibrium
constants between the two MMP-forming compounds of at
least two orders of magnitude was required.
Potency-Directed Compound Pathways. MMP-based
potency-directed compound pathways were introduced to
capture compound series with positive potency progression.
Pathway compounds were required to form stepwise over-
lapping MMPs, e.g., three compounds X, Y, and Z qualified for
a pathway X−Y−Z if the two MMPs [X,Y] and [Y,Z] existed.
In addition, pathway compounds were required to have
stepwise increasing potency (i.e., potency X < Y < Z).
Furthermore, the endpoint of a pathway (i.e., Z) had to belong
to the 10% most potent compounds within a data set (in the
following referred to as D), and the starting point (i.e., X) had
to fall outside of this subset of the most potent compounds.
Two different categories of pathways were distinguished
depending on their origin. In a given compound data set, all
activity cliffs were determined, and each highly potent activity
cliff partner not belonging to the top 10% most potent
compounds, in the following referred to as B, provided a
potential starting point for activity clif f-dependent compound
pathways. Weakly potent activity cliff partners (referred to as A)
were not considered as pathway starting points. The activity
cliff compound defined the beginning of the time course for
pathway progression. In addition, all compounds in a data set
not involved in the formation or progression of any activity cliff
and not belonging to the top 10% most potent compounds, in
the following referred to as C, provided potential starting points
for activity clif f-independent compound pathways. All pathways
formed by a minimum of two compounds including the starting
point were calculated. The pathway model is schematically
illustrated in Figure 1. Increasingly potent pathway candidate
compounds were only considered if they became available
during the same or subsequent years compared to the
preceding pathway compound (i.e., a more potent analog was
not included in a pathway if it became available earlier than the
preceding compound). Thus, pathway analysis monitored
possible SAR progression over a time course.
Compound data analysis and pathway calculations were
carried out with in-house generated Java programs or KNIME14
protocols.
Pathway Frequency. A normalized pathway frequency was
calculated for activity cliff-dependent and -independent
compound pathways. Therefore, for each of the top 10%
most potent compounds (D in Figure 1A), the ratio of
qualifying pathways originating from B (i.e., activity cliff-
dependent) or C compounds (i.e., activity cliff-independent)
over all possible compound pathways was calculated (i.e., all
possible MMP sequences leading from B or C to D,
respectively). For each data set, the average normalized
frequencies were calculated for all D compounds that were
pathway endpoints.
Compound Data Sets. To evaluate SAR progression in a
systematic manner, we searched ChEMBL15 (release 14) for
target-based compound data sets that evolved over time and in
which at least a 10% average frequency for activity cliff-
dependent or -independent pathways was observed. Each data
set had to contain at least 100 compounds active against a
human target with direct interactions (ChEMBL relationship
type “D”) at the highest confidence level (ChEMBL confidence
score “9”).15 In addition, equilibrium constants (Ki values) had
to be available as potency measurements for all data set
compounds. If several Ki values were available for a compound,
the most recent measurement was used. To account for data set
evolution over time, the condition was applied that compounds
comprising a set had to be reported in increments over a period
of at least five subsequent years. During each year, the addition
of a new compound subset was required.
Figure 1. Compound pathways. (A) Schematic illustration of different
categories of qualifying potency-directed compound pathways. Highly
potent activity cliff partners (B compounds) represent potential
starting points of activity cliff-dependent pathways. The weakly potent
cliff partners are denoted as A compounds and not further considered.
Data set compounds not involved in a cliff formation and not a part of
a cliff-dependent pathway (C compounds) represent potential starting
points of activity cliff-independent pathways. Activity cliff-dependent
and -independent pathways can merge either within the subsets of the
10% most potent data set compounds (D) or prior to reaching these
compounds. Intermittent pathway compounds are depicted in gray.
(B) D compounds belonging to different types of pathways.
Compound 1 belongs only to an activity cliff-dependent pathway.
Compounds 2 and 3 belong to a merging pathway. Compounds 4 and
5 belong only to an activity cliff-independent pathway.
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■ RESULTS AND DISCUSSION
Pathway Model of SAR Progression. Our compound
pathway model was designed to capture SAR progression in a
compound activity class. Series of structurally analogous
compounds with steady potency progression toward the most
potent compounds found in a data set served as a model for
compound optimization paths. Therefore, structural relation-
ships between compounds were established on the basis of
sequentially overlapping MMPs with size-restricted structural
changes. Furthermore, the formation of pathways was limited
to series of increasingly potent compounds that were reported
during the same or subsequent years. Hence, a more potent
analog in a pathway was not permitted to be reported earlier
than a less potent one. This additional restriction was
introduced to model compound optimization over time.
Pathways were differentiated according to their origins and
potential overlap, as further discussed below.
Activity Cliff-Dependent and -Independent Pathways.
Applying the pathway model, we systematically determined
qualifying pathways that originated from active compounds and
compared activity cliff-dependent and -independent pathways.
Figure 1A illustrates the different pathway categories we
considered. Activity cliff-dependent pathways start from the
highly potent activity cliff partner and contain compounds with
further increasing potency. The assumption underlying the
Figure 2. Exemplary pathway. Example of a merging pathway from the leukocyte elastase inhibitor data set shown in detail. Pathway starting points
are color-coded according to Figure 1. Structural changes between pairs of compounds in a pathway are highlighted using corresponding colors, and
compounds are labeled with their pKi values.
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activity cliff concept is that comparison of the cliff partners
provides interpretable SAR information and identifies potential
SAR determinants that might aid in the design of compounds
with further increased potency. For activity cliff-independent
pathways that can originate from any other data set compound,
no such SAR information is available at the beginning. In
addition, merging pathways can be found that combine
compounds from activity cliff-dependent and -independent
pathways either before or after reaching the top 10% most
potent compounds. Figure 1B shows D compounds dependent
on their pathway membership(s). For statistical analysis,
merging pathways are counted as both activity cliff-dependent
and -independent pathways because their D compounds can be
separately reached by both pathway categories. Figure 2 shows
an exemplary merging pathway in detail.
Pathway Detection. Key questions of our analysis included
whether (i) the pathway model would reveal differences in the
distribution of different compound pathway categories and
whether or not (ii) SAR information associated with activity
cliffs might more frequently result in compound pathways with
SAR progression than the use of other active compounds as
starting points.
Table 1. Evolving Compound Data Sets and Pathway Statisticsa
no.
ChEMBL target
ID target #Cpds
#D from
only B
#D from
only C
#D from B
and C
B norm.
freq.
C norm.
freq.
Δ norm.
freq.
1 4617 phenylethanolamine N-
methyltransferase
148 10 0 1 0.85 0.08 0.77
2 249 neurokinin 1 receptor 211 7 1 0 0.88 0.17 0.71
3 299 protein kinase C alpha 168 9 2 2 0.76 0.17 0.59
4 2243 anandamide amidohydrolase 101 1 6 0 1.00 0.43 0.58
5 248 leukocyte elastase 192 0 7 7 0.93 0.48 0.45
6 3795 melanocortin receptor 1 134 5 0 0 0.38 0.00 0.38
7 211 muscarinic acetylcholine receptor M2 199 5 0 0 0.36 0.00 0.36
8 3837 cathepsin L 201 11 2 0 0.40 0.13 0.27
9 268 cathepsin K 272 18 0 0 0.26 0.00 0.26
10 1997 equilibrative nucleoside transporter 1 118 4 0 0 0.25 0.00 0.25
11 1855 gonadotropin-releasing hormone
receptor
267 12 5 5 0.33 0.08 0.24
12 4822 beta-secretase 1 116 2 0 0 0.22 0.00 0.22
13 5071 G protein-coupled receptor 44 376 18 8 5 0.35 0.15 0.20
14 3759 histamine H4 receptor 334 13 6 7 0.32 0.13 0.19
15 4561 neuropeptide Y receptor type 5 234 11 8 2 0.31 0.16 0.15
16 213 beta-1 adrenergic receptor 175 7 3 1 0.30 0.18 0.12
17 344 melanin-concentrating hormone
receptor 1
870 32 18 28 0.20 0.09 0.11
18 1889 vasopressin V1a receptor 318 13 0 7 0.41 0.32 0.09
19 2954 cathepsin S 371 14 6 2 0.19 0.11 0.08
20 2014 nociceptin receptor 599 14 17 12 0.23 0.17 0.06
21 4308 bradykinin B1 receptor 415 19 6 3 0.13 0.08 0.05
22 219 dopamine D4 receptor 436 8 21 0 0.18 0.15 0.03
23 244 coagulation factor X 1198 25 32 26 0.14 0.11 0.03
24 245 muscarinic acetylcholine receptor M3 343 10 13 0 0.28 0.25 0.02
25 234 dopamine D3 receptor 881 26 25 12 0.12 0.10 0.02
26 214 serotonin 1a (5-HT1a) receptor 938 16 49 2 0.14 0.12 0.02
27 1800 corticotropin releasing factor receptor 1 477 14 15 9 0.26 0.24 0.01
28 228 serotonin transporter 1099 21 63 3 0.14 0.13 0.01
29 204 thrombin 808 23 21 13 0.12 0.12 0.00
30 259 melanocortin receptor 4 1273 51 21 45 0.09 0.10 −0.01
31 231 histamine H1 receptor 187 1 9 0 0.33 0.38 −0.04
32 3371 serotonin 6 (5-HT6) receptor 888 3 54 1 0.02 0.12 −0.10
33 3798 calcitonin gene-related peptide type 1
receptor
246 2 16 0 0.11 0.21 −0.10
34 284 dipeptidyl peptidase IV 276 8 13 0 0.21 0.38 −0.17
35 1836 prostanoid EP4 receptor 194 3 9 0 0.08 0.28 −0.20
36 264 histamine H3 receptor 1515 9 94 8 0.06 0.28 −0.22
37 1945 melatonin receptor 1A 215 0 11 0 0.00 0.29 −0.29
38 1946 melatonin receptor 1B 262 1 16 0 0.04 0.42 −0.38
39 1914 butyrylcholinesterase 159 0 13 0 0.00 0.87 −0.87
aAll 39 compound data sets meeting the selection criteria are listed. For each set, the number of compounds (#Cpds) and the ChEMBL target ID
are given. In addition, the numbers of D compounds detected only by activity cliff-dependent pathways (#D from only B), only by activity cliff-
independent pathways (#D from only C), or by merging pathways (#D from B and C) are reported. Furthermore, the normalized frequencies of
activity cliff-dependent (B norm. freq.) and -independent (C norm. freq.) and the frequency difference (Δ norm. freq.) are given. Data sets are
ranked in the order of decreasing frequency difference.
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Therefore, we have systematically determined all activity cliff-
dependent, -independent, and merging pathways in the 39
evolving compound data sets.
Table 1 reports that differences in relative pathway frequency
of different magnitude were indeed observed in many data sets.
In a few data sets, activity cliff-dependent or -independent
pathways originated on average from nearly each B or C
compounds, respectively, whereas in other sets one and/or the
other pathway category occurred with only very low frequency,
as further discussed below. The presence of compound
pathways represented a general diagnostic of SAR information
content in the evolving compound data sets. Substantial
differences in SAR information content were observed on the
basis of pathway frequency.
Concerning pathway statistics, the following general criteria
were taken into consideration. On average, there were 8.9 and
45.6 B and C compounds per data set, respectively, which met
the starting point criteria. Because the data sets contained more
qualifying C than B compounds, there was an intrinsically
higher statistical probability to observe cliff-independent
pathways. On the other hand, B compounds as pathway
starting points would have a higher likelihood to reach the most
potent D compounds in a data set provided the potency of B
compounds was generally higher than the potency of (noncliff)
C compounds. This possibility was examined by comparing the
potency distribution of B and C compounds across all data sets,
as reported in Figure 3. The results show that the potency
distribution and median potency values for starting points of
activity cliff-dependent and -independent pathways were very
similar. Hence, there was no significant potency level advantage
for pathways originating from activity cliffs.
Pathway Comparison. Given the general differences in the
number of B and C compounds, pathway utilization was
quantified and compared by calculating the relative frequency
of activity cliff-dependent and -independent pathways with SAR
progression normalized with respect to the number of all
possible pathways within each category, i.e., all MMP sequences
originating from either B or C compounds. As rationalized
above, for statistical analysis, merging pathways qualified as
both cliff-dependent and -independent pathways. The results of
pathway frequency calculation and comparison reported in
Table 1 reveal differences in the normalized frequency of
pathways originating from B and C compounds of more than
10% in 23 of 39 data sets. In 16 data sets, the pathway
frequencies were comparable, although their magnitude varied
considerably (reflecting data set-dependent differences in SAR
information content). The frequency difference distribution for
the 23 data sets with more than 10% difference is monitored in
Figure 4. In 17 of these 23 data sets, activity cliff-dependent
pathways were observed with in part much higher relative
frequency than cliff-independent pathways. For example, for
phenylethanolamine N-methyltransferase inhibitors, there were
on average 0.85 qualifying pathways per B and close to 0
pathways per C compound. On the other end of the pathway
frequency spectrum, the butyrylcholinesterase inhibitor data set
stood out in which the relative frequency of qualifying pathways
originating from C compounds was 0.87, while no activity cliff-
dependent pathways were observed (despite the presence of
activity cliffs in this data set). However, overall there were only
six of 23 data sets in which activity cliff-independent pathways
occurred with higher frequency, as shown in Figure 4.
In addition to pathway frequencies, we also determined
which D compounds were reached by pathways belonging to
different categories, as also reported in Table 1. On average,
72.0% of all D compounds in a data set were reached by
pathways. In 21 of 39 cases, activity cliff-dependent pathways
detected more D compounds than cliff-independent pathways,
although on average five to six times more C than B
compounds were available per data set. Furthermore, pathways
originating from 53.9% and 28.1% of all B and C compounds,
respectively, reached D compounds. Table S1 of the Supporting
Information reports statistics of B, C, and D compounds and
their pathway engagement for all data sets.
Concluding Remarks. We have investigated a compound
pathway model to systematically detect compound series with
Figure 3. Potency distribution of pathway starting points. Potency
distribution of the pathway starting points B and C from all data sets in
boxplots.
Figure 4. Pathway frequency difference. Difference between
normalized frequencies of activity cliff-dependent and -independent
pathways targets reported for all 23 data sets with a more than 10%
difference. Positive and negative differences indicate larger frequencies
of activity cliff-dependent and -independent pathways, respectively.
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SAR progression in diverse evolving data sets. Hence, pathway
and SAR progression were monitored over time. Different
pathway categories were defined to distinguish between
compound pathways originating from activity cliffs and
pathways originating from other active compounds. Activity
cliffs present in all data sets were identified, and all qualifying
activity cliff-dependent, -independent, and merging pathways
were determined. The pathway model does not reveal how
compounds are chemically explored and how activity cliffs are
generated that serve as pathway start points. In fact,
optimization efforts might produce compounds forming
multiple and overlapping cliffs as a part of a variety of
compound series. In our analysis, all activity cliffs were
individually considered as potential pathway origins at the
level of compound pairs. Compound pathways were required to
follow a time course such that they also might represent
optimization paths. Yet, it was not possible to determine on the
basis of our analysis whether or not pathways represented
actual optimization paths. However, the pathway model is
designed to determine in a consistent manner where compound
series with defined potency progression originate that lead to
the most potent compounds present in a data set, and activity
cliff-dependent and -independent pathways are clearly dis-
tinguished.
A key finding of our analysis has been that activity cliff-
dependent pathways with desirable SAR progression were
detected with higher relative frequency among potential paths
than cliff-independent ones. Furthermore, pathways originating
from the majority of activity cliffs reached highly potent
compounds. Hence, there has been evidence for better SAR
progression originating from activity cliffs than other
compounds, consistent with the assumption that activity cliffs
often reveal SAR determinants.
Hence, taken together, our findings supported the utility of
the pathway model to monitor SAR progression in compound
data sets and indicated that activity cliff-dependent pathways
were more likely to yield well-defined SAR progression than
pathways originating from other active compounds.
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CHAPTER 6: SUMMARY
Summary
Herein, we have introduced a compound pathway model to capture positive
SAR progression in compound series evolving over time. Pathways originating
from activity cliffs (cliff-dependent), starting from any other data set compound
(cliff-independent), and combining compounds from activity cliff-dependent and
-independent pathways (merging) were systematically determined. Our results
revealed that cliff-dependent pathways with positive SAR progression occurred
with higher relative frequency than cliff-independent ones. Furthermore, on av-
erage, 72% of the most potent data set compounds were reached by pathways.
In addition, 53.9% and 28.1% of all cliff-dependent and cliff-independent path-
ways have reached the most potent compounds, respectively. Taken together,
our findings provided clear evidence for improved SAR progression originating
from activity cliffs. My contributions to this study have been the implementa-
tion and analysis of the pathway model.
Having found an indication for SAR information gain associated with ac-
tivity cliffs, we have next investigated the question whether or not we can find
evidence to what extent activity cliffs are utilized as starting points in practical
compound optimization efforts.
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Chapter 7
Do Medicinal Chemists Learn
from Activity Cliffs? A
Systematic Evaluation of Cliff
Progression in Evolving
Compound Data Sets
Introduction
Activity cliffs are associated with high SAR information content and their study
is of major importance for practical medicinal chemistry. Although the concept
of activity cliffs is becoming increasingly attractive, it is currently unknown to
what extent SAR information provided by activity cliffs is utilized in compound
optimization efforts. This is a nontrivial question and difficult to address, es-
pecially from a computational perspective. However, providing answers to this
question would provide an indication of the proportion of currently unexplored
activity cliffs and potentially point of further opportunities for activity cliff anal-
ysis in medicinal chemistry. To investigate this question, we have carried out a
comprehensive analysis of publicly available compound data sets that evolved
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over time and systematically searched for analogues of cliff-forming compounds
with increasing potency.
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ABSTRACT: Activity cliffs are defined as pairs of structurally similar compounds with a
significant difference in potency. These compound pairs have high SAR information content
because they represent small structural changes leading to large potency alterations. Accordingly,
activity cliffs are of prime interest for SAR exploration and compound optimization. It is currently
unknown to what extent activity cliff information is utilized in practical medicinal chemistry.
Therefore, we have assembled 56 compound data sets that evolved over time and searched for
analogues of activity cliff-forming compounds with further increased potency. For ∼75% of all
activity cliffs, there was no evidence for further chemical exploration. For ∼25% of all cliffs, potency
progression was detected. In total, for ∼15% of all activity cliffs, positive cliff progression was
observed that often involved multiple analogues. Given these findings, chemically unexplored
activity cliffs should provide significant opportunities for further study in medicinal chemistry.
■ INTRODUCTION
The study of activity cliffs has experienced increasing interest in
medicinal chemistry.1,2 Activity cliffs have been defined as pairs
of structurally similar or analogous compounds with large potency
differences.1 Such compound pairs are an immediate source of SAR
information, which makes the activity cliff concept attractive for
medicinal chemistry.2 In addition, activity cliffs represent the most
prominent features of activity landscape representations3 that
are modeled to make SARs contained in compound data sets
graphically accessible.
Activity cliffs have been systematically surveyed in publicly
available compounds, and cliffs were consistently found in sets of
compounds with activity against a wide range of targets.4,5 In a
detailed search for activity cliffs in currently available active
compounds, ∼5% of all pairs of structural analogues formed
activity cliffs spanning a potency difference of at least 2 orders of
magnitude.5 More than 20% of all active compounds participated
in these cliffs, albeit at different frequencies. Hence, although
activity cliffs were widely distributed, only a small percentage of
all pairs of structurally analogous compounds formed cliffs of
significant magnitude. On the other hand, on average, every fifth
compound was involved in at least one activity cliff. Thus, activity
cliffs were often available in compound data sets as potential
starting points for SAR exploration.
There is little doubt that the study of activity cliffs is relevant
from a data analysis perspective, taking statistical, information-
theoretic, and/or SAR criteria into account. But what about the
practice of medicinal chemistry? Activity cliffs are certainly
considered in hit-to-lead and lead optimization. Intuitively and
on the basis of casual individual experiences, one would assume
that activity cliffs are given serious consideration in lead optimi-
zation projects. However, is there an objectively measurable
general impact on optimization efforts? Can one find firm evidence
for the generation of increasingly potent compounds originating
from activity cliffs? Analyzing these questions would help to
further evaluate the relevance of the activity cliff concept for
medicinal chemistry. Currently, there is little, if any, information
available concerning the general impact of activity cliff infor-
mation on compound optimization.
In order to explore this question in a systematic way, we have
assembled compound data sets evolving over time and identified
activity cliffs formed by structural analogues. We then determined
for all qualifying activity cliffs whether analogues of potent cliff
partners became available over time and studied the potency
distribution of analogues. For a thorough assessment of activity
cliff progression, different categories of cliffs were introduced.
The results of our analysis are reported herein.
■ MATERIALS AND METHODS
Compound Data Sets. Target-based compound data sets evolv-
ing over time were selected from ChEMBL,6 version 14. Candidates
for evolving data sets were prescreened for the presence of clearly
defined activity cliffs, as further specified below. Only compounds
active against human targets at the highest confidence level
(ChEMBL confidence score 9) with reported direct binding interactions
(ChEMBL relationship type D) and with equilibrium constants (Ki)
available as potency measurements were selected. If several Ki values
were reported for a compound, the most recent measurement was used.
A qualifying target-based compound set had to contain at least 100
compounds reported in increments over a period of at least 5 sub-
sequent years (i.e., for each year, addition of a subset of new compounds
was required). Periods over which evolving compound data sets were
monitored ranged from 5 to 18 years. The progression of an exemplary
data set over time is reported in Table 1, and all 56 data sets are listed in
Table 2.
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Size-Restricted Matched Molecular Pairs. A matched molecular
pair (MMP)7 is defined as a pair of compounds that only differ at a single
site, i.e., that can be interconverted by the exchange of a fragment. An
exemplary MMP is shown in Figure 1. For all target sets, MMPs
were systematically generated using an in-house implementation of the
Hussain and Rea algorithm.8 ForMMP generation, size restrictions were
applied to the common core structure of compounds forming an MMP
and the exchanged fragments, as reported previously.9
The size of exchanged fragments was limited to a maximum of 13
non-hydrogen atoms, and the maximal difference in size between frag-
ments was limited to eight non-hydrogen atoms. In addition, the core
structure of MMP-forming compounds was required to have at least
twice the size of the larger fragment. These upper-limit size restrictions
were introduced to ensure that chemical replacements were small and
chemically intuitive. Specifically, given these restrictions, the largest
permitted substitutions would include the addition of a substituted six-
membered ring to a compound or the replacement of a 5- or 6-
membered ring by a substituted 2-ring system containing a maximum of
10 ring atoms.
If alternative substructure exchanges were possible to generate an
MMP, the smallest structural transformation was applied. Introducing
these size limitations ensured that MMPs consisted of closely related
structural analogues.9 This protocol was applied to all 56 target sets and
resulted in the generation of 370−15890 MMPs per set.
Activity Cliff Criteria. For a consistent description of activity cliffs,
two criteria must be clearly defined including compound similarity and
the potency difference threshold. We followed the definition of MMP-
cliffs;9 i.e., two compounds qualified as structurally similar if they formed
a size-restricted MMP. This structurally conservative definition of activity
cliffs avoided ambiguities associated with calculation of numerical similarity
values on the basis of molecular descriptors.2 As a potency difference
threshold, a difference in equilibrium constants of at least 2 orders of
magnitude was required, which limited the analysis to activity cliffs of
significant magnitude5 and avoided potential bias due to the use of
approximate activity measurements.5 An exemplary MMP-cliff is shown
in Figure 1. The number of activity cliffs per compound set ranged from
51 to 1236.
Activity Cliff Categorization. Activity cliffs were systematically
identified in all evolving data sets, and the highly potent cliff partners
(hpCPs) were subjected to chemical neighborhood analysis over time by
searching for structural analogues. The search was carried out on the
basis of size-restricted MMPs; i.e., all subsequently reported compounds
were identified that formed MMPs with a highly potent cliff partner.
Then each activity cliffwas assigned to one of three categories (CAT), as
illustrated in Figure 2A.
(1) CAT I: No structural analogues of the hpCP were found in
evolving compound data sets.
(2) CAT II: One or more structural analogues of the hpCP with
further increased potency were identified.
(3) CAT III: One or more structural analogues of the hpCP were
found that did not display potency improvements or had reduced
potency.
Compound data analysis and activity cliffs calculations were
carried out with in-house generated Java programs or KNIME10
protocols.
■ RESULTS AND DISCUSSION
Analysis Concept. How can one obtain evidence for the
potential use of activity cliff information in medicinal chemistry?
This is a nontrivial question, especially if one would like to
explore it systematically. It is not possible to quantify medicinal
chemists’ intuition of how to best approach a compound optimi-
zation task. Neither is it possible to determine with certainty
whether activity cliffs have been taken into consideration nor
whether the notion of activity cliff(s) has served as a starting
point for an optimization effort.
However, it is possible to determine for each activity cliff
detected in a data set whether or not structural analogues of
potent cliff-forming compounds have subsequently been
reported. If SAR information provided by an activity cliff has
been utilized, analogues of the potent cliff partner might become
available. If this is not the case, i.e., if an activity cliff has remained
“isolated”, it can be concluded with certainty that the cliff has not
been further chemically explored. If analogues are available, the
situation is different. Although it cannot be confirmed that cliff
compounds have provided an immediate starting point for the
design of these analogues, it can be concluded with certainty that
the structural neighborhood of a cliff has been explored, a process
we refer to as “activity cliff progression”. Although lead optimi-
zation is a multiparametric process, the primary goal of exploring
activity cliff information is further increasing compound potency,
consistent with the SAR information provided by a cliff. Accordingly,
one can distinguish two principal outcomes of activity cliff
progression, i.e., either analogues of potent cliff partners display
further increased potency or not. The former case represents the
desirable positive result for consideration of activity cliffs in the
context of SAR analysis; i.e., the structural neighborhood of an
activity cliff has been explored, leading to the generation of
compounds with further increased potency.
On the basis of the above considerations, activity cliffs have
been categorized for the analysis of cliff progression, as detailed in
the section Materials and Methods. CAT I represents isolated
Table 1. Evolving Data Seta
Carbonic Anhydrase I Inhibitors (ChEMBL target no. 261)
year compd potency range (pKi) MMP activity cliff hpCP CAT I CAT II CAT III
1999 12 4.7−7.9 6 3 2 1 0 1
2004 107 1.3−9.2 164 17 9 0 2 7
2005 291 0.04−8.7 610 106 34 7 20 7
2006 89 2.6−8.1 231 49 10 2 4 4
2007 77 1.6−8.5 185 35 13 6 6 1
2008 88 1.9−8.8 246 63 14 3 4 7
2009 154 0.9−9.0 655 97 34 16 9 9
2010 194 0.5−7.7 707 41 7 5 1 1
2011 274 1.2−8.5 1432 159 44 44 0 0
aA representative example of a data set evolving over time is given (carbonic anhydrase I inhibitors). For each of 9 years, the number of newly
reported compounds and their potency range are provided as well as the number of MMPs and activity cliffs these compounds formed. In addition,
the number of highly potent cliff partners (hpCPs) the activity cliffs contained is given. According to the definition in the text, hpCPs were classified
into three categories (CAT I, CAT II, and CAT III). For consistency, all 56 evolving data sets we assembled included all compounds reported during
2011 as the final year.
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Table 2. Data Sets and Category Distributiona
CAT I CAT II CAT III
no. ChEMBL target no. target compd hpCP hpCP % hpCP % hpCP %
1 244 coagulation factor X 1198 313 225 71.9 82 26.2 6 1.9
2 237 κ opioid receptor 1304 185 94 50.8 64 34.6 27 14.6
3 261 carbonic anhydrase I 1286 167 84 50.3 46 27.5 37 22
4 256 adenosine A3 receptor 1710 178 84 47.2 46 25.8 48 27
5 205 carbonic anhydrase II 1361 118 56 47.5 33 28.0 29 24.6
6 3594 carbonic anhydrase IX 946 85 48 56.5 28 32.9 9 10.6
7 249 neurokinin 1 receptor 211 47 21 44.7 24 51.1 2 4.3
8 233 μ opioid receptor 1391 153 111 72.5 21 13.7 21 13.7
9 259 melanocortin receptor 4 1273 147 113 76.9 20 13.6 14 9.5
10 4617 phenylethanolamine N-methyltransferase 148 35 6 17.1 19 54.3 10 28.6
11 264 histamine H3 receptor 1515 146 98 67.1 18 12 30 20.5
12 253 cannabinoid CB2 receptor 1403 180 143 79.4 18 10 19 10.6
13 234 dopamine D3 receptor 881 115 88 76.5 15 13 12 10.4
14 1855 gonadotropin-releasing hormone receptor 267 59 35 59.3 14 23.7 10 16.9
15 251 adenosine A2a receptor 2114 208 179 86.1 13 6.3 16 7.7
16 1914 butyrylcholinesterase 159 29 11 37.9 13 44.8 5 17.2
17 238 dopamine transporter 628 52 38 73.1 11 21.2 3 5.8
18 3759 histamine H4 receptor 334 47 36 76.6 11 23.4 0 0.0
19 228 serotonin transporter 1099 59 43 72.9 10 16.9 6 10.2
20 218 cannabinoid CB1 receptor 1320 85 63 74.1 9 10.6 13 15.3
21 204 thrombin 808 93 82 88.2 8 8.6 3 3.2
22 344 melanin-concentrating hormone receptor 1 870 124 98 79.0 8 6.5 18 14.5
23 217 dopamine D2 receptor 1431 70 52 74.3 8 11.4 10 14.3
24 222 norepinephrine transporter 853 36 19 52.8 8 22.2 9 25
25 4822 β-secretase 1 116 22 12 54.5 8 36.4 2 9.1
26 226 adenosine A1 receptor 1859 120 102 85.0 7 5.8 11 9.2
27 4308 bradykinin B1 receptor 415 114 101 88.6 5 4.4 8 7.0
28 1800 corticotropin releasing factor receptor 1 477 85 78 91.8 5 5.9 2 2.4
29 214 serotonin 1a (5-HT1a) receptor 938 63 53 84.1 5 7.9 5 7.9
30 255 adenosine A2b receptor 798 57 46 80.7 4 7 7 12.3
31 284 dipeptidyl peptidase IV 276 26 19 73.1 4 15.4 3 11.5
32 268 cathepsin K 272 48 44 91.7 3 6.3 1 2.1
33 2014 nociceptin receptor 599 115 110 95.7 3 2.6 2 1.7
34 236 δ opioid receptor 1197 101 92 91.1 3 3 6 5.9
35 2954 cathepsin S 371 85 81 95.3 3 3.5 1 1.2
36 3798 calcitonin gene-related peptide type 1 receptor 246 29 23 79.3 3 10.3 3 10.3
37 1836 prostanoid EP4 receptor 194 28 25 89.3 3 10.7 0 0.0
38 3371 serotonin 6 (5-HT6) receptor 888 34 27 79.4 2 5.9 5 14.7
39 1997 equilibrative nucleoside transporter 1 118 13 11 84.6 2 15.4 0 0
40 245 muscarinic acetylcholine receptor M3 343 53 51 96.2 1 1.9 1 1.9
41 1889 vasopressin V1a receptor 318 43 42 97.7 1 2.3 0 0
42 213 β-1 adrenergic receptor 175 29 28 96.6 1 3.4 0 0
43 219 dopamine D4 receptor 436 22 17 77.3 1 4.5 4 18.2
44 5071 G-protein coupled receptor 44 376 54 54 100 0 0 0 0
45 4561 neuropeptide Y receptor type 5 234 51 51 100 0 0 0 0
46 299 protein kinase C alpha 168 35 33 94.3 0 0 2 5.7
47 224 serotonin 2a (5-HT2a) receptor 657 34 34 100 0 0 0 0
48 3837 cathepsin L 201 34 34 100 0 0 0 0
49 1946 melatonin receptor 1B 262 28 27 96.4 0 0 1 3.6
50 2243 anandamide amidohydrolase 101 28 28 100 0 0 0 0
51 211 muscarinic acetylcholine receptor M2 199 24 22 91.7 0 0 2 8.3
52 231 histamine H1 receptor 187 24 24 100 0 0 0 0
53 240 HERG 619 23 22 95.7 0 0 1 4.3
54 248 leukocyte elastase 192 18 18 100 0 0 0 0
55 3795 melanocortin receptor 1 134 17 15 88.2 0 0 2 11.8
56 1945 melatonin receptor 1A 215 15 15 100 0 0 0 0
aAll 56 evolving compound data sets are listed in the order of decreasing numbers of CAT II hpCPs. Target names and ChEMBL target
identifications are provided. Abbreviations are used according to Table 1. For each class, the distribution of hpCPs over CATs I, II, and III is
reported.
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cliffs, whereas CAT II and CAT III represent different cases of
cliff progression.
In addition, another point should be considered. Activity cliffs can
be defined in a number of different ways including the application of
alternative structural/similarity and potency difference criteria.2 How-
ever, because our cliff progression analysis is based on the detection of
compound analogue series, the application of awell-defined structure-
based definition of activity cliffs such as MMP-cliffs is essential.
Activity Cliff Progression. In the exemplary data set reported
in Table 1, a steady increase in the number of compounds, MMPs,
and activity cliffs occurred over time. During each recorded year,
newly formed activity cliffs were identified. In compound subsets
that became available during the following years, an MMP-based
search for analogues of each highly potent cliff partner was
carried out to categorize these cliffs. For example, from 2005 to
2006, there was an increase in the number of unique activity cliffs
from 126 to 175. The 49 new cliffs that became available during
2006 involved 10 new hpCPs. For these potent cliff partners,
analogue searches were carried out using all subsequently re-
ported compounds. The generally observed difference in growth
rates between activity cliffs and hpCPs was due to the fact that an
hpCP typically formed multiple activity cliffs with weakly potent
analogues (Table 1). Since our analysis of activity cliff progression
focused on potency changes relative to each hpCP (rather than
weakly potent cliff partners), all cliffs formed by an hpCP had to be
considered only once.
In the evolving carbonic anhydrase I inhibitor set in Table 1, a
total of 167 hpCPs were available at the 2011 end point, which
formed 84 CAT I, 46 CAT II, and 37 CAT III cliffs. Hence, about
half of these activity cliffs were isolated and no structural evidence
was found for further exploration. By contrast, analogues were
identified for 83 other hpCPs and in 46 of these cases, analogues had
further increased potency. Figure 2B shows representative examples
of CAT II cliff progression.
In our analysis of all data sets, as discussed in the following,
we identified only 10 hpCPs (CAT III) for which all available
analogues had conserved potency. Given this very small number,
we considered CAT III and CAT II to represent “negative” and
“positive” cliff progression, respectively.
Figure 1. MMP-cliff. Two small inhibitors of carbonic anhydrase 1 are
shown that form a size-restricted MMP. The distinguishing fragments
are highlighted. The potency difference between these compounds is
larger than 2 orders of magnitude, and hence, the two compounds form
an activity cliff (MMP-cliff). The compound at the top is the highly
potent cliff partner (hpCP).
Figure 2. Activity cliff categories. (A) Schematic representation of three
different categories of activity cliffs. Compounds are depicted as colored
nodes (red, high potency; green, low potency). Activity cliff-forming
compounds are represented as unfilled nodes and structural analogues of
the highly potent cliff partner (hpCP, red) as filled nodes. The hpCP
served as a reference point for activity cliff progression monitored over
time. (B) Two representative examples of CAT II cliffs are shown
including dopamine d3 receptor antagonists and carbonic anhydrase
I inhibitors.
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Large-Scale Progression Analysis. In Table 2, cumulative
results are reported for the 2011 end point of all 56 evolving
compound sets. We note that hpCPs were frequently occurring
in these data sets, ranging from 13 for equilibrative nucleoside
transporter 1 ligands to 313 for coagulation factor X inhibitors,
which provided a sound basis for cliff categorization and
Figure 3. Category distribution. For each compound data set, the absolute numbers of hpCPs are reported that form CAT I (gray), CAT II (red), or
CAT III (green) activity cliffs. Bars represent cumulative counts (i.e., red + green + gray). For data sets, ChEMBL target identifications are provided. For
example, for the first data set (ChEMBL target no. 244), there are 82 CAT II, six CAT III, and 225 CAT I cliffs.
Figure 4. Potency distribution and maximal gain. For all target sets, box plots are shown that monitor the (A) potency distribution of hpCPs from CAT
II cliffs and (B) maximal potency gain during activity cliff progression. For data sets, ChEMBL target identifications are provided. At the bottom of each
box plot, the number of CAT II hpCPs per data set is reported.
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progression analysis across many different targets. In Figure 3,
the distribution of cliff categories is monitored over all data
sets to complement the statistics provided in Table 2. Several
observations are made. In the majority of compound data sets
(53 of 56), isolated activity cliffs were more frequent than
progressing cliffs, regardless of absolute cliff numbers in the sets.
In eight data sets, only CAT I cliffs were observed. Thus, as
illustrated in Figure 3, for the majority of all hpCP activity cliffs
(∼75%), no evidence for further chemical exploration was
detectable. By contrast, in 48 compound sets, at least limited
activity cliff progression was observed. In these cases, CAT II
cliffs (positive progression) were overall more frequent (total
count 611) than CAT III cliffs (negative progression, total count
426). In 43 of 56 sets, positive cliff progression was detected. The
examples of CAT II cliff progression shown in Figure 2B were
representative of many cases. Single more potent analogues of an
hpCP were frequently detected as well as series of analogues with
gradually increasing potency indicative of optimization paths. In
total, for ∼15% of all activity cliffs, hpCP analogues with further
increased potency were identified.
Potency Distribution. Despite SAR information associated
with activity cliffs, it might often be difficult to translate this
information into compounds with further increased potency if
activity cliffs already involve highly potent compounds. This
point should also be taken into account in the analysis of activity
cliff progression. Although we determined activity cliffs over the
entire potency range, many hpCPs of progressing cliffs were
potent in the mid to low nanomolar range. In Figure 4A, the
potency distribution of CAT II hpCPs is monitored over all 43
compound sets containing CAT II cliffs. In 25 cases, the median
potency of hpCPs was 10 nM or higher. In Figure 4B, the dis-
tribution of the maximal potency gain for CAT II cliffs is reported
for all 43 data sets. In 21 and 19 cases, median potency increases
of up to 1 order of magnitude and of 1−2 orders of magnitude
were observed, respectively. In three instances, potency increases
of 3−4 orders of magnitude were detected. In addition, individual
analogues with large increases in potency relative to their hpCPs
were often found. Given the prevalence of highly potent hpCPs,
as revealed in Figure 4A, the frequently observed 10- to 100-fold
increases in compound potency during CAT II cliff progression
were considered significant. In Figure 5, the potency distribution
of all compounds involved in positive activity cliff progression
versus all others is illustrated for four exemplary data sets. In each
case, compounds associated with CAT II cliffs were among the
most potent compounds in the data set.
Concluding Remarks.We have investigated the question to
what extent activity cliff information might be utilized in medicinal
chemistry, which is not straightforward to address. The approach
taken was based on the concept of activity cliff progression.
Specifically, if activity cliffs reveal SAR determinants and if such
insights are considered in medicinal chemistry, then one should
expect to observe a further exploration of the immediate chemical
neighborhood of cliffs. In successful cases, this exploration should
result in analogues of activity cliff compounds with further in-
creased potency. To investigate activity cliff progression in a
systematic manner, we assembled data sets evolving over time,
identified all activity cliffs, and searched for subsequently reported
analogues of potent cliff partners. For systematic analysis of activity
Figure 5. Compound frequencies and potency ranges. The number and the potency range distribution of compounds not involved in positive activity
cliff progression (gray) and of all compounds associated with CAT II cliffs (red) are compared. Histograms are shown for four exemplary compound
data sets: (A) dopamine D3 receptor antagonists (ChEMBL target no. 234), (B) coagulation factor X inhibitors (no. 244), (C) melanocortin receptor 4
antagonists (no. 259), and (D) cathepsin S inhibitors (no. 2954).
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cliff progression, a categorization of cliffs was introduced. Care
was taken to limit the analysis to clearly defined activity cliffs.
Therefore, only activity cliffs were considered that consisted of
structural analogues with a potency difference of at least 2 orders
of magnitude on the basis of equilibrium constants as activity
measurements. In our analysis, we found no structural analogues
of potent cliff partners for ∼75% of the activity cliffs across all
compound sets. Hence, there was no evidence that these cliffs
were chemically further explored. On the basis of these findings,
one would conclude that activity cliff information is currently
underutilized in the practice of medicinal chemistry, despite the
substantial interest the activity cliff concept has been experiencing.
There are likely reasons for this. Activity cliffs do not represent an
a priori and immediately accessible data structure for medicinal
chemistry. Rather, they are subject to clear definition, systematic
exploration, and importantly, representation in a chemically
intuitive format. Challenges associated with these requirements
might currently limit the utility of the activity cliff concept for
lead optimization. On the other hand, for ∼25% of all activity
cliffs, progression was detected and for ∼15% of all cliffs,
analogues of potent cliff partners with potency increases of often
1 or 2 orders of magnitude were identified. In total, positive
progression was confirmed for more than 600 activity cliffs dis-
tributed over 43 different target sets. For a subset of these cliffs,
multiple analogueswith gradually increasing potencywere observed,
forming apparent optimization paths.
Taken together, the results indicate that activity cliffs currently
are not a major focal point of practical medicinal chemistry efforts.
On average, there is evidence for the exploration of the chemical
neighborhood of only every fourth activity cliff present in diverse
data sets having evolved over time. However, positive activity cliff
progression is observed for every sixth to seventh cliff, and in
these cases, structural analogues of activity cliff compounds with
significantly increased potency are available. In light of these
findings, activity cliffs with as of yet unexplored chemical neigh-
borhoods should provide many opportunities for further ex-
ploitation of activity cliff information focusing on compound
potency improvement.
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CHAPTER 7: SUMMARY
Summary
In this study, we have investigated the question of whether SAR information
encoded in activity cliffs is utilized in medicinal chemistry. The concept of ac-
tivity cliff progression was introduced to mimic the exploration of the chemical
neighborhood of cliff-forming compounds. Activity cliffs were categorized based
on whether or not activity cliff progression was detected and whether such pro-
gression ultimately led to a potency increase. For nearly 75% of the activity
cliffs, there was no evidence for further chemical exploration. Accordingly, for
∼25% of the cliffs, activity cliff progression was detected, and in ∼15% of all
instances the progression introduced a significant potency increase of 1 or 2
orders of magnitude. The findings indicated that activity cliffs were not major
focal points in chemical optimization efforts. Hence, the significant number of
still unexplored activity cliff neighborhoods should provide many opportunities
for further analysis and compound potency improvement. My contributions
to this work have been to the design and implementation of the activity cliff
progression model.
In the previous studies, key aspects of the activity cliff concept (e.g., their
global distribution across different targets, SAR advantage and utility in medic-
inal chemistry) have been addressed. Another important question related to
activity cliffs is their coordination, i.e., whether or not cliff formation involves
multiple active compounds and cliffs. A recent systematic survey2 has reported
that the majority of activity cliffs are coordinated, rather than isolated, yet
their composition and topologies have thus far not been investigated. This
question has been explored in the next study.
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Chapter 8
Composition and Topology of
Activity Cliff Clusters Formed
by Bioactive Compounds
Introduction
Conventionally, activity cliffs are explored on the basis of individual compound
pairs. However, cliffs often occur in a coordinated (i.e., cliff-forming compounds
participate in additional cliffs), rather than isolated manner (i.e., two cliff part-
ners form a single cliff).2 Higher-order configurations are thought to be more
SAR informative than isolated cliffs, however, their compositions and topolo-
gies are currently unknown. The study of coordinated cliffs, their size and
topological organization further refines the activity cliff concept and shed light
on another as of yet unexplored activity cliff facet. To these ends, we have
carried out a systematic survey of all activity cliff configurations formed by
currently available bioactive compounds. These configurations have been fur-
ther classified and their frequency of occurrence and target distribution has
been determined.
105
 
Composition and Topology of Activity Cliff Clusters Formed by
Bioactive Compounds
Dagmar Stumpfe, Dilyana Dimova, and Jürgen Bajorath*
Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische
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ABSTRACT: The assessment of activity cliffs has thus far mostly focused on compound pairs,
although the majority of activity cliffs are not formed in isolation but in a coordinated manner
involving multiple active compounds and cliffs. However, the composition of coordinated
activity cliff configurations and their topologies are unknown. Therefore, we have identified all
activity cliff configurations formed by currently available bioactive compounds and analyzed
them in network representations where activity cliff configurations occur as clusters. The
composition, topology, frequency of occurrence, and target distribution of activity cliff clusters
have been determined. A limited number of large cliff clusters with unique topologies were
identified that were centers of activity cliff formation. These clusters originated from a small
number of target sets. However, most clusters were of small to moderate size. Three basic
topologies were sufficient to describe recurrent activity cliff cluster motifs/topologies. For
example, frequently occurring clusters with star topology determined the scale-free character of the global activity cliff network
and represented a characteristic activity cliff configuration. Large clusters with complex topology were often found to contain
different combinations of basic topologies. Our study provides a first view of activity cliff configurations formed by currently
available bioactive compounds and of the recurrent topologies of activity cliff clusters. Activity cliff clusters of defined topology
can be selected, and from compounds forming the clusters, SAR information can be obtained. The SAR information of activity
cliff clusters sharing a/one specific activity and topology can be compared.
■ INTRODUCTION
The activity cliff concept1−4 has experienced increasing attention
in computational and medicinal chemistry.2−4 Originally, activity
cliffs were defined as pairs of structurally similar active
compounds having a large difference in potency.1,2 Given this
definition, the specification of similarity and potency difference
criteria is of critical relevance for the assessment of activity
cliffs.2−4 The popularity of the activity cliff concept in medicinal
chemistry is primarily due to the underlying “small chemical
changes−large biological effects” paradigm, which assigns high
structure−activity relationship (SAR) information content to
activity cliffs.2,3 In addition to SAR exploration, activity cliffs are
of interest for computational analysis because they can be
explored through systematic mining of compound activity data3,4
and because they are focal points of activity landscape
modeling.5,6 A variety of molecular representations have been
utilized to asses compound similarity in the analysis of activity
cliffs, typically in combination with Tanimoto similarity
calculations.2,3,7 However, in medicinal chemistry, activity cliffs
defined on the basis of such whole-molecule similarity
calculations are often difficult to interpret.3 Therefore, activity
cliffs have also been defined on the basis of substructure
relationships between active compounds,3 for example, by
employing the matched molecular pair (MMP) formalism.8 An
MMP is generally defined as a pair of compounds that only differ
by a structural change at a single site,8,9 i.e., the exchange of two
substructures, a so-called chemical transformation.9 By introduc-
ing transformation size restrictions,10 such structural changes can
be limited to small and chemically meaningful replacements that
relate analogous compounds to each other. The formation of
such transformation size-restricted MMPs has been applied as a
similarity criterion for activity cliffs, leading to the introduction of
MMP-cliffs.10 The potency difference criterion is also critical for
activity cliff analysis. Given the high relevance of activity cliffs for
SAR analysis, the exclusive consideration of high-confidence
activity data is strongly recommended.3,4 A generally preferred
activity cliff definition has been put forward that requires the
formation of a transformation size-restricted MMP for cliff
partners and the presence of a potency difference of at least 2
orders of magnitude on the basis of equilibrium constants (Ki
values) as activity measurements.4 Activity cliffs have been
systematically identified in publicly available compounds active
against current targets.11,12 Depending on chosen molecular
representations,∼20−35% of all compounds with available high-
confidence activity data have been found to participate in the
formation of at least one well-defined activity cliff, with MMP-
cliffs being the structurally most conservative representation of
cliffs.12
Following their original definition, activity cliffs have generally
been considered at the level of compound pairs, i.e., by separately
studying each compound pair forming an “isolated” cliff.3
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However, higher-order activity cliff configurations involving
multiple highly and lowly potent compounds and “coordinated”
activity cliffs have also been detected in compound data sets.13 In
fact, a recent statistical analysis of isolated vs coordinated activity
cliffs has revealed that on average more than 95% of all activity
cliffs are not formed in isolation but in a coordinated manner.4
This means that series of compounds with varying potency form
multiple overlapping cliffs. Coordinated activity cliffs have higher
SAR information content than activity cliffs considered in
isolation, which further increases the attractiveness of coordi-
nated cliffs for medicinal chemistry. Hence, the conventional
compound pair focus of activity cliff analysis is subject to revision
and extension. The prevalence of coordinated activity cliffs
implies that many active compounds must participate in the
formation of multiple activity cliffs. However, how compounds
form such activity cliff configurations and what their sizes and
topologies might be is currently unknown. Therefore, we have
extracted all activity cliff configurations from currently available
bioactive compounds and characterized them in detail. The
analysis involved the generation of a global activity cliff network
in which cliff configurations form disjoint clusters that can be
individually studied.
■ MATERIALS AND METHODS
Compound Data Sets. Compounds and activity data were
assembled from ChEMBL (version 17).14 We restricted our
analysis to compounds with precisely specified equilibrium
constants for human targets at the highest confidence level
(ChEMBL confidence score 9).14 A compound with multiple Ki
measurements for the same target was only selected if all potency
values fell within the same order of magnitude. Then, the average
potency was calculated as the final activity annotation. On the
basis of these selection criteria, a total of 77 415 compounds were
obtained for further analysis. These compounds were active
against 661 different targets (with one to 2601 compounds per
target set).
MMP-Cliffs. Activity cliffs were defined as MMP-cliffs10 with
a potency difference of at least 2 orders of magnitude between
cliff-forming compounds.4 Transformation size-restricted
MMPs10 were systematically generated for all qualifying
compounds using an in-house implementation of the Hussain
and Rea algorithm.9
Network Analysis. All MMP-cliffs were pooled, and a target-
based activity cliff network was generated. In this network, nodes
represented cliff-forming compounds and edges, activity cliffs.
Network representations were drawn with Cytoscape,15 and
network characteristics16 were assessed. In addition to global
network topology and average node degrees, network “hetero-
geneity” and “centralization” were calculated as parameters
related to the neighborhood of a given node.17 The network
heterogeneity is an index accounting for the variance of
connectivity and reflecting the tendency of a network to contain
hubs.17 In addition, the network centralization index is a measure
of the centrality of nodes; i.e., it describes the extent to which
subsets of nodes are more central than others in the network
based on their connectivity. For example, the centralization score
of networks with a star-like topology is usually close to 1, whereas
the score of uniformly connected networks is close to 0.17 For
activity cliff networks, these indices have been calculated using
the Cytoscape NetworkAnalyzer plug-in.18
■ RESULTS AND DISCUSSION
Activity Cliff Statistics. For activity cliff analysis, all bioactive
compounds were selected for which high-confidence activity data
were available. No data set size restrictions were applied to
ensure maximal target coverage. For the 77 415 qualifying
compounds, a total of 20 080 MMP-cliffs were identified in 293
target sets. Many small or very small sets did not yield MMPs or
MMP-cliffs. These 20 080 activity cliffs included a total of 18 567
unique cliffs detected in one or more target sets. The number of
cliffs exclusively identified in a single target set (intraclass cliffs)
was 17 287, whereas only 1280 cliffs were found inmore than one
set (interclass cliffs). Hence, only 6.9% of all MMP-cliffs are
multitarget cliffs. The activity cliff statistics are reported in Table
1. The large number of activity cliffs were formed by 11 783
unique compounds, which yielded 14 044 activity cliff com-
pounds. A total of 1766 compounds with multitarget activity
participated in the formation of activity cliffs in different target
sets (thus rationalizing the difference between the number of
unique and cliff-forming compounds). The number of MMP-
cliffs per target set varied between one and 1241. Among the cliff-
forming compounds, 7358 exclusively acted as highly potent cliff
partners, 6414 exclusively as lowly potent partners, and only 272
compounds were found to participate as highly and lowly potent
partners in different activity cliffs. All activity cliffs were subjected
to network analysis to visualize the configurations they formed.
Activity Cliff Network. A global activity cliff network was
generated and analyzed in detail. In the network, nodes
represented compounds and edges, activity cliffs. The network
organized all isolated and coordinated activity cliffs formed by
compounds active against 293 targets.
Composition. In Figure 1a, the complete activity cliff network
is displayed, which consisted of 14 044 distinct nodes and 20 080
edges. Each edge represented a cliff formed by compounds active
against a specific target. For interactive visualization and analysis,
the network is also provided as Figure S1 of the Supporting
Information. Figure 1a illustrates that the majority of activity
cliffs were coordinated, consistent with earlier findings from
statistical analysis.4 Only 769 of all 20 080 activity cliffs were
formed in an isolated manner (3.8%), i.e., as compound pairs
without structural neighbors forming cliffs. As further discussed
below, the degree of coordination among cliffs varied
significantly. In the network, coordinated activity cliffs appeared
as separate network components of varying size, which we term
activity clif f clusters in our analysis.
Table 1. MMP-Cliff Distributiona
# MMPs 385 653
# target-based cliffs 20 080
(5.2%)
# unique cliffs 18 567
(4.8%)
# interclass cliffs 1280
(6.9%)
# intraclass cliffs 17 287
(99.7%)
aThe table reports the total number of MMPs and the number of
target-based activity cliffs. In addition, the number of unique activity
cliffs (as explained in the text), interclass cliffs (identified in more than
one target set), and intraclass cliffs (exclusively identified in a single
target set) are reported.
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Figure 1. continued
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Characterization. The activity cliff network contained a total
of 2072 differently sized clusters (including isolated cliffs). The
cluster order distribution is reported in Table 2. Cluster order
refers to the number of nodes (compounds) per cluster. Twenty-
six clusters withmore than 50 nodes were detected including four
clusters with more than 100 nodes. The largest activity cliff
cluster contained 152 nodes. This cluster represented a total of
636 activity cliffs. The overall largest number of cliffs per cluster
was 680 detected in another cluster containing 141 nodes. In
addition, 420 clusters comprising six to 15 cliff-forming
compounds were detected, which also reflected the overall
high degree of activity cliff coordination.
On the basis of global network analysis, we determined that
the union of all clusters followed the power law P(k)∼ k−γ, with γ
having a value of 2.5, which is characteristic of scale-f ree networks
that typically yield γ values of 2−3.16 Here, P(k) is the subset of
nodes in the network having k connections to others.
Table 3 reports the node degree distribution in the network.
Node degrees varied between 1 and 67, with an average node
degree of 2.9. Overall, 1552 nodes with a degree of 5−9 were
detected and 496 nodes with a degree of 10−20, revealing the
presence of many densely connected nodes. Thus, nodes with a
degree ≥ 5 were considered activity clif f hubs. In total, the
network contained 2166 (15.4%) and 614 (4.4%) hubs with a
degree ≥ 5 and a degree ≥ 10, respectively.
Modification. In the activity cliff network, there were 463
(22.3%) clusters containing at least one hub including 116
clusters with at least one hub with a degree ≥ 10. Thus, activity
cliff hubs were integral components of the network. To evaluate
the role of these hubs for the network and its global topology, two
Figure 1. Activity cliff networks. In a, the complete MMP-cliff network is shown. Nodes are colored green if a compound is a highly potent cliff partner,
red (lowly potent cliff partner), or yellow if a compound is involved in different activity cliffs both as a highly and lowly potent partner. In b and c, nodes
with a degree ≥ 5 and ≥ 10 were removed, respectively, and the network representation was recalculated.
Table 2. Activity Cliff Cluster Order Distributiona
cluster order # cluster
1−5 1463
6−10 306
10−15 114
15−20 65
21−30 56
31−40 27
41−50 15
51−60 11
61−70 4
71−80 2
81−90 3
91−100 2
101−152 4
aThe distribution of activity cliff cluster orders (i.e., numbers of nodes
per cluster) across the network is reported.
Table 3. Node Degree Distributiona
node degree # nodes
1−4 11878
5−9 1552
10−14 341
15−20 155
21−30 85
31−40 17
41−50 9
51−60 4
61−70 3
aThe node degree distribution of the activity cliff network is reported.
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network variants were generated after removal of hubs with a
degree ≥ 5 and ≥ 10, respectively. These network variants are
displayed in Figure 1b and c. In addition, a comparison of the
statistics for the original network and its two variants is presented
in Table 4. The absence of increasing numbers of hubs led to
increasing randomness of the network variants. As expected,
these modifications reduced network heterogeneity, a measure
for the tendency of a network to contain hubs, and also network
centralization, thus indicating increasingly uniform connectivity.
Taken together, these findings were also consistent with the
global scale-free character of the original activity cliff network.
Activity Cliff Cluster Topology. Next, we systematically
determined activity cliff cluster topologies present in the network
and compared topological features. Given the very low
proportion of multitarget (interclass) activity cliffs formed by
ChEMBL compounds, as reported above, all recurrent top-
ologies identified in our analysis are formed by single-target
(intraclass) activity cliffs.
Distribution. Table 5 reports the cluster topology distribution
of the activity cliff network. The global network consisted of 2072
activity cliff clusters that represented 450 distinct cluster
topologies. A small set of 39 cluster topologies (including
isolated cliffs) accounted for 1630 different clusters. These
clusters were of small to moderate size (with up to 12
compounds) and contained a total of 5323 compounds forming
3866 activity cliffs. In addition, 416 clusters with fewer than 50
compounds yielded 385 distinct topologies. Hence, these
topologies were detected only once or twice. The corresponding
clusters contained 6722 compounds that formed∼55% (11 083)
of all activity cliffs. Furthermore, there were 26 large clusters with
unique topologies that contained a total of 1999 compounds
forming 5131 cliffs. As further discussed below, large clusters
were typically characterized by a high degree of activity cliff
density.
The cluster frequency distribution of unique topologies is
reported in Table 6. A total of 381 clusters with unique topology
were observed only once, whereas six and seven distinct
topologies were each observed 10 or more and 20 or more
times, respectively (i.e., in the latter case, 20 or more clusters
were found to share one of seven unique topologies). Thirteen of
the 39 topologies that were observed at least three times
contained a hub with a degree ≥ 5.
Topological Categories. We determined that the 1630
clusters with recurrent topology could be assigned to only
three main topology categories and a limited number of
extensions of these categories, as schematically shown in Figure
2. The main categories included the star, chain, and rectangle
topologies. For the star and chain topologies, frequently observed
extensions included the twin star andmodif ied chain, respectively.
In addition, the rectangle topology had three well-defined
extensions including the modif ied, nested, and fused rectangle, as
illustrated in Figure 2. Taken together, this limited set of
topologies or combinations of these topologies covered all small
and moderately sized activity cliff clusters for compounds active
against current targets.
Complex Topologies. Figure 3 shows examples from the set of
the 26 largest clusters with unique topology. The cluster in
Figure 3a consists of 56 opioid receptor agonists forming 70
activity cliffs. This cluster combines different star and rectangle
Table 4. Activity Cliff Network Statisticsa
network
statistics
complete
network
subnetwork 1:
no hubs
with degree ≥ 5
subnetwork 2:
no hubs
with degree ≥ 10
# clusters 2072 2171 2173
# nodes 14 044 7265 (51.7%) 11 115 (79.1%)
# edges 20 080 5508 (27.4%) 11 381 (56.7%)
average node degree 2.9 1.5 2.0
network heterogeneity 1.3 0.5 0.79
network centralization 0.005 0 0.001
aSubnetworks 1 and 2 were derived from the original activity cliff
network by removal of nodes with a degree of five and 10 or more,
respectively, followed by recalculation of the network representation.
Table 5. Cluster Topology Distributiona
topology # clusters # compounds # cliffs
39 topologies 1630 5323 3866
instances ≥ 3
26 topologies 26 1999 5131
instances = 1
# compounds > 50
385 topologies 416 6722 11 083
instances < 3
# compounds ≤ 50
total
450 topologies 2072 14 044 20 080
aAll activity cliff clusters are organized according to their topologies
and compound composition.
Table 6. Cluster Frequency for Unique Topologiesa
cluster frequency # topologies
≥ 20 7
≥ 10 6
≥ 5 10
≥ 3 16
= 2 30
= 1 381
aThe cluster frequency for unique topologies is reported. For example,
the first row of the table means that seven distinct topologies were
each represented by at least 20 different clusters.
Figure 2. Topology categories. The three most frequently observed
activity cliff cluster topologies (left) and their extensions (right) are
schematically illustrated. The three main topology categories were
termed star, chain, and rectangle, respectively. Squared nodes represent
variable node numbers (n).
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motifs with another less well-defined motif. Combinations of the
three main topologies were often observed in large clusters.
Similarly, the cluster consisting of 55 adenosine receptor
antagonists forming 71 cliffs in Figure 3b displays a further
extended twin star topology with 14 edges connecting the two
star motifs. Furthermore, the cluster in Figure 3c (with 84
carbonic anhydrase inhibitors forming 169 cliffs) also contains a
peripheral combination of star, rectangle, and chain motifs. In
addition, its central component is characterized by a high density
of activity cliffs, giving rise to a complex topology that is difficult
to resolve into individual motifs. Such central components with a
high density of activity cliffs were characteristics of the largest
clusters in the network. The circle layout of these densely
connected components was generated to accommodate high
activity cliff density and hence does not represent an
independent topology. The target distribution of activity cliff
clusters and topologies is reported below.
Frequency of Occurrence. Table 7 reports the most
frequently observed topologies (including isolated cliffs) and
cluster size variations. With 335 instances, chains with three
compounds represented the most frequent activity cliff clusters,
followed by stars with four (122 instances) and five compounds
(70), chains with four (53), and twin stars with five compounds
(43). The basic rectangle consisting of four compounds was 26
times observed. Thus, the most frequently occurring activity cliff
clusters were of relatively small size. Larger clusters that were also
at least three times observed included, among others, stars with
12, twin stars with 11, or modified rectangles with nine
compounds.
As also reported in Table 7, chains and stars were much more
frequently observed than rectangles. Overall, there were 243
instances of stars covering a total of 1222 compounds and 979
cliffs and 388 instances of chains with 1217 compounds and 829
cliffs. Hence, chains with three or four nodes were the overall
most frequent topologies. However, clusters with star and chain
topologies had very similar compound coverage. Stars
Figure 3. Large activity cliff clusters. Three exemplary large activity
clusters with unique topology are shown in detail. These clusters
comprise 56 (a), 55 (b), and 84 (c) compounds with different specific
activities that form 70, 71, and 169 activity cliffs, respectively. Recurrent
topological motifs are highlighted in yellow (chains), orange (rectangles),
and pink (stars).
Table 7. Frequently Occurring Topologies of Activity Cliff
Clusters of Varying Sizea
# instances topology category # cpds per topology # target sets
769 isolated clif f 2 202
335 chain 3 127
122 star 4 74
70 star 5 53
53 chain 4 42
43 twin star 5 39
26 rectangle 4 22
19 star 6 17
18 mod. rect. 5 14
16 nested rect. 5 15
14 twin star 6 14
11 star 8 11
10 star 7 9
9 twin star 7 9
8 nested rect. 6 8
8 nested rect. 6 7
8 twin star 7 8
7 chain 5 7
7 twin star 6 7
6 mod. rect. 6 6
6 twin star 8 6
5 mod. chain 6 5
5 twin star 7 5
5 fused rect. 6 5
4 mod. rect. 6 4
4 mod. rect. 7 4
4 twin star 8 4
4 star 9 4
4 star 10 4
3 twin star 6 3
3 twin star 7 3
3 mod. rect. 7 3
3 nested rect. 7 3
3 mod. rect. 7 2
3 mod. rect. 8 3
3 twin star 9 3
3 mod. rect. 9 3
3 twin star 11 3
3 star 12 3
aThe first row reports that a total of 769 isolated activity cliffs, which
consisted of two compounds (cpds), were found in 202 target sets. In
the second row, it is reported that an activity cliff “chain” containing
nine compounds was 335 times detected across 127 target sets. “mod.”
stands for modified and “rect.” for rectangle.
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represented activity cliff configurations resulting from combina-
tions of a highly potent compound with multiple lowly potent
analogs and vice versa. In medicinal chemistry, such compound
series are likely to originate from hit-to-lead and lead
optimization efforts. Clusters with star topology included many
hubs and were found to be mostly responsible for the global
scale-free character of the activity cliff network.
Figure 4 shows the 12 most frequently occurring cluster
topologies (including isolated cliffs). For nine of the 11 multicliff
topologies, different subsets with alternative arrangements of
highly and lowly potent activity cliff partners were identified. The
exceptions were isolated cliffs, the rectangle, and chain with four
compounds each for which no alternative subsets were possible.
Small chains with three compounds representing two activity
cliffs formed by two highly and one lowly potent cliff partner
(170 instances) or one highly potent and two lowly potent
partners (163) dominated the topology distribution. In addition,
stars with four compounds representing three cliffs or five
compounds representing four cliffs were also frequently
observed, with a total of 122 and 70 instances, respectively.
These topologies required the combination of a highly potent
cliff compound with three or four lowly potent ones or vice versa.
Chains with four compounds including two highly and two lowly
potent cliff partners that formed three activity cliffs were detected
53 times (compared to 26 instances of the basic rectangle having
the same compound composition but forming four cliffs). As
shown in Figure 4, topology extensions such as modified and
nested rectangles or modified chains were also recurrent.
Target Distribution. As reported in Table 7, cluster topologies
were widely distributed over different target sets. Stars, chains,
and rectangles were found in 142, 144, and 70 target sets,
respectively. Isolated activity cliffs were detected in 202 target
sets, but their frequency of occurrence was very low. Only 21 of
these 202 sets contained more than 10 isolated cliffs. Table 8 lists
the top 10 target sets with most isolated activity cliffs. The
maximum number of isolated cliffs per set was 24. This target set
consisted of 1384 dopamine D3 receptor antagonists, 259 of
which participated in the formation of activity cliffs.
Figure 4. Frequently occurring activity cliff cluster topologies. Shown are the 12 most frequently observed cluster topologies. The number of
occurrences is reported. Nodes representing highly and lowly potent cliff partners are colored red and green, respectively. Compounds that were both
highly and lowly potent partners in different activity cliffs did not occur in clusters having the most frequent topologies (all of which represented
topologies and extensions depicted in Figure 2).
Table 8. Target Sets with Largest Numbers of Isolated Activity Cliffsa
# isolated cliffs ChEMBL TID target name target family # active compounds # cliff compounds
24 234 dopamine D3 receptor monoamine receptor GPCR family 1 1384 259
22 233 mu opioid receptor short peptide GPCR family 1 1582 359
21 3594 carbonic anhydrase IX carbonic anhydrase family 1313 143
20 217 dopamine D2 receptor monoamine receptor GPCR family 1 2038 227
20 261 carbonic anhydrase I carbonic anhydrase family 1656 360
19 226 adenosine A1 receptor nucleotide-like receptor GPCR family 1 2172 283
19 264 histamine H3 receptor monoamine receptor GPCR family 1 2012 319
18 205 carbonic anhydrase II carbonic anhydrase family 1697 276
18 237 kappa opioid receptor short peptide GPCR family 1 1491 451
17 253 cannabinoid CB2 receptor lipid-like ligand receptor GPCR family 1 1994 504
aTarget-based compound data sets, their number of activity cliff-forming compounds, and the number of isolated activity cliffs they contain are
reported. TID stands for target ID.
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Many target sets yielded activity cliff clusters with different
topologies. In 30 target sets, at least 10 different topologies were
detected. Table 9 lists the top 10 target sets having the largest
number of cluster topologies. Both adenosine A2 and
cannabinoid CB2 receptor antagonists yielded 33 different
cluster topologies. These data sets consisted of 2601 and 1994
compounds, 496 and 504 of which formed activity cliffs,
respectively. Target sets containing at least 100 compounds
yielded seven to 13 different cluster topologies. In addition, sets
containing at least 200 compounds yielded 10 to 25 topologies
and sets with more than 400 compounds, 16 to 33 topologies.
Thus, as would be expected, the number of cluster topologies
generally increased with the size of data sets and the number of
activity cliff-forming compounds.
Table 10 reports clusters with the largest numbers of activity
cliffs and their target distribution. As discussed above, the 26
largest clusters alone contained 1999 cliff-forming compounds
(14.2%) and accounted for 5131 activity cliffs (25.6% of all cliffs).
Hence, these clusters were centers of coordinated activity cliff
formation in the global network. The largest clusters originated
from a small number of target sets. For example, the clusters in
Table 10 included three different clusters of coagulation factor Xa
inhibitors and three others with different adenosine receptor
ligands. Overall, ligands of different G protein coupled receptors
formed the majority of large activity cliff clusters.
Interpretation and Utility. Activity cliff cluster topologies
were extracted from network representations. At the level of
subgraphs, cluster topologies can be systematically compared. As
we have shown, a comparison at this level is sufficient to obtain a
detailed view of currently available cluster topologies, which were
thus far unknown. However, one can go beyond this level and
view the compounds forming clusters of interesting topology.
From compounds forming coordinated activity cliffs within a
cluster, SAR information can be directly obtained and
substituents can be identified that are responsible for activity
cliff formation or characteristic of highly potent compounds.
Thus, cluster topologies provide immediate access to SAR
exploration, and characteristic topologies such as stars or
rectangles can be prioritized depending on the specific
applications. Two representative examples for SAR analysis
from activity cliff clusters of defined topology are provided in
Figure 5. Furthermore, for the analysis of coordinated activity
cliffs, which is much more complex than cliff assessment at the
level of compound pairs, network-derived topologies have the
Table 9. Target Sets with Largest Numbers of Different Activity Cliff Cluster Topologiesa
# cluster topologies ChEMBL TID target name target family # active compounds # cliff compounds
33 251 adenosine A2a receptor nucleotide-like receptor GPCR family 1 2601 496
33 253 cannabinoid CB2 receptor lipid-like ligand receptor GPCR family 1 1994 504
25 218 cannabinoid CB1 receptor lipid-like ligand receptor GPCR family 1 1760 342
23 256 adenosine A3 receptor nucleotide-like receptor GPCR family 1 2095 566
22 226 adenosine A1 receptor nucleotide-like receptor GPCR family 1 2172 283
22 264 histamine H3 receptor monoamine receptor GPCR family 1 2012 319
21 217 dopamine D2 receptor monoamine receptor GPCR family 1 2038 227
20 233 mu opioid receptor short peptide GPCR family 1 1582 359
18 234 dopamine D3 receptor monoamine receptor GPCR family 1 1384 259
18 236 delta opioid receptor short peptide GPCR family 1 1315 238
aTarget-based compound data sets, their number of activity cliff-forming compounds, and different activity cluster topologies are reported. TID
stands for target ID.
Table 10. Clusters with Largest Numbers of Activity Cliffsa
# cliffs ChEMBL TID target name target family # cluster compounds
680 237 kappa opioid receptor short peptide GPCR family 1 141
636 256 adenosine A3 receptor nucleotide-like receptor GPCR family 1 152
364 244 coagulation factor X serine protease family 74
330 244 coagulation factor X serine protease family 88
292 255 adenosine A2b receptor nucleotide-like receptor GPCR family 1 88
283 256 adenosine A3 receptor nucleotide-like receptor GPCR family 1 133
224 2014 nociceptin receptor short peptide GPCR family 1 78
211 244 coagulation factor X serine protease family 104
180 259 melanocortin receptor 4 short peptide GPCR family 1 53
169 261 carbonic anhydrase I carbonic anhydrase family 84
168 259 melanocortin receptor 4 short peptide GPCR family 1 96
148 4409 phosphodiesterase 10A phosphodiesterase family 54
147 204 thrombin serine protease family 69
141 1914 butyrylcholinesterase type-B carboxylesterase/lipase family 65
127 205 carbonic anhydrase II carbonic anhydrase family 91
126 222 norepinephrine transporter sodium:neurotransmitter symporter (SNF) family 53
117 1855 gonadotropin-releasing hormone receptor short peptide GPCR family 1 68
108 249 neurokinin 1 receptor short peptide GPCR family 1 53
107 259 melanocortin receptor 4 short peptide GPCR family 1 52
105 1997 equilibrative nucleoside transporter 1 SLC29A/ENT transporter family 70
aThe top 20 clusters with largest numbers of activity cliffs and their composition are reported. TID stands for target ID.
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advantage that they immediately reveal all compounds
participating in a cluster and all activity cliffs comprising the
cluster, as illustrated in Figure 5, without the need to search for
additional compounds that might further extend given activity
cliff(s). Moreover, a cluster of similar size sharing the same
topology can be selected from a given target set and analyzed in a
comparative manner, which further increases the amount of SAR
information that can be extracted in an organized manner from
Figure 5. Exemplary cluster topologies and compounds. Shown are compounds forming representative activity cliffs of exemplary cluster topologies (a
star, b rectangle). Structural modifications are highlighted and colored according to compound activity (red, low activity; green, high activity). Examples
are taken from the (a) adenosine A2a receptor and (b) adenosine A2b receptor target sets.
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structurally heterogeneous sets of specifically active compounds.
SAR information obtained from the topology-supported analysis
of coordinated activity cliffs might then be utilized in the context
of compound exploration and optimization.
■ CONCLUSIONS
Following their original definition, activity cliffs have predom-
inantly been studied at the level of individual compound pairs. As
has recently been shown, most activity cliffs are not formed in
isolation but as higher-order configurations involving multiple
cliffs. However, the composition, structure, and topology of these
activity cliff arrangements are currently unknown. Our analysis
provides a first view of activity cliff cluster topologies. The
analysis is descriptive in nature, aiming at providing a
comprehensive account of activity cluster topologies found in
currently available bioactive compounds. To elucidate activity
cliff configurations, cliffs have been systematically extracted from
bioactive compounds on the basis of high-confidence activity
data. Maximal target coverage of compound data sets was
ensured. More than 20 000 well-defined activity cliffs were
obtained that were formed by compounds active against nearly
300 different targets (to our knowledge, the largest collection of
activity cliffs studied to date). A global target-based activity cliff
network was generated to identify and visualize all cliff
configurations. In the network, activity cliff configurations
formed individual clusters that were systematically analyzed.
The network provides a basis of the extraction and further
characterization of activity cliff cluster topologies. Activity cliff
clusters of very different sizes were identified that were widely
distributed over target sets. A limited number of very large
clusters with complex topology was formed that represented
centers of coordinated activity cliff formation and originated
from a small number of target sets. However, most clusters were
of small to moderate size and characterized by only three basic
topologies and several extensions of these topologies. Large
activity cliff clusters often contained different combinations of
these basic topological motifs. Small clusters with chain topology
were overall most frequently observed. These clusters were
produced by series of pairwise analogs with significantly varying
potency. Clusters with star topology were largely responsible for
the scale-free nature of the global activity cliff network that
contained many cliff-forming hubs. Star topology of clusters
resulted from the presence of a highly potent compound forming
multiple activity cliffs with lowly potent partners and vice versa. A
characteristic feature of activity cliff clusters with frequently
observed topology was that they did not contain compounds
involved in multiple activity cliffs as both highly and lowly potent
cliff partners. Thus, compounds with variable potency relation-
ships were rare within activity cliff clusters. In general, activity cliff
clusters have higher SAR information content than isolated cliffs
and are thus of particular interest for large-scale SAR exploration.
The finding that small to moderately sized activity cliff clusters
had well-defined topologies across many different target sets
implied that structure−activity relationships captured by these
types of clusters might often be similar. This represents an
interesting aspect for the study of activity cliff configurations
from a medicinal chemistry perspective. Taken together, the
results of our analysis have provided a detailed view of activity
cliff configurations formed by compounds active against the
current spectrum of targets.
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CHAPTER 8: SUMMARY
Summary
The total of 20, 080 MMP-cliffs formed by currently available bioactive com-
pounds were organized in a global activity-cliff based network consisting of a
total of disjoint 2072 clusters. Most of these cliff communities were of small to
moderate size and represented 450 distinct topologies. In addition, 39 topolo-
gies were detected that occurred more than three times. Based on frequency
analysis, three main topology categories (i.e., star, chain, and rectangle) and
a few extensions of these topologies were identified. Chains of limited size
represented the most frequent topology. Surprisingly, compounds having both
highly and weakly potent partners were only rarely detected. Overall, the ma-
jority of the clusters were small and had well-defined topologies indicating that
they might display similar SAR characteristics. My contributions to this study
have been to aid in the analysis and classification of the activity cliff cluster
topologies.
To further extend the activity cliff concept, we have introduced the notion of
promiscuity cliffs formed by structurally similar compounds having significant
differences in the number of target annotations. On the basis of promiscu-
ity cliffs, the relation between chemical structures and compound promiscuity
(structure-promiscuity relationship) can be explored.
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Chapter 9
Matched Molecular Pair
Analysis of Small Molecule
Microarray Data Identifies
Promiscuity Cliffs and Reveals
Molecular Origins of Extreme
Compound Promiscuity
Introduction
Compound promiscuity, or the property of a small compound to specifically in-
teract with multiple biological targets, is a major topic in drug development and
pharmaceutical research.3 However, the molecular origin of compound promis-
cuity is currently only little understood and mostly studied on the basis of
molecular frameworks. We have further extended the activity cliff concept
to explore compound promiscuity from a phenotypic point of view. To these
ends, we have utilized the MMP framework to search a recently released small
molecule microarray data set comprising 15, 252 publicly available compounds
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screened against 100 unrelated proteins4 for structural modifications that might
ultimately change the degree of compound promiscuity.
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ABSTRACT: The study of compound promiscuity is a hot topic in medicinal chemistry and
drug discovery research. Promiscuous compounds are increasingly identified, but the molecular
basis of promiscuity is currently only little understood. Utilizing the matched molecular pair
formalism, we have analyzed patterns of compound promiscuity in a publicly available small
molecule microarray data set. On the basis of our analysis, we introduce “promiscuity cliffs” as
pairs of structural analogs with single-site substitutions that lead to large-magnitude differences
in apparent compound promiscuity involving between 50 and 97 unrelated targets. No
substructures or substructure transformations have been detected that are generally responsible
for introducing promiscuity. However, within a given structural context, small chemical
replacements were found to lead to dramatic promiscuity effects. On the basis of our analysis,
promiscuity is not an inherent feature of molecular scaffolds but can be induced by small
chemical substitutions. Promiscuity cliffs provide immediate access to such modifications.
■ INTRODUCTION
Target promiscuity of small molecules is a much investigated
topic in medicinal chemistry, for several reasons. First, the
binding behavior of a promiscuous compound might be
associated with nonspecific binding events, as exemplified by
frequent hitters in biological screens.1 Second, specific
interactions of compounds with multiple (related or unrelated)
targets might give rise to polypharmacological behavior2−5 and
also provide a basis for drug repurposing.6,7 Third, increasing
evidence that many bioactive compounds do act on multiple
targets is beginning to change the single-target specificity
paradigm that has long governed drug discovery and design
efforts.8−11 Previous studies have mostly addressed compound
promiscuity through database mining,5,12,13 for example, by
identifying molecular scaffolds that are recurrent in promiscu-
ous compounds,12 or have focused on polypharmacology by
detecting new targets for existing drugs5 and by studying side
effects.13
Most information about compound promiscuity is currently
obtained from target annotations of bioactive compounds
collected from literature resources and stored in major
compound data repositories, such as ChEMBL.14 In addition,
promiscuity information might also be obtained by comparing
screening libraries across different bioassays available in
PubChem,15 although this information is limited at present
and principally confined to screening hits. Compound
promiscuity can experimentally be assessed by systematically
testing compound collections on arrays of diverse targets.
Unfortunately, such compound profiling data is currently rarely
available, at least in the public domain. However, there are a
few notable exceptions. For example, a data set recently
released by a group from Abbott Laboratories contains 1473
compounds with reported activities against 1−122 different
kinases from a representative sample of the kinome.16 While
this data set provides an excellent test case for large-scale SAR
exploration,17 it is not suitable for promiscuity analysis beyond
kinases. Furthermore, Schreiber and colleagues have reported a
small molecule microarray experiment that involved screening
of diverse compounds against a total of 100 sequence-unrelated
targets.18 The data released as a part of this investigation are
highly attractive for a systematic assessment of compound
promiscuity. In their original study, Clemons et al. assembled a
total of 15 252 compounds from three different sources
including compounds commercially available from medicinal
chemistry vendors (CCs), natural products (NPs), and
compounds originating from diversity-oriented synthesis
(DCs).18 These compounds were then printed on glass slides
through surface chemistry or noncovalent absorption and
tested against 100 sequence-unrelated soluble proteins. These
proteins were selected to represent a total of 145 different
InterPro domain classification types.19 Purified tacked proteins
were incubated on microarrays, and proteins bound to array
compounds were detected with labeled monoclonal antibodies.
These experiments produced a binary readout of activity, i.e., a
compound was classified as active against a target or not.
Hence, given the nature of microarray experiments, no exact
activity measurements were obtained. However, these data
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reflect binding patterns of compounds across a large array of
different targets and are thus suitable for the analysis of
compound promiscuity or specificity. Clemons et al.
determined the distribution of active compounds and analyzed
their data primarily considering measures of stereochemical and
shape complexity. They found that NPs generally yielded lower
hit rates than synthetic compounds and that both NPs and DCs
produced many more specific hits than CCs. Increasing
stereochemical and shape complexity generally favored
compound specificity, as one might anticipate. However, it
was also observed that 16% of CCs and 3% of DCs were
promiscuous in nature. Clemons et al. found that a
spirooxindole moiety was recurrent in the promiscuous subset
of DCs. By contrast, possible structural origins of promiscuity
among CCs did not become apparent in the course of the
analysis. However, a key finding has been that compounds with
apparent target selectivity were clearly enriched among DCs
compared to CCs.18
We have been interested in exploring compound promiscuity
from a structural perspective, encouraged by the microarray
analysis efforts of Schreiber and colleagues involving 100
sequence-unrelated targets. For a thorough structural assess-
ment, we have carried out a matched molecular pair (MMP)
analysis20 of all compounds in this data set. We reasoned that
MMPs might provide direct access to structural features
implicated in promiscuity because compounds forming an
MMP are only distinguished by the exchange of a single
substructure with limited size. On the basis of our analysis,
structural relationships between nonpromiscuous and highly
promiscuous compounds were established and substructures
were identified that induced large-magnitude promiscuity
within a given structural context. MMPs included compounds
with very large differences in the number of targets they were
active against, leading to the introduction of promiscuity cliffs.
■ MATERIALS AND METHODS
Compound Data. The publicly released microarray data set18
contained 15 252 compounds. Each compound was screened against
100 sequence-unrelated proteins. A total of 3433 compounds were
active against 1−97 proteins. Compound structures were examined
and standardized using the Molecular Operating Environment21 and
transformed into SMILES strings.22 Compounds with unique SMILES
strings were retained. Following these procedures, 15 042 compounds
remained for MMP generation including 6151 CCs, 6437 DCs, and
2454 NPs.
Matched Molecular Pair Analysis. An MMP is defined as a pair
of compounds that only differ by a structural change at a single
site,20,23 as illustrated in Figure 1. Compounds forming an MMP are
interconverted by the exchange of two substructures, which is termed a
chemical transformation.23 Accordingly, the MMP formalism is
descriptor-independent, metric-free, and chemically intuitive. For
example, it has been applied to characterize activity cliffs and
bioisosteric replacements.24−26 MMPs were generated using an in-
house implementation of the Hussain and Rea algorithm.23 Following
this approach, conserved core structures and variable substituents of
MMPs are stored as keys and values in an index table, respectively.
The size of an exchanged substructure (value) was limited to
maximally 13 non-hydrogen atoms and the size difference between
exchanged substructures to maximally eight non-hydrogen atoms. This
was done to restrict the size of exchanged fragments to chemically
meaningful replacements.26 In addition, MMP formation was further
restricted by the requirement that the core structure of a qualifying
compound (key) had to be at least twice the size of each exchanged
substructure (value). Application of these size restrictions previously
yielded chemically intuitive transformations in an MMP-based study of
activity cliffs.26 Furthermore, if several transformations generated the
same MMP, only the transformation comprising the smallest number
of atoms was retained. Following this protocol, MMPs were
systematically generated for all 15 042 microarray compounds.
All MMP and data-mining calculations were carried out with in-
house generated Java programs or KNIME27 protocols. An MMP-
based compound network was drawn with Cytoscape.28
Promiscuity Cliff Criteria. On the basis of our analysis, so-called
“promiscuity cliffs” were introduced by applying the following criteria:
(1) A compound pair formed a transformation size-restricted MMP
(as explained above).
(2) The number of activity annotations of the compounds forming
an MMP differed by at least 50 targets, hence indicating large-
scale differences in apparent promiscuity.
Accordingly, promiscuity cliffs represented closely related com-
pounds (mostly analogs) with limited structural variations, but large
differences in the number of target annotations. These cliffs were
systematically explored in the small molecule microarray data set.
■ RESULTS AND DISCUSSION
MMP Distribution. From the entire compound set, a total
of 30 954 nonredundant MMPs were generated that involved a
total of 8010 compounds and yielded 7256 different trans-
formations. Most of these transformations were represented by
a single MMP or small numbers of MMPs. Differences in the
number of target annotations between compounds forming an
MMP were evaluated. Therefore, for each MMP, the target
profiles of its two compounds were compared. The results are
reported in Figure S1 of the Supporting Information. Figure 2
reports the distribution of MMPs over increasing differences in
target numbers. Compounds forming 18 251 MMPs (∼59%)
did not differ in the number of targets they were active against.
Only 995 of these MMPs were active against the same number
of targets, but different targets (Figure S1 of the Supporting
Information). Hence, compounds comprising these 18 251
MMPs displayed the same or comparable levels of promiscuity
and were thus of low priority for our analysis.
By contrast, compounds in 829 (∼2.7%) and 126 MMPs
(∼0.4%) differed in their activity by 10 or more and 50 or more
targets, respectively, thus revealing structurally similar com-
pounds associated with unexpectedly large differences in
apparent promiscuity. As a pinnacle of these trends, 33
MMPs were identified in which compounds differed by 90 or
more targets. Taken together, these findings were rather
surprising. The 126 MMPs in which activity annotations of
compounds differed by 50 or more targets (highlighted in
Figure 2) were classified as promiscuity cliffs and subjected to
further analysis.
Figure 1. Matched molecular pairs. Two pairs of compounds forming
exemplary MMPs are shown. Exchanged fragments are colored in red
(left) or blue (right).
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Given currently available data, one cannot be certain that
binding to a large number of targets might always be specific
(in fact, in some instances, this might be unlikely), and which
role local concentration effects on arrays might play. Given that
compound promiscuity can have several origins and is
influenced by multiple factors, as discussed in the Introduction,
the analysis of apparent promiscuity on the basis of compound
activity profiles takes these factors implicitly into account. On
the basis of the original array data analysis reported by Clemons
et al., experimental variances were clearly limited to the level
expected for microarrays.
We also identified a total of 1146 MMPs that were formed
between an inactive compound and an active compound with at
least five target annotations, as reported in Figure S2 of the
Supporting Information. These MMPs contained compounds
active against 5−95 targets. Of these, 58 MMPs qualified as
promiscuity cliffs.
Molecular Properties. For 117 compounds involved in the
formation of the 126 promiscuity cliffs, four different
physicochemical properties were calculated using the Molecular
Operating Environment,21 including molecular weight, octanol/
water (o/w) partition coefficient (log P), and the numbers of
acidic and basic atoms. The distribution of molecular weight is
reported in Figure 3a. Compounds that were inactive or active
against less than five targets (left region of the plot) covered a
broad range, from about 400 to nearly 1000 Da. However, most
of the promiscuous compounds (right region) displayed a
narrower range. Figure 3b reports the correlation between the
changes in molecular weight and promiscuity for individual
cliffs. No obvious trends were observed.
Figure 2. MMPs and target annotations. MMP counts are reported
(on a logarithmic scale) for increasing differences in the number of
targets MMP-forming compounds were active against. On the
horizontal axis, “Δ target annotations” reports binned differences in
target numbers. For example, “1”, “10”, and “100” mean that
compounds forming an MMP differed by exactly 1, 6−10, and 91−
100 targets, respectively. Sections of the histogram that represent
MMPs with a difference of 50 or more targets are highlighted.
Figure 3. Distribution of molecular properties. For compounds involved in the formation of promiscuity cliffs, the distributions of their molecular
weight and o/w partition coefficient (log P) are shown in parts a and c, respectively, as a function of the number of target annotations. In these plots,
each dot represents a cliff-forming compound. In addition, for promiscuity cliffs, the distributions of the difference in molecular weight and log P are
shown in parts b and d, respectively, as a function of the difference in the number of target annotations (i.e., differences in the degree of
promiscuity). Here, each dot represents a compound pair forming a promiscuity cliff.
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Figure 3c shows the distribution of log P values. Analogously
to the observations made for molecular weight, inactive and
nonpromiscuous compounds also covered a broad range of log
P values. Most of the promiscuous compounds had a much
narrower range, i.e., from 6 to 10. On the other hand, in the
area of high lipophilicity (upper region of the plot), both
nonpromiscuous and promiscuous compounds were found.
Although many promiscuous compounds had relatively high
log P values (as one might expect), there was no detectable
correlation between the changes in lipophilicity and the
difference in promiscuity, as shown in Figure 3d.
In addition, the protonation states of these compounds were
analyzed by counting the numbers of acidic and basic atoms.
Nearly all compounds were neutral and only one compound
was found to be basic.
Transformations. The 126 MMPs representing promiscu-
ity cliffs encoded 38 unique transformations representing
different structural changes (as reported in Table S1 of the
Supporting Information). These transformations were ranked
according to the number of promiscuity cliffs they occurred in.
Table 1 reports the 10 top-ranked transformations. Individual
transformations were detected in up to 11 promiscuity cliffs.
Notably, eight of the top 10 transformations involved an
azocane ring. We calculated the total number of MMPs that
represented each of the 38 transformations (including
promiscuity cliffs and others). The results for the top 10
transformations are also reported in Table 1. The total number
of MMPs ranged from six to 148. We next determined whether
these transformations exclusively occurred in MMPs with large
target number differences, i.e., whether they represented
promiscuity-inducing transformations. Therefore, target num-
ber differences in all MMPs representing a given transformation
were analyzed. For the top 10 transformations, the minimal and
maximal differences in target numbers between MMP-forming
compounds and median values are reported in Table 1. For
example, for the top-ranked transformation, the median value
was 6.5 and MMPs with no target number differences existed.
In three other cases, median values of 1 were obtained. Hence,
many promiscuity cliff-containing transformations also occurred
in MMPs with small target number differences (or no
differences). None of the 38 transformations was found to
exclusively occur in promiscuity cliffs or other MMPs with large
target number differences. Hence, no chemical transformations
were detected that consistently induced large-magnitude
compound promiscuity.
Substructures. Following the analysis of transformations,
we ranked individual substructures involved in these trans-
formations according to the number of promiscuity cliffs in
which they occurred (excluding substructures comprising single
atoms). Table 2 shows the top five substructures that were
Table 1. Ranked Transformationsa
aThe top 10 transformations most frequently found in promiscuity cliffs are listed. The number of promiscuity cliffs and the total number of MMPs
containing each transformation are reported. In addition, the minimal (Min) and maximal (Max) differences in the number of target annotations
among MMP-forming compounds and median values are given.
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found in more than 10 promiscuity cliffs. Table S2 of the
Supporting Information reports all 37 qualifying substructures
involved in the formation of cliffs. These substructures were
diverse. Corresponding to observations made for trans-
formations, the azocane ring found in 68 promiscuity cliffs
was the top-ranked substructure in Table 2. The top five
substructures occurred in a total number of 90−272 MMPs and
84−1834 compounds. As also reported in Table 2, the number
of targets that compounds containing each substructure were
active against greatly varied and also yielded low median values.
In three instances, median values of zero were obtained,
indicating that at least half of the compounds containing a
highly ranked substructure were inactive. As expected on the
basis of our transformation analysis, no substructure was found
to exclusively occur in promiscuous compounds.
Promiscuous Compounds. All 117 compounds involved
in the formation of the 126 promiscuity cliffs were used to
generate a molecular network in which nodes represented
compounds and edges promiscuity cliffs, as shown in Figure 4a.
In this network representation, a number of “promiscuity hubs”
became apparent, i.e., compounds with a large number of target
annotations involved in the formation of multiple cliffs. It
should be noted that these compounds were not only highly
promiscuous, but also could be transformed into multiple
compounds with limited or no promiscuity through small
chemical modifications. The five most prominent promiscuity
hubs are highlighted in Figure 4a. These hubs were active
against more than 90 targets each and involved in the formation
of 9−11 promiscuity cliffs. Their structures are shown in Figure
4b. A characteristic feature of all five compounds was that they
contained both the azocane ring and spirooxindole rings (the
latter identified by Schreiber and colleagues18 as a single
promiscuity marker in DCs; vide supra). Because of the very
large number of targets that promiscuity hubs were active
against, it is conceivable that they might at least in part also
engage in nonspecific interactions (vide supra).
Promiscuity Cliffs. The co-occurrence of the azocane and
spirooxindole substructures in many highly promiscuous
compounds suggested the possibility that combinations of
substructures (rather than individual ones) might be pro-
miscuity determinants. This possibility could be directly
explored because the hubs we identified participated in the
formation of multiple promiscuity cliffs. Figure 5 shows
examples of prominent promiscuity cliffs containing the
azocane and spirooxindole substructures (additional examples
are provided in Figure S3 of the Supporting Information).
Comparison of cliff-forming compounds clearly revealed that
co-occurrence of the azocane and spirooxindole moieties was
not a major promiscuity determinant. In the promiscuity cliffs
in Figure 5a,b, removal of the azocane ring rendered highly
promiscuous compounds (with activity against 95 and 94
targets, respectively) inactive. All compounds in these cliffs also
contained the spirooxindole moiety. The cliff forming
compounds in Figure 5c both contained the azocane and
spirooxindole rings. However, a change in the position of an
aliphatic substituent from the para to ortho in the phenyl ring
at the lower right was sufficient to transform a highly
promiscuous compound into an inactive one. In Figure 5d,
the compound containing the para-substituted phenyl ring was
also highly promiscuous (i.e., active against 93 targets), whereas
the presence of a hydroxyl group at the same position
dramatically reduced promiscuity to five targets. However, the
ortho-substituted phenyl ring in a different structural context,
shown in Figure 5e, was highly promiscuous in contrast to the
corresponding analog in Figure 5c. Moreover, compounds
containing the para-substituted phenyl ring but different
substitutions at the spirooxindole moiety displayed very
different degrees of promiscuity (Figure 5e). Taken together,
these comparisons revealed a strong structural context
dependence of chemical modifications, leading to the formation
of promiscuity cliffs. There was no individual substructure or
transformation that consistently caused large-magnitude
Table 2. Ranked Substructuresa
aThe top five substructures most frequently found in promiscuity cliffs are listed. The number of promiscuity cliffs and the total number of MMPs
that contain each substructure are reported. In addition, the total number of compounds containing each substructure is reported. Furthermore, the
minimal (Min) and maximal (Max) number of target annotations among these compounds and median values are given.
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Figure 4. Promiscuity cliff network. (a) MMP-based compound network focusing on promiscuity cliffs. Nodes represent compounds, and edges
indicate promiscuity cliffs. Nodes are gray-scaled according to the number of target annotations using a continuous spectrum from black (0 targets;
inactive) to white (97 targets; most promiscuous). Five highly promiscuous compounds that were active against more than 90 targets and involved in
the formation of 9−11 cliffs are boxed and numbered. Their structures are shown in part b. For each compound, the number of targets it was active
against and the number of cliffs it was involved in are reported. For example, “95 | 10” means that the compound was active against 95 targets and
involved in the formation of 10 promiscuity cliffs.
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promiscuity effects and exclusively occurred in promiscuous
compounds.
What Do We Learn about Promiscuity from a
Medicinal Chemistry Perspective? On the basis of the
data available to us, it is not possible to conclude with certainty
to what extent highly promiscuous compounds engage in
specific and/or nonspecific interactions with targets. It is of
course unlikely that a compound might form specific
interactions with 90 or more diverse targets, even if the
interactions were clearly detectable under the given exper-
imental conditions. Hence, it is appropriate to consider
promiscuity from a phenotypic point of view in the context
of our analysis, given the requirement to analyze the data at face
value and avoid overinterpretation. However, it should be
Figure 5. Promiscuity cliffs. Shown are representative MMPs in which activity annotations of compounds differed by more than 80 targets. For each
compound, the compound ID and the number of targets it was active against are reported. The promiscuous compound of each cliff is shown on the
left and the exchanged fragments are colored red.
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noted that only a small fraction of the array compounds were
promiscuous in nature and that the formation of promiscuity
cliffs was a rare event, thus indicating that the microarray data
were suitable for a systematic analysis of promiscuity effects. As
we have shown, only a small fraction of MMPs generated from
the entire microarray data set combined compounds with
notable differences in the number of targets they were active
against. Taking this into account, the detection of cliffs in which
structurally similar compounds differed in their activity by 50 or
more targets is considered a striking finding, regardless of
underlying molecular mechanisms.
For medicinal chemistry, a number of findings reported
herein are of immediate relevance. It is evident that the MMP-
based approach provides a direct and chemically intuitive access
to small structural modifications, leading to large-magnitude
promiscuity effects. Previously, a number of structural frame-
works have been identified that were highly recurrent in
promiscuous compounds across different target families.12
However, it has remained largely unclear from a medicinal
chemistry perspective thus far whether certain molecular
frameworks carry an intrinsic likelihood of promiscuity and/
or might have frequent hitter character. After all, promiscuity is
determined for compounds, not their frameworks. Importantly,
the findings presented herein do not promote a framework-
centric view of promiscuity. Thus, for the evaluation and
prioritization of compound series for medicinal chemistry,
frameworks should not primarily be considered as an intrinsic
source of promiscuity and potential lack of compound
specificity. Rather, we demonstrate that small chemical
modifications can trigger large-magnitude promiscuity effects.
Importantly, these effects depend on the specific structural
environment in which these modifications occur. On the basis
of our analysis, substitutions that induce promiscuity in any
structural environment were not identified. Thus, in medicinal
chemistry, it is important to evaluate promiscuity for individual
compounds in series that are preferred from an SAR
perspective; observed specificity of certain analogs within a
series does not guarantee that others are not highly
promiscuous. Taken together, these findings further extend
our view of molecular origins of promiscuity, putting strong
emphasis on the context-dependence of promiscuity-inducing
structural modifications. The analysis of compounds in cliff
forming MMPs provided a focal point for the identification of
such chemical changes that might have otherwise not been
detected.
■ CONCLUSIONS
Herein, we have analyzed compound promiscuity on the basis
of small molecule microarray data involving ∼15 000
compounds and 100 sequence-unrelated targets. These micro-
array data provide a binary readout of compound activity and
are likely influenced, for example, by variance and local
concentration effects associated with printing of compounds on
solid surfaces by different mechanisms. Nevertheless, as clearly
indicated by the results of Clemons et al., who conducted the
microarray experiments, the data revealed meaningful binding
patterns and systematic trends concerning compound selectiv-
ity and, as demonstrated in our study, promiscuity. In the
current analysis, we have focused on identifying closely related
compounds with large difference in promiscuity, leading to the
introduction of promiscuity cliffs. From these compound pairs,
chemical modifications at individual sites have become apparent
that led to promiscuous binding behavior. Chemical changes
were identified that caused large-magnitude promiscuity effects.
We have shown that no individual substructure or trans-
formation involved in these effects exclusively occurred in
promiscuous compounds. Rather, they were distributed across
compounds with different levels of promiscuity or no apparent
promiscuity. On the basis of currently available data,
promiscuity is not an inherent feature of certain structural
frameworks. However, we have shown that chemical
modifications could trigger promiscuity within specific
structural contexts. Exemplary promiscuity cliffs have revealed
that similar substitutions in different structural environments
can lead to promiscuity effects of different magnitude, or even
opposite effects (i.e., increase vs reduction in target numbers).
On the basis of our analysis, small structural modifications of
nonpromiscuous compounds can lead to substantial promiscu-
ity. However, these effects are structural-context-dependent.
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CHAPTER 9: SUMMARY
Summary
A total of 30, 954 MMPs were systematically generated for the set of 15, 252
microarray compounds screened against 100 unrelated targets. In addition, 126
MMPs formed by 117 compounds were identified that differed by 50 or more
target annotations and qualified as promiscuity cliffs. These 126 cliffs encoded
a total of 38 transformations involving 37 distinct substructures. Our find-
ings revealed that no single chemical transformation or a substructure existed
that exclusively occurred in promiscuous compounds. In addition, promiscu-
ity hubs were detected that were represented by highly promiscuous compounds
involved in multiple promiscuity cliffs. A key observation was that these promis-
cuity hubs contained both the azocane and spirooxindole rings, suggesting that
combinations of substructures (rather than individual ones) might be promis-
cuity determinants. Taken together, there was a strong context-dependence
of promiscuity-inducing chemical modifications. My contributions to the work
presented herein include the MMP and promiscuity cliff analysis.
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Chapter 10
Conclusions
The analysis of SARs of small bioactive compounds is a central task in medicinal
chemistry. However, the multi-faceted nature of SARs and the rapidly growing
molecular data greatly challenge SAR exploration. A variety of computational
approaches have been introduced thus far to aid in the systematic SAR anal-
ysis, with activity landscapes being popular and widely used computational
models. Furthermore, the concept of activity cliffs, the cardinal features of ac-
tivity landscape representations, provides a direct access to SAR determinants
in active compounds. Therefore, the major objectives of this dissertation have
been the development of novel activity landscape representations and the sys-
tematic exploration of activity cliffs in public domain compound repositories.
A number of representative studies have been presented.
First, a newly designed activity landscape was introduced for compounds
active against multiple targets. This method was based on a numerical encod-
ing scheme of activity profiles of compounds. On the basis of this methodology,
compounds forming multi-target activity cliffs could be easily identified and the
contribution of individual compounds to global multi-target SARs monitored
(Chapter 2). This method was applied to sets of compounds active against
a limited number of targets. Furthermore, the LTD map was introduced to
navigate high-dimensional activity spaces defined by compounds active against
50 or more targets (Chapter 3). A key feature of the LTD map was that it
greatly reduced the complexity of high-dimensional activity spaces by account-
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ing for pairwise potency differences between compounds. Furthermore, pairwise
activity profile comparisons were made graphically assessable.
The analysis of activity cliffs is of major importance for medicinal chem-
istry. However, thus far, their study has mostly focused on individual sets of
compounds active against a given target. Therefore, a systematic survey was
carried out to account for the global distribution of single- and multi-target
cliffs across different targets. The results revealed that the majority of activity
cliffs were single-target cliffs, yet instances of multi-target cliffs were also de-
tected. In addition, the propensity of active compounds to form activity cliffs
was determined (Chapter 4).
In a large-scale SAR profiling experiment, fingerprint-dependent changes in
SAR information were determined. For approximately 70% of the test com-
pounds changes in the local SAR discontinuity score were observed when alter-
native fingerprint representations were used. Further, nearly 30% of the com-
pounds shifted their SAR phenotype. Hence, SAR characteristics were often
highly fingerprint-dependent (Chapter 5).
The remainder of the thesis was dedicated to the concept of activity cliffs
and their utility to aid in the practical medicinal chemistry. First, the ques-
tion was investigated whether there was a detectable SAR advantage associated
with exploring activity cliffs. To these ends, a computational compound path-
way model was designed to represent compound series with steadily increas-
ing potency ultimately leading to highly potent data set compound. Different
pathway categories were introduced on the basis of their origin. It was demon-
strated that the majority of the most potent data set compounds were reached
by pathways. In addition, activity cliff-dependent pathways reached potent
data set compounds with a higher relative frequency than activity-cliff inde-
pendent pathways, clearly indicating an SAR information gain associated with
activity cliffs (Chapter 6).
The concept of SAR progression was developed to mimic the exploration
of the chemical neighborhood of cliff-forming compounds and indicate to what
extent activity cliffs were utilized as starting points for compound optimization
efforts (Chapter 7). For the majority of activity cliffs, no structural analogs of
the highly potent cliff-forming compounds were reported and hence there was no
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evidence for further chemical exploration. On the other hand, for every sixth to
seventh cliff, instances of activity cliff progression were detected that resulted
in a significant potency increase of 1 or 2 orders of magnitude. The large
fraction of as of yet unexplored chemical neighborhoods indicated that there
are many opportunities for further exploration and exploitation of activity cliff
in practical medicinal chemistry.
To further complement the activity cliff analysis, the composition and topol-
ogy of activity cliffs formed by currently available bioactive compounds were
thoroughly examined (Chapter 8). The majority of the cliffs were coordinated,
i.e., their formation involved multiple active compounds and cliffs. All distinct
topologies were systematically determined and recurrent topologies classified.
The majority of the cliff communities were of small size and had well-defined
topologies, which might be indication of similar SAR patterns present in these
communities.
Finally, the concept of activity cliffs was extended to account for structure-
promiscuity relationships. By introducing the concept of promiscuity cliffs,
promiscuity-inducing structural modifications were identified that significantly
altered the degree of compound promiscuity (Chapter 9).
In conclusion, in this thesis computational methods were introduced de-
signed to assist in large-scale SAR exploration. Furthermore, systematic data
mining efforts were reported to provide a detailed and further refined view of the
activity cliff concept and its utility to aid in the practice of medicinal chemistry.
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